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Summary 
The use of chemical probes is a powerful tool that can help to address important 
biological questions. 
The study presented in this thesis aims to target reader domains of chromatin-
associated proteins with small molecules, in order to provide information on their 
ligandability, useful to develop - potent chemical probes. 
This thesis work is divided in three parts. 
In the first and second part it is shown how structural information obtained by the use 
of synthetic peptides to study the binding mode of reader domains with their natural 
binding partner can be combined with fragment screening to gauge future optimization 
of small molecules. 
The first section described the disclosure of the binding mode of the H3 histone tail by 
the PHD zinc finger of BAZ2A. A crystal structure of the complex of BAZ2A with the H3 
10-mer peptide identified a helical conformation of H3 upon binding with the PHD.  This 
information coupled with further structural and biophysical analysis led to the 
identification of a subfamily of PHD characterized by an acidic patch on the helical turn, 
which is responsible of inducing helicity on H3 tail upon binding. 
The second part of the work investigated the ligandability of the PHD zinc finger domains 
of BAZ2A and BAZ2B. Using a combination of biophysical techniques and X-ray 
crystallography it was probed that it is possible to target these reader domains. Despite 
the similarities of the two PHDs, comparison of the fragment-bound crystal structures 
of the two proteins highlighted some differences in the binding mode.  
The last part of the project describes the several attempts performed in trying to 
elucidate the histone binding partner of the PHD-BrD tandem of the chromatin-related 
proteins BAZ1B and TRIM66, both involved in diseases. 
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CHAPTER 1. 
INTRODUCTION 
1.1 FUNDAMENTALS OF EPIGENETICS 
 
In eukaryotic organisms, gene expression and many cellular processes, such as cell 
differentiation, are under the control of epigenetic regulation. Epigenetics defines all 
those changes that affect the phenotype of an organism, without any alteration on the 
DNA sequence 1, 2. Epigenetics can be considered as a fundamental process that 
monitors physiological events of the eukaryotic cell in response to environmental stimuli 
3, 4. This regulation is based on the coordination of several interdependent molecular 
mechanisms that modulate two distinct states of chromatin: euchromatin (associated 
with gene activity) and heterochromatin (associated with gene repression). Modulation 
of chromatin states affects many important cellular phenomena, such as transcription, 
replication, repair and recombination of DNA. 
 
Chromatin is the packaging of DNA within the nucleus. The basic unit of chromatin is the 
nucleosome, forming the first level of compaction of DNA. The first structure of the 
nucleosome was solved by Luger et al 5 in 1997 and revealed that the nucleosome is 
composed of approximately 146 base pairs of DNA wrapped in a double super-helical 
turn around a histone octamer. Histone octamers consist of two copies of histone 
proteins H2A, H2B, H3 and H4. The core of the histone proteins is predominantly 
globular, while basic and unstructured N-terminal tails protrude away from the core of 
the nucleosome (figure 1.1A). Histone tails can contain many diverse post-translational 
modifications (PTMs) that play a key role in epigenetic regulation. PTMs are covalent 
and reversible modifications occurring on the side chains of specific amino acid residues 
(Lys, Arg, Tyr, Ser, Thr). PTMs, together with non-coding RNAs and covalent 
modifications on DNA e.g. DNA methylation 6, constitute a fundamental chemical 
platform underpinning epigenetic regulation.  
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Figure 1.1. Nucleosome and histone modifications readout. 
(A) Structure of the nucleosome showing the histone core and protruding histone tails as surface. In 
cartoon the DNA base pairs wrapped around the histone core. (PDB: 1KX5). (B) (C) and (D) respectively 
report a schematic representation of writers, readers and erasers of PTMs acting on the histone tails. 
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Deciphering epigenetics: DNA methylation and PTMs 
 
1.1.1 DNA methylation and reading proteins 
 
DNA methylation constitutes one of the mechanisms which actively regulate the 
transcriptional states of the chromatin. Methylation is mainly occurring at the position 
C5 on the cytosine residue (5mC) preceding a guanine residue (CpG) 6. The transfer of 
the methyl group to the pyrimidine base is catalysed by the DNA methyltransferase 
(DNMT) through the S-adenosyl methionine (SAM) cofactor 7.   
This methylated base can be further oxidised to hydroxymethylated cytosine (5-hmC), 
to formylcytosine (5-fC)  and to 5-carboxylcytosine (5-caC) and to cytosine again, as 
shown in figure 1.2.  
 
Figure 1.2. Cytosine and its derivatives. 
Cytosine, methylcytosine and its oxidised derivatives. 
 
DNA methylation has been mainly associated with gene silencing, blocking the 
interaction of transcription factors with the DNA  while the understanding of the 
biological function of the oxidised derivatives is still under investigation.  
Methyl-binding domain proteins, also known as MBD proteins, constitutes the major 
family capable of binding to modified DNA 6. An example is represented by the MeCP2 
(methyl-CpG binding protein2) which was the first MBD protein to be identified 6. 
Conversely, MBD3 was the first MBD protein discovered to bind the 5-hmC motif 6.  The 
zinc- finger (ZF) and SET and RING-associated (SRA) family are also known to recognise 
5-mC and derivatives 6.  
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1.1.2 Post-translational modifications (PTMs) 
 
PTMs are chemical modification that  occur on histone tails, such as acetylation, 
methylation, phosphorylation, ubiquitination, amongst others 4. This class of 
modifications has been the main focus of this thesis work.  
These modifications can be attached or removed from two antagonist classes of 
enzymes, respectively, called writers and eraser (figures 1.1B and 1.1D). They exert a 
fine-tuned epigenetic control in two ways: (i) directly, through changes on the structure 
of chromatin, for example, introducing repulsive interactions between histones and 
DNA (like acetylation or phosphorylation) or (ii) indirectly, modulating the binding of 
reader modules on the nucleosome.  
Readers or effectors are a class of proteins capable of recognising specific pattern of 
sequence and structure on histone tails, containing modified or unmodified residues 
(figure 1.1C) 8, 9. These readers, upon binding, can recruit enzymatic machineries able to 
translate this binding into a biological meaningful event 4, 10.  
 
Two examples of PTMs that play a great role in epigenetics are acetylation and 
methylation. Basic science and pharmaceutical research have revealed the role of these 
modifications and their importance. Many cellular signalling pathways events regulated 
by these modifications are often associated with diseases. 
 
Acetylation was the first modification to be identified in 1964 by the Allfrey group 11. It 
is introduced by histone acetyltransferase (HATs) which transfers an acetyl group from 
the cofactor acetyl-CoA on the ε-amino group of the Lys side chain 12. Histone 
deacetylases (HDACs) are antagonist enzymes which remove the acetyl group from Lys 
12. Addition of the acetyl moiety on Lys neutralizes the charge of the residue with 
remarkable impact on chromatin structure, weakening the interaction of histones with 
DNA, and as a result inducing a more open conformation of chromatin, becoming 
accessible to transcriptional machineries 13. This can explain how acetylation is often 
uniquely associated with high transcriptional activity 13.  
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Another important modification occurring on both Arg and Lys residues is methylation14. 
It is a dynamic modification 15, which is regulated by RMTs (arginine methyltransferase) 
and KMTs (lysine methyltransferases) antagonistic to the R(K)DMs (demethylases) 16 17-
23.  These PTMs are simultaneously found in association either with repressive or 
activating states, according to the level of methylation and to the position of the 
residues on the histone. Methylation on Lys can occur as mono-, di- or tri-methylation. 
On the Arg, methylation can occur as mono- or di-methylation in a symmetric (on both 
nitrogens of the guanidinium group) or asymmetric (only on one nitrogen of the 
guanidinium) manner 14, 24. Arg methylation does not affect the overall charge of the 
residue but it can modulate the types of interactions that the side chain can establish. A 
remarkable example of how these marks can have different biological outcomes is 
mono-methylated K4 (H3K4me) which is often associated with gene activation in 
combination with H3K27ac 4, while H3K9me3 and H3K27me3 are examples of 
methylation found associated to repressive states in heterochromatin 4, 25. 
 
Phosphorylation is another modification occurring on serine, threonine and tyrosine. It 
is found on histone and non-histone proteins on which it is dynamically regulated by 
kinases and phosphatases, two antagonistic enzymes. This modification adds a negative 
charge on the histone with consequent effects on the chromatin structure. It is often 
found associated with other modifications with which it acts in cross-talk 26. 
 
β-N-acetylglucosamine (O-GlcNAc) has also been recently identified as a novel 
epigenetic mark of the histone code 27. This modification, occurring on the side chain of 
serine or threonine, is mainly involved in regulatory processes of non-histone proteins 
28. Work from Sakabe et al., in 2010, identified for the first time glycosylation marks on 
histone tails 27. From that seminal study, this PTM has emerged as involved in gene 
expression and regulation of chromatin remodelling complexes 29.  
 
Figure 1.3 depicts a schematic illustration of the major PTMs identified on the N-terminal 
histone tails of the nucleosome. 
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Figure 1.3. Simplified illustration showing PTMs on the four histone tails 
protruding from the nucleosome. 
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1.1.3 PTMs reader domains  
 
Reader domains are protein modules able to bind specific sequences and marks on 
histone tails 8, 9 with the final aim to translate this binding in a biological meaningful 
event.  
Table 1.2 (adapted from Taverna et al. review 8) groups the different known reader 
domains and the relative PTM recognized. 
 
 
 
Table 1.1. Summary of reader domains and associated PTMs 8. 
Summary of the principle reader domains (left column) and the marks recognized (right column). 
 
One of the most studied reader domains is the bromodomain, which recognizes Kac 
marks on histone tails as well as other proteins 30, 31. Bromodomains play a key role in 
many protein-protein interactions in cell 30, thereby motivating intense interest in this 
domain 32. Methyllysine reader domains have also received attention in the last few 
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decades. Amongst these readers are: PHD zinc fingers, chromodomain, chromo barrel, 
tudor domain and MBT (malignant brain tumor) domain 8, 9. The specificity of these 
modules is dictated by peculiar features of the histone binding pocket. According to the 
level of methylation of recognized residues, the hydrophobicity of the binding pocket is 
increased 8.  
 
Much less is known about recognition of phosphorylated marks. Indeed to date only a 
couple of examples of effector modules have been reported in literature: the 14-3-3 
scaffold and the BRCT domain of MDC1, which, respectively, recognizes H3S10ph 33 and 
S139ph on H2A.X 34. 
 
Herein, I will examine in greater details two of the reader domains that were the subject 
of investigation of this PhD thesis – the bromodomain and the PHD finger domain. 
 
1.1.3.1 Bromodomain 
 
The bromodomain specifically recognises ε-N-acetylated lysine. It is a highly structurally 
conserved domain despite the relatively low sequence identity. This effector module 
was identified for the first time in 1992 in the Brahma gene of the Drosophila 
melanogaster 35. It is composed of a central hydrophobic pocket determined by a left-
handed bundle of four α-helices (designated as α Z, α A, αB and αC) linked with loops of 
variable length (named as ZA and BC loops) 8, 36, 37. A highly conserved asparagine residue 
is responsible for the coordination of the bound Kac together with a network of 
structurally conserved water molecules 36, 37. In the human genome, 61 different 
bromodomain modules have been identified, belonging to 46 different chromatin-
associated proteins 37. A phylogenetic tree (figure 1.4B) groups the different 
bromodomain in seven subfamilies, according to structural similarities 37. These proteins 
are involved in different transcription networks, and are often associated with disease 
pathways, for example, cancer, inflammatory response or viral infections 30. For these 
reasons, bromodomains have been identified as potential therapeutic targets 30 and 
several inhibitors have been generated to disrupt protein-protein interactions involving 
these effectors 36 38-41. 
30 
 
 
 
Figure 1.4. Bromodomain structure and phylogenetic tree. 
A- Cartoon structure of the bromodomain of BAZ2B in complex with K14ac in sticks (PDB:4QC1). The five 
conserved waters of the pocket are reported as sphere and the two conserved residues as stick. 
B- Phylogenetic tree of the bromodomain reporting eight different subfamilies (I, II. III etc.). Classification 
is based on structure similarity. Figure was adapted from Filippakopoulos et al. 37. 
 
1.1.3.2 PHD zinc fingers  
 
Plant Homeodomain (PHD) zinc finger is a small domain constituted of 50-80 amino acids 
characterized by the highly conserved motif of Cys3-His-Cys4 that coordinates two zinc 
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ions in an interleaved fashion, as shown in figure 1.5. It takes the name from the plant 
homeodomain of Arabidopsis thaliana where was identified for the first time in 1993 42.  
 
 
 
Figure 1.5. PHD zinc finger fold. 
Schematic view of the PHD zinc finger fold characterized by the double β-strands responsible of the 
interaction with the histone and the conserved motif Cys4-His-Cys3 that coordinates two zinc ions. (Figure 
adapted from Musselman et al. 43). 
 
More than 120 sequences have been annotated as PHD zinc fingers. Figure 1.6 illustrates 
the phylogenetic tree grouping the different domains according to their sequence 
similarities.  
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Figure 1.6. Phylogenetic tree of PHD obtained from the ChromoHub, GSK.44. 
Phylogenetic tree is obtained from sequence similarities upon alignment. 
 
In contrast to other reader domains that selectively bind specific modifications, PHD 
fingers have been shown to be much more diverse with respect to the choice of their 
binding partner. This diversity can be related to the multiple biological functions in which 
they are involved. Some PHD fingers can specifically recognise unmodified regions of the 
N-terminal tail carrying H3K4 with no modifications (figure 1.7 C) 45-49. Other PHDs 
specifically  recognise H3K4me3 or H3K9me3 (figure 1.7 A and 1.7 B) 50, 51. One PHD 
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finger displayed preference of binding for H3K36me3 52. Another subset of PHDs, 
recently identified, reported binding toward different acylation states on position K14 
53; peculiarity of the pocket of this specific subset is the presence of a conserved Gly in 
the first β-strand that replaces the bulky residue found in other PHDs 53. 
 
 
Figure 1.7. A-C. Structural basis on the recognition mode of PHD fingers. 
(A) Crystal structure of PHD of BPTF in complex with H3K4me3 (PDB: 2F6J). (B) Crystal structure of PHD of 
BHC80 in complex with H3K4me0 (PDB: 2PUY). (C) Crystal structure of the PHD of TRIM33 in complex with 
H3K4me0K9me3 (PDB: 3U5N). PHD is represented as surface and histone peptides as yellow sticks with 
nitrogen and oxygen, respectively, in blue and red. 
 
PHD domains involved in H3K4me3 recognition contain a conserved aromatic cage 
(figure 1.7 A). PHD fingers that lack such a signature instead recognize unmethylated K4 
(figure 1.7 B-C). At low methylation states, hydrogen bond acceptors facilitate the 
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interaction with K4. In contrast, at increasing methylation states, aromatic residues such 
as F,Y or W play an important role in the molecular recognition, due to the formation of 
stable cation-π interactions with the charged methylated primary amine group 54.  
PHD zinc fingers have recently been investigated as potential targets for therapeutic 
intervention, as several biological and genetic studies have linked many proteins 
containing PHD finger domains to human diseases 43, 55. However, in contrast to 
bromodomains, not many studies have addressed the ligandability of these reader 
domains. To date, there are only two papers reporting inhibitors of PHD zinc fingers. In 
the work presented from Wagner et al., a chemical scaffold was identified that disrupted 
the interaction of the PHD finger of JARID1A with a H3K4me3 peptide 56. Mutagenesis 
experiments and modelling studies suggested a hypothetical region of binding for the 
small molecule, however no structural or biophysical data were provided to confirm 
specific, reversible protein-ligand binding 56. In 2014, Miller et al., using in silico and NMR 
screening, identified several fragments able to bind the PHD finger of the protein Pygo. 
Amongst them, the best compound led to the first fragment-bound structure (figure 
1.8). A  KD of 2.5 mM was estimated by CSPs 57. This work can be considered pioneering 
in terms of fragment screening to identify potential starting points toward the 
development of small-molecule inhibitors of the PHD-histone interaction. 
 
 
 
Figure 1.8 First fragment bound structure of a PHD finger. 
Crystal structure of the PHD of Pygo2 (grey surface) in complex with a chemical fragment CF4 (in stick). 
PDB: 4UP5.57 
 
1.1.4 Combinatorial readout by tandem modules 
 
Epigenetic proteins often contain more than a single reader/writer/eraser domain. 
Genome-wide sequence analyses have led to the identification of a frequent 
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concurrence of multiple reader domain within the same protein. This observation led to 
the hypothesis of a possible combinatorial readout associated with multivalent binding 
to impart sequence specificity, and concomitant recognition of distinct post-
translational modifications 8, 9. Adjacent reader domains could act in cross-talk by 
binding different combinations of marks on the histone tails. Examples are the PHD 
domains from MOZ, DPF2 or MYST3 that are able to recognize unmodified lysine on one 
PHD and acetylated K14ac on the adjacent PHD 8, 58. Also the PHD fingers of CHD5 
constitute an example of multivalent engagement of two adjacent PHDs both binding to 
unmodified H3 tails 59. 
Thus, combination of modifications can actually act as a single unit, a ‘modification 
cassette’ 60, able to be recruited by different effectors in a concerted manner. 
Combinatorial modifications are not only found on the same histone tail but they can 
also play in cross-talk on different histones belonging to the same nucleosome or on 
distinct nucleosomes 61. Picture 1.9 illustrates the different possibilities offered.  
The relevance of this multivalent mode of action is in the opportunity of modulating the 
same system in different way, in order to explicate distinct biological outcomes. 
 
 
Figure 1.9. Multivalent engagement by reader domains. 
(A) Examples of adjacent reader domain recognizing in cis and trans histone tail situated on the same 
nucleosome. (B) Examples of adjacent readers recognising histone tail located on different nucleosome.  
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An example of combinatorial action in cis is offered by the PHD-Bromodomain of TRIM33 
and TRIM24 which respectively recognize H3K9me3K18ac 51 and H3K4me0K23ac 62. 
Both these tandem modules contain reader domains connected by a small loop that 
facilitate mutual interaction of the two reader domains and recognition of the 
modification cassette on the same histone tail H3. The PHD-Bromdomain of BPTF, 
instead, is a representative example of recognition in trans. In this protein, the two 
effectors are connected by a α-helical linker which keeps them far apart, so that the PHD 
binds the H3K4me3 mark, while the bromodomain recognizes H4K16ac on a separate 
histone tail 50, 63.  
 
Multivalent engagement can be explained by introducing the concept of cooperativity 
64. The recognition of specific marks is not an isolated event involving only a single 
residue but is rather influenced by adjacent residues or PTMs that can fine-tune 
(positively or negatively) the binding affinity.  For example, the Sp100C PHD, which 
recognizes unmethylated H3, showed higher affinity for the histone tail in presence of 
phosphorylated S10 65. For the PHD-Bromodomain tandem of TRIM24 and TRIM33, it 
was observed that the longer length of the peptide is critical to achieve binding affinity 
and specificity 51, 62. By contrast, a negative tuning is observed for the binding of HP1 to 
H3K9me2/3 which is disrupted in presence of H3pS10  60. This antagonistic mechanism 
is also known as ‘binary switch’ 60. 
 
Study of the cooperative effect on reader tandem modules have the advantage to be 
more informative than studies with a single domain, allowing better understanding of 
the mechanism of engagement of the histone tails by chromatin-associated proteins 64. 
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1.2 TARGETING THE EPIGENOME 
 
Despite progress achieved in this last decades in the understanding of the mechanisms 
underpinning epigenetic regulation, several questions remain to be addressed. In this 
context, a valuable approach can be the development of chemical probes able to bind 
with high affinity and selectivity a particular reader domain. Such probes could be used 
as tools to dissect the role and explore the function of a protein or of its individual 
domains 66 67. The advantage of using chemical inhibitors is in the possibility to edit a 
specific function of the protein 68 instead of blocking the expression of the whole protein 
as it is the case with gene knockout or knockdown approaches. An example of recent 
successful application of chemical probes to biological discovery is the work presented 
from Sdelci et al that used small molecules to reveal how TAF1 and BRD4 synergistically 
control proliferation of cancer cells 69.  
 
There is strong evidence of the involvement of the epigenome in the establishment of 
important human diseases such as cancer, inflammation, diabetes, neurological 
disorders, amongst others 43, 55, 70-72. Several studies have documented clinical relevance 
of reader domains, electing them as potential therapeutic targets. Many chromatin-
associated proteins have been shown to have medical relevance and amongst these, 
chromatin-modifying enzymes have proven to be enticing drug targets which has led to 
five drugs now approved by the FDA (Food and drug administration) 73. In the last 
decades a large number of human cancers has been often associated with DNA 
methylation 74. For instance, mutations occurring on the IDH1/2 (isocitrate 
dehydrogenases) proteins, which inhibit the activity of histone demethylases and DNA 
methylases, lead to a hypermethylation of DNA and histone which is characteristic of 
the phenotype of the acute myeloid leukemia (AML) 74. Decitabine, marketed as 
Dacogen, is an example of epigenetic drug proven to be effective against AML. 
Decitabine is a cytosine analogue which can be incorporated in DNA and RNA, reducing 
the level of methylation through inhibition of the methyltransferases 75.  Also Histone 
deacetylases (HDACs) have been strongly targeted in the last decades since their 
overexpression has often been  linked to certain types of human cancer 76. Vorinostat,  
commercially known as Zolinza 77, represents another example of epigenetic drug 
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already on the market. It acts as inhibitor of the HDACs of class I, II and IV which contain 
a zinc in the active site. Its mechanism of action is based on the chelation of the catalytic 
zinc 78 and it was proven to be mainly effective against the cutaneous T cell lymphoma 
79.  
Amongst reader domains, bromodomains represent the most targeted domains. About 
19 lead compounds targeting bromodomains are currently being evaluated in clinical 
trials, notably inhibitors of the BET bromodomains family 80, as for example I-BET762 81 
and (+)-JQ(1) 82. Amongst other reader domains, potent inhibitors have also been 
discovered for methyllysine binders like the MBT (malignant brain tumor) domain, 
chromodomains and tandem tudor domains 83. 
 
In light of these developments, drugging the epigenome can be perceived as a great 
opportunity to: 1) provide chemical probes as useful tools to advance in the 
understanding of the humane interactome [84] and 2) expand the druggable human 
genome, an important goal for drug discovery today. 
 
1.2.1 The challenge of targeting protein-protein interactions of epigenetic 
readers 
 
Targeting epigenetic reader domains requires addressing protein-protein interactions 
(PPIs) 84. The challenge in targeting PPIs with small molecules emerges from the 
observation that the surface involved in the binding between two proteins is much 
larger when compared to the area covered by small molecules. It is been estimated that 
on average the surface area between two interacting proteins is ~ 1500–3000 Å2 85 while 
the size of a small molecule is ~ 300–1000 Å2  86. The region of interaction between two 
proteins is generally a flat and shallow surface that tends to lack grooves and deep 
pockets which are typically found on proteins that bind natural small molecules (such as 
kinase or GPCR receptors) 87. Indeed, in drug discovery approaches, targeting kinases or 
GPCR families, the chemical scaffold of endogenous ligands is often used as starting 
point to develop synthetic, artificial antagonist.  
Albeit PPIs seem to involve a large surface area, it has been shown that, in many cases, 
only few residues are de facto contributing to the energy of binding. These residues are 
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called hot spots of interaction 87 88, 89. These hotspots are generally clustered at the 
centre of the interface and can cover an area comparable to the size of a small 
molecule.  .  
PPI can be classified in three categories, according to the kind of epitope which they 
recognise:  
(i) primary, if one side of the interface can associated with a linear protein sequence, as 
the case of PTMs recognition; 
 (ii) secondary, if they recognise epitope with one secondary structure; 
(iii) tertiary, if they recognise a more complex epitope characterized by a tertiary 
structure organization.  
Peptides are useful tools in structural biology to gain insight the molecular recognition 
of PPIs 87, 90. In the case of primary or secondary PPIs, peptides can simulate the protein 
surface, resembling the amino acid sequence of the natural binding partner. Their usage, 
coupled with biophysical techniques and mutagenesis experiments, can lead to the 
identification of the hotspots of interaction. The identification of hotspots may 
therefore assist in the generation of novel small molecules as specific disruptors of the 
PPIs. 
 
1.2.1.1 Targeting the epigenome: druggability or ligandability studies? 
 
There is often confusion in the usage of the terms “druggability” and “ligandability”, 
which are erroneously used as interchangeable terms. They actually refer to two 
different concepts. The term ligandability generally describes the possibility to identify 
a chemical scaffold able to bind a designated target with a certain affinity 91. If the 
targeted binding site is involved in the binding of a natural binding partner e.g. another 
protein or a small-molecule substrate or cofactor, then a ligandable binding site implies 
the propensity to generate suitable ligands of good chemical properties, that can 
effectively compete with the natural binding partner. The concept of ligandability can 
be visualized adopting the lock and key hypothesis, introduced by E. Fisher and L. 
Pauling, and  generally used to describe the mode of action of the enzymes  92 . The lock 
is the target protein with its pocket/surface and the keys are the different molecules 
that can potentially bind the pocket.  Only one key will be able to enter the lock – 
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exemplifying how only one molecule will bind specifically the target. Target ligandability 
provides a first necessary (but not sufficient) step towards target druggability. Target 
ligandability is the concept to which I will mainly refer in this thesis work. 
 
Druggability is a notion that engages multidisciplinary concepts because it implies that 
a suitable small molecule also satisfies certain pharmacodynamic and pharmacokinetic 
parameters and criteria that make it compliant and acceptable as potential drug i.e. 
drug-like 93. Moreover, such molecule should be able to abolish or at least reduce the 
aberrant effects of the disease pathway in which the target is involved, in order to 
generate a therapeutic effect for the patient 94. 
 
1.2.1.2 How to target protein-protein interactions: Fragment-based lead discovery 
(FBLD) 
 
In the last years several approaches have been developed and applied to target protein-
protein interactions. The established high-throughput screening of a large library of 
compounds (HTS) has been rivalled by the advent of fragment-based lead discovery 
(FBLD). The paternity of the concepts and theory behind fragment-based approaches is 
ascribed to Jencks’ work in the far 1981, on the additivity of binding energies of small 
molecules 95. His work paved the way to the idea that smaller component (fragments) 
could be productively assembled and optimized to produce larger molecules capable of 
better quality of binding and increased binding affinity. The difference in concept 
between HTS and fragment approach is illustrated in figure 1.10. 
 
 
Figure 1.10. Schematic differences between HTS and FBDD approach. 
A- Poor quality of protein-ligand interactions in HTS. B- The small size of the fragments allow each 
molecule to bind specific region of the interface in an optimal way. 
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In HTS screening large molecules typically make non-optimized interactions due to non-
specific binding. In contrast, in the fragment-based approach, each fragment can 
specifically target a small region of the protein. The potential of the FBLD approach is 
the possibility of combining in different ways the best hits obtained from screening 
(merging, linking or growing them) in order to develop a bigger scaffold with optimized 
interactions toward the target 96. Optimization steps of the fragments are generally 
addressed using structural knowledge on the mode of binding of the fragment itself. X-
ray crystallography and protein-observed NMR are leading techniques to provide these 
information.  
Fragment screening can be performed in silico or involving a cascade of complementary 
biophysical techniques which provide high sensitivity in detection of low affinities. 
Estimation of the affinities of the ligand is a key step to help to rank the fragments 
through the determination of either a KD or IC50 and the relative ligand efficiency (LE) 97. 
The concept of ligand efficiency is often used in medicinal chemistry to capture in a 
single metric how much binding affinity is contributed by each atom of the molecule. 
This metric provides a useful criteria for selecting the best fragments to pursue for 
further optimization, and can be much more informative than binding affinity alone. LE 
is defined by a simple equation (1) which divides the free energy of binding by the 
number of non-hydrogen atoms. Fragments with LE higher than 0.3 kcal  mol-1 per 
atom are generally considered efficient binders, albeit LE of ligands can closely depend 
on the ligandability of the target-binding site. For examples, ATP binding sites of protein 
kinases readily yield fragment binders with LE > 0.4, while flat and featureless PPIs often 
yield hits with LE ~ 0.2.  
𝐿𝐸 =  
𝛥𝐺
𝑁𝐻𝐴
          (1) 
 
Other considerations in addition to binding affinity and LE should be kept in account 
when selecting fragment hits. For example, knowledge on the binding mode of the 
fragment and chemical tractability of the scaffold for future optimization are other 
important parameters to consider. 
 
 
42 
 
1.3 TARGETING PHD ZINC FINGER AND BROMODOMAIN TANDEM 
MODULE 
 
In this thesis project I was interested in the study of PHD - Bromodomain tandem module 
of proteins involved in important biological pathways and linked to diseases: BAZ 
proteins and TRIM66. In the next subchapter I will give a brief introduction about these 
proteins and why it was decided to study them.  
 
1.3.1 BAZ family: bromodomain adjacent to zinc finger 
 
In 2000, the Shimane group in Japan identified a new family of four proteins, containing 
bromodomain adjacent to zinc finger, which was named as BAZ family 98 (figure 1.11). 
Members of this family all contain a PHD zinc finger and bromodomain at the C-terminus 
in addition to a DDT domain (DNA binding homeobox and different transcription 
factors). Additionally, BAZ2 proteins specifically contain a MBD (methyl-CpG-
binding domain) motif, also known as TAM  domain. The  WAC motif was a trait 
identified only in BAZ1 proteins and is required for DNA binding 99. 
 
 
 
Figure 1.11. BAZ family. 
Proteins belonging to the BAZ family with representative locations of conserved motif sequences. Most 
sequence variation is seen at the amino terminus where BAZ1A, BAZ1B have a WAC motif while BAZ2A, 
BAZ2B lack  that 45. Picture was obtained using Prosite MyDomain 100 
. 
 
In this project, I focused my attention on three proteins of the family: BAZ2A, BAZ2B and 
BAZ1B, which are described in details below 
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1.3.1.1 BAZ2A (or TIP5) 
 
BAZ2A (also known as TIP5 -Transcription termination factor I-interacting protein 5) is 
one of the more studied members of the BAZ family. It has been previously identified as 
part of NoRC (nucleolar remodelling complex) which uses BAZ2A as scaffold to bind to 
chromatin and subsequently recruit other components of the complex 101, 102 . The role 
of BAZ2A as part of the NoRC complex is essential to assemble and settle the 
heterochromatin state. BAZ2A was found overexpressed in prostate cancer interacting 
with the methyltransferase protein EZH2 to induce aberrant silencing in cancer 103. 
Although its mechanism of action has not been fully elucidated, BAZ2A has been 
identified has a possible biomarker for diagnosis of the prostate cancer 103. These 
discoveries point towards a clinical relevance for this protein. This motivated our 
interest in targeting BAZ2A. The presence of the PHD-BrD tandem modules on the 
protein skeleton makes this protein also an attractive model system for molecular 
recognition studies of multivalent histone binding. 
 
1.3.1.2 BAZ2B 
 
BAZ2B is the less studied protein of the family. Indeed, its biological function is unknown 
and speculations are only arising considering the high similarity with BAZ2A protein, 
especially in the region of the PHD-Brd tandem (60% identity) 45. To date, the only 
relevant knowledge about BAZ2B function is its association with a doubling of sudden 
cardiac death (SCD) risk 104. The lack of a functional role for this protein provides the 
motivation to drive the development of chemical probes useful to explore all the 
possible biological functions and interactions of BAZ2B. 
 
1.3.1.3 BAZ1B (or WSTF) 
 
BAZ1B is an atypical tyrosine-kinase protein 105, also known as WSTF protein. It is 
considered a versatile chromatin-modifying factor since it has been identified in at least 
three different complexes, all involved in distinct chromatin –related processes 106. The 
gene coding for this protein is part of a sequence that if deleted leads to the William-
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Beuren syndrome (WBS) 107, 108.  Insufficiency of BAZ1B protein could be the reason 
behind several anomalies typical of the WBS 109. Expression of this protein is found in 
almost all the tissues, including foetal tissues 106.  
How the binding of this protein is occurring at chromatin level is still unclear. Studies on 
the PHD-Bromodomain module can be a good starting point to answer these questions 
and reach a more complete understanding of its function and involvement in diseases.  
In light of this, to provide a chemical probe able to target and modulate this protein 
could be a strategic approach to unveil the biology of BAZ1B. 
 
1.3.2 TRIM: Tripartite motif family 
 
The tripartite motif family (TRIM) includes a large number of proteins all characterized 
by the presence of a RING domain 110, 1 or 2 B-box motifs 111 and an adjacent coiled-coil 
motif 112 at the N-terminal region. The majority of these proteins are found to be linked 
to cancer either in oncogenic or tumour suppressor activity. Within this family, which 
includes about 70 members, proteins are differentiated in 12 subgroups, based on their 
variations at the C-terminus 113. Transcriptional intermediary factor 1 (TIF1) family is one 
of the subgroups of the TRIM family and includes four proteins characterized by a PHD-
BrD tandem module at the C-terminus (figure 1.12).  
 
 
 
Figure 1.12. TIF1 family. 
Schematic illustration of the domains constituting the four proteins belonging to the TIF1 family. 
Figure was obtained using PROSITE MyDomains 100. 
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In this project I focused the attention on TRIM66, which is the less characterized protein 
of the TIF1 family. 
 
1.3.2.1 TRIM66 (or TIF1δ) 
 
Trim66, also known as TIF1δ, was the last component of the family to be identified, in 
2004 114. While other members of this subgroup have been studied in greater detail, 
very little is known about TRIM66. This protein was discovered as a novel HP1-
interacting member of the transcriptional intermediary factor 1 (TIF1) family 114; indeed 
TRIM66 features a PxVxL motif needed for the binding to HP1, as TRIM24 and TRIM28. 
It shares conserved domains with the other member of the family (figure 1.12). 
Expression of TRIM66 was observed only in testis, differently from the other members 
of the family which are ubiquitously expressed in all tissues. Scientific evidence 
suggested that this protein could be part of transcriptional complexes that regulate a 
repressive state of chromatin 114. TRIM66 was recently linked to lung cancer progression 
115 and it is highly overexpressed in osteosarcoma cells 116.  
This information highlights the need to improve our scientific knowledge on TRIM66 as 
it seems to play a key role in cancer. This motivated the study on the potential 
interaction of TRIM66 with chromatin via its PHD-BrD module. The final aim is to provide 
structural knowledge to underpin and drive future targeting of TRIM66 with small 
molecules. 
1.4 BIOPHYSICAL TECHNIQUES 
 
The following section will briefly introduce the main biophysical and biochemical 
techniques used in this thesis work. 
 
1.4.1 Nuclear magnetic resonance (NMR) 
 
Nuclear magnetic resonance spectroscopy is a powerful technique extensively applied 
in structural biology to study biomolecules interactions in solution. Two formats can be 
used: (i) protein-observed NMR and (ii) ligand-observed NMR. 
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1.4.1.1 Protein-based NMR (1H-15N HSQC) 
 
In protein-observed NMR, observable signals belong to the protein which therefore 
requires to be labelled with isotopes as 15N or 13C and 2H 117.  
(1H-15N)-HSQC (Heteronuclear single quantum coherence spectroscopy) is a widely used  
experiment to study the interaction of proteins with either biomolecules or small 
molecules 118. It requires only 15N labelling. In the HSQC spectrum, peaks are generated 
by the transfer of magnetization from the hydrogen of the peptide bond to the 15N nuclei 
through J-coupling. After a time delay (T1), the magnetization is transferred back to the 
hydrogen where is detected. Each amino acid of the protein can univocally generate a 
peak on the HSQC spectrum, with the exception of Prolines and the N-terminal residue 
(that contains NH3+ which exchanges with the solvent and is not observable). The 
assignment of each peak to a residue can be performed using a set of 3D experiments 
that establish sequential connectivities between residues, therefore the resonances can 
be linked to distinct residues and sequentially assigned.  
Temperature, buffer and pH of the solution can significantly affect the position and 
quality of the peaks observed. Also addition of a ligand to the protein can affect the 
position of the protein resonances generating a shift of the peaks involved in the binding 
with the ligand. Shifts can be quantified using the equation (2).  
Δδweighted =  √|ΔδH|2  + |ΔδN|2 ∗ 0.15          (2) 
Where ΔδH and ΔδN are respectively the shift on H and N scale. 
Analysis of the shifts can lead to the mapping of the binding site on the protein. This 
procedure is called chemical shift perturbation (CSPs) 118, 119. CSPs performed with 
increasing concentration of ligands can allow estimation of a dissociation constant (KD), 
using the equation (3).  
𝛥𝛿 obs = 𝛥𝛿 max
{𝐾𝑑+𝑃𝑡+𝐿𝑡− √(𝐾𝑑+𝑃𝑡+𝐿𝑡)2−4𝑃𝑡+𝐿𝑡}
2[𝑃]𝑡
  
[P]t and [L]t are, respectively, the total concentration of protein and ligand; Δδobs is the 
change observed in the shift from the reference spectrum, while Δδmax is the maximum 
shift change obtained upon saturation and is generally calculated from the fitting, since 
it is not always possible to measure it experimentally.  
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This method is applicable only in the case of low affinities (high µM or mM range) in case 
of fast exchange regime (Kex>>Δω) 118. 
HSQC has a high sensitivity which allows detection of very low affinities of binding (mM 
range). The main limitation in the usage of protein-observed NMR in structural biology 
is due to the size of the protein and the large amount of protein required (~ 0.1 mM 
range). High-quality HSQC spectra can be obtained only for proteins with MW < ~40 KDa, 
otherwise peak overlapping and weakening of signal is usually experienced. In some 
cases, it is possible to circumvent these limitations with predeuteration of the protein 
or using TROSY experiments for larger molecules 120.  
 
1.4.1.2 Ligand observed NMR 
 
In the ligand observed NMR, the observable signals are those from the ligand 121. It is a 
more cost effective technique since there is no need to label the protein and small 
amount of ligand and protein is required for the analysis. It is widely applied in fragment 
screening to select and validated low affinity binders 122. In contrast to the protein 
observed NMR, ligand-observed methods do not have an upper limit for the MW of the 
protein analysed; instead, there are limitations when applied to protein with MW < 10 
KDa since with a small protein the changes on the parameters monitored by NMR on 
the small molecule would be smaller, therefore, the response detected may be too small 
to be detected even in a case of binding event 123. 
 
In this thesis three different techniques were used: saturation transfer difference (STD) 
124, Water-Ligand Observed via Gradient SpectroscopY (WaterLOGSY) 125 and relaxation-
edited Carr-Purcell-Meiboom-Gill (CPMG) 126. 
 
In STD experiments, methyl groups of the protein, generally buried in the core of the 
protein and often close to potential binding pockets, are saturated by a selective pulse. 
If a ligand is added to the protein and is interacting with it, magnetization of the 1H nuclei 
is transferred to the adjacent nuclei through dipole-dipole interactions (also known as 
Nuclear Overhauser Effect, or NOE) and to the ligand located in proximity. If the ligand 
is binding to the protein, its signals during this ‘on resonance’ step are fully saturated 
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while non-binding compound will not be affected. Then an ‘off-resonance’ spectrum is 
recorded with pulses where no saturation is performed. Subtraction of the ‘on-
resonance’ spectrum from the off-resonance spectrum will generate the STD spectrum 
with signal only from the saturated ligand and protein. 
 
In WaterLOGSY experiments, the same physical principles underpinning the STD 
experiment apply, however in this case it is bulk water that is excited, rather than 
protein methyl groups. Magnetization can then be transferred from water to the bound 
ligand via NOE effect, either directly or via solvent-exchangeable protons on the protein. 
If the ligand is only interacting with bulky waters it will experience a low NOE of positive 
sign due to its much faster tumbling. Small molecules bound to the protein will 
experience lower tumbling and this will generate a stronger NOE of negative sign. For 
convenience, signals are generally phased in order to have a negative signal for the free 
ligand, meaning that bound ligands will exhibit positive or less negative signals 
compared to a control sample of ligand in the absence of protein. 
 
CPMG experiments rely on the observations that the signal obtained upon addition of 
macromolecules to the ligand sample is reduced if the macromolecule is interacting with 
the ligand. The principle of this phenomenon is in the different relaxation times 
experienced from small molecules and macromolecules. Macromolecules show faster 
dynamics in solution and as a result relax in a shorter time (T2) than a small molecule. 
Therefore, if the ligand binds to the macromolecule, the signal of the ligand population 
that is bound to the small molecule is broadened, filtered out, and ultimately reduced 
in intensity. The technique is dependent on the spin-lock sequence applied (typically 60 
ms) which requires to be comparable or longer to the T2  of the bound ligand.   
 
1.4.2 X-ray crystallography 
 
X-ray crystallography is a powerful technique to gain structural insights into the 
molecular basis of the protein-protein and protein-ligand interactions 127. The 
bottleneck of the process is in the possibility to crystallize the protein or the protein 
complex. Different techniques and strategies have been developed in recent years in 
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order to improve crystallization of proteins but despite this, many proteins are still 
recalcitrant to the process. On the other side, advances in computational methods and 
robotics applied to crystallography have seen a notable increase in throughput, bringing 
this technique to be routinely used in structural biology and drug discovery 128. The 
application of crystallography in drug discovery relies on the possibilities to obtain ligand 
bound crystals of the protein of interest, through either co-crystallization or soaking 129. 
Structure determination can be assessed from the diffraction pattern generated by the 
crystals upon X-ray irradiation. Processing of the diffraction data collected leads to an 
electron density map reconstruction. Interpretation of this map determines the protein 
structure. Observation of differences in electron density between the holo and apo form 
of the protein can bring to the identification of an extra electron density for the bound 
ligand. 
1.4.3 Bio-layer interferometry (BLI) 
 
BioLayer interferometry (BLI) is a label-free optical technique used to study in real time 
the binding of biomolecules 130. It measures interference pattern of white light in 
response to the interaction between molecules. One interaction partner is immobilized 
(for example, using affinity interactions) on a biolayer at the top of a biosensor tip and 
can potentially interact with the analyte in solution. White light is pulsed across the 
biosensor till the biolayer and is then reflected back. Light reflected back is analysed by 
a CCD array detector. If the thickness of the biolayer at the top of the tip changes as 
consequence of interaction between ligand and analyte, the pathway of the light 
reflected increases and this will result in a wavelength shift of the interference pattern 
of the reflected light. The pattern of reflected light is therefore a function of the 
thickness of the bio-layer at the top of the tip. Detection of the wavelength changes over 
time generates the sensorgram.  
 
1.4.4 Surface plasmon resonance (SPR)  
 
Surface plasmon resonance (SPR) is a label-free optical technique used to monitor 
binding between macromolecules and small molecules or other macromolecules 131.  
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SPR is a phenomenon that occurs when polarized light incident on a thin metal layer has 
all the photons with an equal momentum of the surface plasmon of the metal layer. This 
phenomenon verifies at a specific angle, called resonance angle θ, and the optical energy 
is coupled into the evanescent waves of the metal plasmon which irradiate for ~100-200 
nm out of the surface of reflection. Consequently, the intensity of the reflected light is 
reduced. Any change at the interface between metal and solution will change the 
momentum of the surface plasmon and, therefore, the resonance angle. Thus, in SPR 
the observable is the resonance angle of the light reflected from a metal surface of a 
prism. The SPR response can shift as result of interactions happening at the 
metal/solution interface. In SPR, a microchip coated with gold (or any other relevant 
metal) is generally used and it provides the platform for immobilization of the analyte.  
 
Immobilization of the protein in BLI and SPR can be performed through covalent 
coupling with the chip surface using free amine, thiol or carboxylic group. The issue 
related to this chemical method is the resulting random orientation of the protein. The 
usage of affinity tags (as His-tag) can be a valid alternative to overcome the orientation 
problem. Also biotinylation can be used to immobilize the protein on a streptavidine 
coated chip, relying on the strong affinity between biotin and streptavidine. 
Biotinylation is not site specific, this approach may suffer too of the orientation problem 
of the binding site. 
 
BLI and SPR can be both used for KD estimation either via analysis of kinetic parameters 
or steady state analysis. In the first case, suitable for stronger affinity, KD can be 
calculated as the ratio between the kinetic on-rate and off-rate constants. In the second 
case (preferred in case of weak interactions), KD  can be extrapolated from the fitting of 
the equilibrium responses at different concentrations of ligand. 
 
1.4.5 Isothermal titration calorimetry (ITC) 
 
Isothermal titration calorimetry is a biophysical technique that allows the measurement 
of the heat exchanged during a binding reaction between two components (for example, 
protein and small molecule or peptide) 123. The instrument is made of two cells: a 
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reference cell and a sample cell, both inserted in an adiabatic jacket to minimize the 
exchange with the environment. The temperature between the two cells needs to be 
kept constant during the experiment and the power supplied to maintain this balance 
can be considered as a measurement of the heat, released or absorbed, during the 
binding reaction. ITC equipment is armed with a syringe that allows iteratively injections 
of the ligand into the sample cell, in order to measure the heat of binding. The area of 
the peak associated to each injection is proportional to the heat released (exothermic) 
or absorbed (endothermic) during the reaction. The measured heat upon each injection 
is normalized per mole of injectant (typically the ligand) and plotted vs. the molar ratio 
[L]/[P] to generate an isotherm. Analysis of the isotherm allows the extrapolation of 
important thermodynamic parameters: the association binding constant (Ka, which is 
obtained from the slope of the isotherm at the inflection point), ΔH of binding (obtained 
from the extrapolation of the binding isotherm at [L]/[P] = 0) and the stoichiometry n 
value (the molar ratio at the inflection point). ΔG and ΔS can be calculated considering  
equations (4) and (5): 
𝛥𝐺 =  −RT ln 𝐾        (4)     and        𝛥𝐺 =  ΔH − TΔS        (5) 
 
1.4.6 Differential scanning fluorimetry (DSF)  
 
Differential scanning fluorimetry (DSF) 131, also known as thermal shift assay, is a 
technique that monitors the protein denaturation process upon increase of  
temperature 132. DSF allows monitoring the temperature-dependent unfolding process 
of a protein using an environmentally-sensitive fluorescent dye, generally the SYPRO 
Orange. A fluorophore on the dye absorbs light at a definite wavelength and re-emits 
radiation at a longer wavelength (fluorescence). Fluorescence is quenched in water, but 
it increases when the dye binds to hydrophobic surfaces which get exposed as the 
protein unfolds at increasing temperature. Therefore, monitoring the fluorescence 
signal from the dye, it is possible to follow the denaturation process. Relative 
fluorescence unit are plotted against the temperature and a sigmoidal-type curve is 
generated. The inflection point of this curve determines the Tm, that can be 
extrapolated using the Boltzmann equation 132. 
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This technique is largely used to test the stability of a protein under different conditions, 
which provides helpful information to aid protein crystallization. In addition, DSF is also 
used in early lead discovery as primary fragment screening technique. Indeed, when a 
compound binds a protein, it generally stabilizes the protein, with consequent positive 
shifts on the Tm of the denaturation process. It has however been found that also 
destabilizing compounds can be assessed as true binders 133 134. 
1.4.7 AlphaLISa 
 
AlphaLisa is a biochemical assay that relies on the bead-based technology developed by 
PerkinElmer 135. Two kinds of beads are typically used in this assay: donor and acceptor 
beads. Donor beads contains a photosensitizer (phthalocyanine) which upon light 
irradiation at 680 nm is responsible for the excitation of a ground state O2 into singlet 
oxygen. Singlet oxygen is long lived but, upon interaction with the solvent, its lifetime is 
reduced to 4 µs, and as a result it can then irradiate within a distance of ~200 nm. If the 
acceptor bead, which contains europium chelates, is located in proximity of the singlet 
oxygen, it will be excited from the energy released in the decay of the excited state of 
O2, generating subsequent emission at a specific wavelength (615 nm). The distance 
between acceptor and donor beads will depend from the interaction between the 
molecules that are bound to the acceptor and donor beads. In the assay developed in 
this thesis the donor beads are covered with streptavidin that binds biotinylated protein, 
while the acceptor beads are covered with anti-FLAG antibody that binds the Flag-
tagged histone peptide. The emission spectrum for the AlphaLisa assay is in a narrow 
defined range, which reduces interference from the bulk solution. The illumination (680 
nm) and irradiation (615 nm) wavelengths are very specific so interference from the 
background are minimized and a good signal-to-noise is warranted. AlphaLISA is a high-
throughput assay which allows optimal versatility in the design. Its high sensitivity and 
multiplicity of derivatization sites on the beads facilitate detecting even low affinity 
interactions at very low concentrations of ligands, as these can be artificially enhanced 
by proximity induced multivalency of the interaction on the beads. 
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1.4.8 MODifiedTM  Histone Peptide Array 
 
The Modified histone peptide array is a tool used to screen proteins and their 
interactions with histone peptides carrying multiple post-translational modifications. 
The array is constituted of a coated slide glass where 19-mer peptides conjugated to 
cellulose are spotted onto. Each array contains a double copy of 384 unique histone 
modifications of H2A, H2B, H3 and H4. Each peptide can contain up to four different 
combinations of PTMs in order to test influence of adjacent modifications on the 
recognition of a specific PTM. The high peptide density ensures detection of interaction 
also at low binding affinities. The array works much like a Western blot. A protein of 
interest is first incubated with the array for a short time, typically two hours. 
Subsequently, incubation with a primary antibody is carried out to bind the interacting 
protein. Incubation with a conjugated secondary antibody (horseradish peroxidase, 
HRP) is performed and then chemiluminescent detection is performed using a X-ray film. 
A schematic representation of the process is illustrated in Figure 1.13. 
 
 
 
Figure 1.13. Simplified representation of the histone peptide detection on array. 
 
1.5 AIMS OF THE PROJECT 
 
The aim of this project was to assess the ligandability of a class of reader domains, poorly 
investigated up to date. As model of study were chosen the PHD fingers of BAZ2A and 
BAZ2B. To achieve the goal two main aims were pursued. 
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The first aim was to shed light on the recognition mode of the PHD zinc finger of BAZ2A 
and BAZ2B toward the H3 histone-binding partner. The work performed to achieve this 
aim is described in Chapter 1, and it was performed in collaboration with Dr. Alessio 
Bortoluzzi and Dr. Xavier Lucas (Ciulli Group). The paucity of information on the histone 
recognition mode of these PHD domains inspired the work presented in the first result 
chapter of this thesis. 
 
In the second part of the project, the research focussed on interrogating the ligandability 
of the PHD fingers of BAZ2A and BAZ2B with small molecule fragments. Indeed, from 
literature, bromodomains of BAZ2A and BAZ2B had been perceived as ligandable 40, 136-
139 but no study have yet addressed the ligandability of the PHD zinc finger domains of 
these proteins. It was decided to perform a fragment-based approach to address this 
question, with the objective to identify useful targeting points for chemical probe design 
in future. 
 
In a third part of the project, a study was performed to begin to elucidate the interaction 
of the PHD-BrD of other two proteins containing a PHD-Brd reader binding module, 
BAZ1B and TRIM66, towards their potential histone binding partner. Both these proteins 
are known to be involved in diseases but their biological role is not been completely 
elucidated 109, 115, 116, 140. Herein, we believe that gaining insights on the structural basis 
on the binding of their reader domains with the cognate binding partner would help 
towards the identification of potential chemical probes able to target their histone 
interactions.  
Ultimately, chemical probes could be advantageous in disentangling the complex 
biological networks in which these proteins are involved and could provide key 
knowledge for the development of future modulator of the interaction to be used as 
potential molecular therapeutics. 
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CHAPTER 2. 
Molecular basis of histone tail recognition of PHD of 
BAZ2A/B 
 
2.1 MOTIVATION OF THE WORK 
 
Understanding the structural basis of the interaction of a protein with its natural binding 
partner can lead to the identification of hotspots of interaction, involved in the 
molecular recognition. This knowledge could also steer the discovery of potential 
modulators of the protein-protein interaction (PPI). Indeed, for those PPI where the 
binding involves linear peptidic epitope, as in the case of PTMs recognition, the hotspots 
of interaction have the potential to be used to build a rational design for the 
development of chemical probes able to target this PPI 87.  
 
Drug discovery in the field of epigenetic readers and reader domains has largely 
benefited from this structure-based approach that has driven successful results in the 
identification of small molecules able to disrupt protein-protein interactions. 
Remarkable examples are the generation of potent inhibitors of bromodomains 80 or of 
the histone N-methyl-lysine demethylases (KDMs) 141. For instance, the small molecule 
JQ1(+) deeply binds to a pocket on the bromodomains of BET proteins (BRD2, BRD3, 
BRD4 and BRDT) that recognizes specifically the side chain of acetyl-lysine residues 142. 
In this case, this pocket could be considered the hot-spot of the interaction. 
While successful results have been achieved targeting bromodomain readers, less 
progresses have been reported for targeting other reader domains. For example, PHD 
zinc fingers, often found in proximity of a bromodomain, amongst others, constitute a 
class of readers poorly addressed from the drug discovery point. To date, there are only 
two cases, in literature, assessing a systematic study of their ligandability that led to the 
identification of small molecules able to disrupt histone PPI by acting as competitors 
with the histone binding pocket 56, 57. For these readers, the majority of the efforts has 
been placed in exploring and understanding the readout of the PTMs of the histone tails 
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by PHD zinc fingers.  
The work presented in this chapter aimed to shed light on the structural basis of the 
molecular recognition of the H3 histone tail peptide by the PHD zinc finger of BAZ2A and 
BAZ2B, chosen as model systems for this type of study. The ultimate goal of the research 
was to furnish structural knowledge to guide a drug discovery campaign towards the 
identification of chemical probes able to disrupt the reader-histone interactions of this 
class of proteins.  
This study was performed in collaboration with two postdocs of the Ciulli group, Dr. 
Alessio Bortoluzzi and Dr. Xavier Lucas, who contributed toward the preset goals. 
 
2.2 CRYSTAL STRUCTURE OF PHD OF BAZ2A IN COMPLEX WITH H3 10-
MER PEPTIDE 
 
Previous work in the lab had led to the identification of the unmodified H3 histone tail 
as favourite binding partner for the PHD zinc finger of the two proteins BAZ2A/B 45. 
Single methylation on H3K4 was only partially tolerated, whereas double and triple 
methylation abrogated binding 45. Other modifications such as phosphorylation on T3 or 
methylation on R2 of the H3 histone led to a decrease in binding affinity 45. It was also 
observed that different lengths of the H3 peptide, resembling the N-terminal tail 
recognized by these PHD domains, led to different binding affinities. Isothermal titration 
calorimetric (ITC) experiments reported ~4-fold higher affinity for both proteins 
BAZ2A/B PHD towards H3 10-mer (BAZ2A/B KD ~ 50 µM)  compared to the H3 5-mer 
peptide (BAZ2A/B KD ~ 200 µM) 46. HSQC NMR experiments performed by Dr. Alessio 
Bortoluzzi on both proteins BAZ2A/B PHD in complex with H3 10-mer and H3  5-mer 
showed equivalent CSPs maps for the two peptides. No extra shifts were detected for 
the longer peptide 46. HSQC NMR experiments also highlighted that the binding mode 
was essentially conserved between the two proteins, as expected, since BAZ2A/B PHDs 
harbor 66% of sequence identity. 
 
To investigate the interaction of the PHD BAZ2A/B with their cognate histone binding 
partner H3 at atomic detail, I synthesized and purified a 10-mer peptide (ARTKQTARKS), 
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that resembles the N-terminal tail of the histone protein H3, to investigate its binding 
mode at atomic detail. 
The apo form structures of the PHD of BAZ2A/B were previously described 45. It was 
observed that in these crystal forms the histone binding pocket for the PHD of BAZ2A 
was solvent-exposed and free from crystal contacts, at least in two of the four protomers 
of the asymmetric unit (ASU). In contrast, in the BAZ2B PHD crystal packing, access to 
the pocket was partially occluded by crystal contacts made with protomers from the 
adjacent ASU.  
In light of these observations, to elucidate the molecular details of histone H3 N-terminal 
tail recognition, I soaked H3 10-mer peptide into the apo form crystals of the PHD of 
BAZ2A.  
Apo form crystals of BAZ2A PHD (figure 2.1) were obtained mixing equal volume of 
protein and crystallization buffer on a sitting drop plate. Protein was concentrated up to 
6 mg/mL in 20 mM Tris pH 8.0, 200 mM NaCl, 5 mM DTT and 20 µM ZnCl2. Crystallization 
buffer was 2.2 M Na/K phosphate buffer pH 8.5. Crystals were left to grow for one week 
at 20 °C, till they reached their final size. They were subsequently harvested from the 
mother solution and soaked in 10 µL solution of reservoir containing 2 mM of H3 10-mer 
peptide.  After ~16 h, crystals were flash-frozen in liquid nitrogen after few seconds of 
soaking in a solution containing 1.6 mM H3 10-mer peptide and 20% glycerol for 
cryoprotection.  
 
 
 
Figure 2.1. Crystals of BAZ2A PHD 
Drop containing single crystal of PHD BAZ2A in 2.2 M Na/K phosphate buffer pH 8.5.   
 
The structure was solved by isomorphous refinement with the apo form of BAZ2A PHD 
where the search model for the calculation was the chain A (PDB: 4QF2) 45. Details are 
reported in chapter 6.5. 
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Model validation was carried out using MolProbity 143: each protomer had excellent 
stereochemistry confirmed by no outliers in the Ramachandran plot. Crystallographic R- 
factors for the overall structure were 18.5% and 23.5%, respectively, for Rwork and Rfree .  
Table 2.1 summarizes all the crystallographic data processing and refinement statistics 
for the crystal structure of BAZ2A PHD in complex with H3 10-mer peptide. 
 
 
 
R8 
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Figure 2.2. Crystal structure of PHD of BAZ2A in complex with H3 10-mer 46. 
(A) BAZ2A PHD (surface representation) in complex with H3 10-mer (green ribbon). Protein surface is 
coloured according to the electrostatic potential: blue for positive region and red for negative regions. (B) 
Close-up view of the interactions between BAZ2A PHD (grey cartoon) and the H3 10-mer peptide (green 
sticks, labelled in red). Residues of BAZ2A PHD interacting with the peptide are highlighted as sticks and 
labelled in black. The arrow indicates the direction of the macrodipole µ associated with the helical 
formation. (C) The Fo–Fc map for H3 10-mer is shown in grey and contoured at 2.5σ. 
 
Analysis of the structure led to the identification of the main spots involved in the 
binding. The peptide residues A1-K4 form hydrogen bonds with the first β-strand of the 
protein BAZ2A PHD, anchoring the peptide into the pocket. In detail, the first residue of 
H3, A1 is involved in hydrogen bonds with the carbonyl group of the P1714 and G1716, 
while the rest of the peptide is stabilized through hydrogens bonds with the backbone 
of the residues L1693, L1692, L1691, D1688 and E1689 (Fig. 2.2 B). The methyl groups 
of A1 and T3 are involved in hydrophobic contacts with the protein as well as the side 
chain of K4 that is stabilized by hydrophobic interactions with L1691 and V1677 plus 
hydrogen bonds with the carbonyl group of the backbone of G1685 and V1677 and, 
additionally, by long-term interaction with the carboxylic group D1688. The side chain 
of R2 is involved in electrostatic interactions with the side chain of D1695 and in 
hydrogen bond with a structural water, located between the carbonyl group of L1693 
and the carboxylic group of D1695; this water also mediates important interactions of 
the protein with the backbone amide NH of R2 (Fig. 2.3.). The peptide adopts a helical 
fold after residue K4 and till R8, forming an α-helical loop stabilized by intramolecular 
hydrogen bonds between the carboxylic groups of T3 with the amide group of A7 and 
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between K4 and the amide group of R8 (Fig. 2.2. A-B). Also the hydroxyl group of the 
side chains of the residues T3 and T6 are contributing to the stabilization of the peptide 
through the formation of intermolecular hydrogen bonds, respectively, with the amide 
group of T3 and T6 (Fig. 2.2 B). The helical conformation is associated with the formation 
of a helix macrodipole which is the sum of the dipoles directed from the negative pole 
of the oxygen of the peptidic bond to the positive pole of the hydrogen. The arrow in 
figure 2.2 B illustrates the direction of the dipole.  There is no interpretable electron 
density for the side chain of R8 after Cβ, as well as for the residues K9 and S10, implying 
that these are disordered residues (Fig. 2.2 C). Inspection of the asymmetric unit found 
the peptide bound to two of the four protomers, chains A and C, exactly as expected. 
The histone pockets of these two protomers are free from any crystal contact that may 
interfere with the structural rearrangement of the peptide itself. Therefore, it is highly 
unlikely that the helical fold is an artefact of the crystal packing and soaking procedure. 
Conversely, crystal packing occludes the binding sites of the other two protomers, chains 
B and C, where no peptide is found bound. 
No conformational changes were observed between the bound and unbound form of 
the PHD of BAZ2A. This was expected since the PHD pockets, as in other methyllysine 
readers, are defined as static pockets which induce conformational changes into the 
histone peptide without significant perturbation on their own structure 8. 
 
 
Figure 2.3. Detailed view of H3R2 interacting with BAZ2A PHD. 
Close-up view of the intermolecular interactions mediated by the structural water (red sphere) between 
R2 of H3 10-mer peptide (green) and L1693 and D1695 of BAZ2A PHD (grey).  
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This structure (PDB: 5T8R) was compared with the structure, previously solved in the 
Ciulli lab 45, of the PHD of BAZ2A in complex with H3 5-mer peptide ARTKQ (PDB: 4Q6F) 
(figure 2.4). 
 
 
Figure 2.4. Superposition of PHD BAZ2A in complex with H3 10-mer and 5-mer 
peptides. 
PHD of BAZ2A (surface in grey) in complex with H3 5-mer peptide (orange, 4Q6F) and H3 10-mer peptide 
(green, 5T8R). Peptide residues are labelled in red. 
 
Superposition of the structures (Fig. 2.4) did not highlight any further interaction 
established by the longer H3 10-mer peptide directly with the protein. Indeed, residues 
T6-S10 were not involved in binding except for the methyl group on A7 that forms a long 
range hydrophobic contact with the side chain of L1693 (Fig. 2.2 B) 46. 
In light of these results, a reasonable hypothesis formulated to justify the increase of 
affinity of the longer H3 peptide was the stabilization of the helicity of the peptide within 
the histone pocket. This helicity is required to avoid clashes of the peptide onto the 
protein 46.  
 
2.1.1 Co-crystallization efforts of the PHD of BAZ2B -H3 10-mer complex  
 
In order to validate our observations, arising from NMR data, on the binding mode of 
the H3 N-terminal tail by the PHD of BAZ2B as well, I performed several crystallization 
trials. As mentioned above, the inspection of the histone pocket within the apo form of 
the crystals of the PHD of BAZ2B (PDB: 4QF3) showed this pocket as partially occluded 
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by crystal contacts with protomers of the symmetry related unit. This discouraged 
soaking attempts, and I preferentially undertook co-crystallization. 
Three sparse matrix screening were used: Proplex, Classic and PegRX, each at 4°C and 
20°C. 
Two different protein concentrations were used ~6mg/mL and ~14 mg/mL in a protein: 
peptide ratio of 1:5. At 20°C the majority of the drops showed amorphous or 
microcrystalline precipitate. Instead, at 6mg/mL drops appeared mainly to be clear as 
well as at 4°C, despite the high concentration of protein. 
Interesting hits were obtained from one of the conditions (G1 from classic screening: 0.1 
M HEPES sodium salt pH 7.5, 2% PEG400 and 2M (NH4)2SO4 ) (Fig. 2.5). The high 
concentration of the salt raised some doubts about the nature of the crystal hits. This 
was elucidated using the Izit crystal dye (Hampton) (Fig. 2.5 B). Izit is a small molecule 
dye which fills the solvent channels in protein crystals, colouring the crystals in blue. If 
the crystals are made of protein molecules, this dye would leave a clear drop with blue 
crystals. Salt crystals do not possess these large solvent channels and the dye cannot 
enter the crystal. Thus, in case of a salt crystal this will remain clear and the drop will 
appear blue. Izit crystal dye was added to the crystal found and after ~1 h incubation the 
crystals remained clear (Figure 2.5 B) confirming that these were salt crystals. 
 
 
 
 
 
Figure 2.5. Izit test with crystal hits. 
(A) Crystal hits observed from G1 condition in Classic screening at 20°C. (B) Crystal hits after Izit uniformly 
coloured the drop. 
 
The majority of the drops from these co-crystallization screening showed only 
microcrystalline formations, heavy precipitation or clear drops. No other potential hits 
were observed. 
A B 
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2.3 CHANGE IN H3 N-TERMINAL TAIL HELICITY CORRELATE WITH 
DIFFERENT BINDING AFFINITIES FOR BAZ2A/B PHD ZINC FINGER 
 
To gain a better understanding of the histone molecular recognition by the PHD of 
BAZ2A, the energetic contribution of the residues on H3 involved in binding was 
investigated [7]. An alanine scanning was performed, by Manuel Blank and Dr. Alessio 
Bortoluzzi in the Ciulli lab, mutating to alanine residues from 2 to 6 on the H3 peptide 
46. This experiment highlighted that that residues R2 and T3 were essential for binding 
46 while K4-T6 were found not critical for the binding but, unexpectedly, double 
mutation to alanine (H3 - ARTAATARKS) increased the affinities for both BAZ2A/B PHDs  
compared to the wild-type H3 46. These results were unexpected since the removal of 
the K4 sidechain was predicted to lead to a decrease of binding as consequence of loss 
of contacts between peptide and PHD (Fig. 2.2 B).  
Therefore, the hypothesis was that the K4A and Q5A mutations could stabilize the 
helicity of the peptide, indeed, alanine is known to be a helix-stabilizing residue 144. To 
support this idea, K4G and Q5G double mutations on H3 (ARTGGTARKS) showed 
remarkable reduction of affinity in the ITC experiments performed by Dr. Alessio 
Bortoluzzi 46. This was expected since glycine has the lowest helix propensity among all 
the natural amino acids 144. 
To further validate these observations and gaining more details at molecular level of this 
interaction, I solved the crystal structure of the PHD of BAZ2A in complex with H3 10-
mer AA mutant at 1.9 Å.  
The apo form crystal of BAZ2A PHD was soaked overnight in a solution containing 
crystallization buffer (2.2 M Na/K phosphate pH 8.5) and 2.5 mM H3 AA mutant 10-mer 
peptide and subsequently flash frozen in liquid nitrogen after few seconds soaking in the 
reservoir with 20% glycerol as cryoprotectant. Structure of the complex was solved 
(figure 2.6) following the same procedure described in chapter 6.5, as for the complex 
BAZ2A PHD-H3 10-mer WT. Crystallographic data of the AA mutant are reported in Table 
2.1.  
Inspection of the structure led to the consideration that the helical binding mode for H3 
10-mer peptide AA mutant was conserved compared to the wild-type (figure 2.7 A-C). 
Superposition of the two peptide bound forms of BAZ2A PHD showed that no changes 
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in the conformation of the PHD pocket were observed between the proteins, which 
perfectly superimposed. The hydrogen bond distances between protein and peptide 
were analysed and for the first three residues (ART) they were the same in both peptides 
(values are reported in figure 2.7 B). Remarkable differences in H-bonds distance were 
observed between protein and peptide in the region of the mutated residues (figure 2.7 
B and C). Indeed the intermolecular H-bond involving the N-H of H3K4 and H3A4 are 
respectively of 3.0 Å and 2.4 Å and the H-bonds between the C=O in D1688 and NH from 
H3Q5 and H3A5 are respectively 3.4 Å and 2.5 Å. Shorter distances were observed also 
for the intermolecular peptide H-bonds within the double mutant peptide compared to 
the wild-type (figure 2.7 A).  These shorter distances suggested a tighter conformation 
of the peptide within the pocket which could account for the increased affinity for the 
alanine mutant peptide (H3 AA mut). 
 
 
Figure 2.6. Crystal structure of BAZ2A PHD in complex with H3_AA_mutant. 
Crystal structure of BAZ2A PHD (in gray) in complex with H3 10-mer double mutant (in pink). (A) The Fo–
Fc map contoured at 2.5σ (shown in gray) for H3 10-mer AA mutant. 
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Figure 2.7. A. Superposition of the complex of BAZ2A PHD with H3 10-mer wild-type 
and mutant peptide. 
Superposition of PHD BAZ2A (grey) in complex with H3 10-mer (green sticks, 5T8R) and H3 10-mer AA 
mutant (pink sticks, structure not deposited). Intramolecular peptide bonds are drawn in dash and 
distances are reported in Å, in green for H3wt and in pink for H3 mutant. 
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Figure 2.7 B-C. Superposition of the complex of BAZ2A PHD with H3 10-mer wild-type 
and mutant peptide. 
Superposition of PHD BAZ2A (grey) in complex with H3 10-mer (green sticks, 5T8R) and H3 10-mer AA 
mutant (pink sticks, structure not yet deposited). Hydrogen bonds are in dashed lines and distance in Å.  
In panels B and C, differences of the intermolecular distances. Residues are labelled in black and the 
peptide is in green for the wt H3 10-mer and in pink for the H3 10-mer AA mutant.  
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Protein ID BAZ2A PHD BAZ2A PHD 
Ligand ARTKQTARKS ARTAATARKS 
Processing statistics  
Space Group P43212 P43212 
Unit cell parameters  
a, b, c (Å) 72.61, 72.61, 99.43 72.7, 72.7, 99.9 
α, β, γ (°) 90, 90, 90 90, 90, 90 
Resolution  limits (Å) 45.62 -2.4 (2.49 – 2.4) 45.7 -1.9 (1.9 – 1.94) 
Unique observations 10901 (1132) 21777 (1371) 
Completeness (%) 99.6 (100) 99.9 (99.8) 
Redundancy 5.4 (5.8) 9.7 (10.3) 
Rmerge (%) 10.2 (72.8) 9.8 (96) 
I/σI 9.3 (2.3) 12.3 (2.6) 
CC1/2 (%) 99.4 (71.8) 99.5 (79.4) 
Wavelength (Å) 0.9762 0.9762 
Refinement statistics  
Rwork/Rfree (%) 18.5  / 23.5 19.3 / 24.5  
Average B factors (Å)2 52.13 52.13 
RMSD bond (Å) 0.01 0.02 
RMSD angle (°) 1.50 2.50 
Ramachandran Statistics  
Favored (%) 97.2 94.9 
Allowed (%) 2.8 9 
Outliers (%) 0.0 0.9 
PDB 5T8R XXXX 
 
Table 2.1. Crystallographic data processing and refinement statistics 46. 
Value in parenthesis are relative to the highest resolution shell. 
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2.4 IDENTIFICATION OF THE ACIDIC WALL ON THE PHD OF BAZ2A/B AND 
ITS ROLE IN THE MOLECULAR RECOGNITION OF H3 PEPTIDE 
 
The helical conformation adopted by the peptide was found as a critical feature essential 
to avoid the clash of the histone peptide with the 310 helix of the histone pocket. 
Moreover, structural analysis led to the observation that the 310 helix or a small turn, 
preceding the first β-strand of the PHD, is characteristic of all those PHDs recognizing 
the histone tail in α-helical conformation. Bioinformatic analysis performed by Dr. 
Bortoluzzi, highlighted that this region is often characterized by an acidic patch which 
was found mutually exclusive with the conserved tryptophan, needed for the K4me 
recognition. This region was named as ‘acidic wall’, since it was found to contain at least 
one acidic residue and  prevent the binding of the peptide in an extended conformation 
46. 
 
In order to gain a better understanding on the role of this newly identified acidic patch 
on the PHD of BAZ2A/B towards the recognition of the H3 N-terminal tail, it was decided 
to perform some mutagenesis experiments on the proteins.  Residues E1689 on BAZ2A 
and E1944 on BAZ2B were mutated to Gln and Lys in order to neutralize and/or invert 
the negative charge of the acidic wall. In order to compare the binding affinity of the H3 
peptide toward the mutant proteins relative to wild type, I performed ITC experiments. 
Since the helical fold of the acidic wall was thought to be an essential structural feature 
to regulate the binding with H3 peptide, it was expected that a disruption of this wall 
could have led to a reduction of affinity between protein and peptide.  
ITC were performed titrating peptide into proteins, in triplicate or duplicate. 
Peptide/protein concentrations were kept consistently identical through all the 
titrations in order to compare them appropriately. 
Mutation to Gln of the acidic wall of BAZ2B led to ~8-fold reduction in affinity compared 
to the wild type, while the effect upon the same mutation on BAZ2A was less 
pronounced. Inversion of charge with mutation to Lys completely abrogated binding for 
the PHD of BAZ2B and reduced the affinity for the PHD of BAZ2A of ~2.5 fold (Table 1.3). 
Therefore in BAZ2B complete disruption of binding was reported while the acidic wall 
mutant in BAZ2A weakened binding. This could perhaps suggest that adjacent residues 
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could have compensating the effect on the mutation on the acidic wall. Indeed, it was 
further observed in the structure of the PHD BAZ2A in complex with H3 that the residue 
flanking E1689 is also an acidic residue D1688 and its side chain contributes to the 
formation of the pocket that accommodates the side chain of K4 onto the H3 peptide. 
In addition, despite the fact that the electron density for R8 on H3 peptide in our 
structure is not visible, superposition of the complex BAZ2A PHD - H3 10-mer peptide 
with the structure of MORF DPF in complex with H3K14bu 145 (PDB: 5U2J) suggests the 
formation of a salt bridge interaction between the side chain of R8 and the carboxylate 
group of D1688 (Figure 2.8).  
 
 
 
Figure 2.8. Superposition of BAZ2A PHD in complex with H3 peptide with the MORF 
DPF in complex with H3K14bu. 
Superposition of the cartoon representation of PHD BAZ2A (grey): H3 10-mer (green) complex (PDB 
5T8R) with the MORF DPF (yellow): H3K14bu (aqua green) complex. In stick the residues involved in the 
salt-bridge interaction. 
 
Based on these observations, it was surmised that this residue could actually 
compensate the E1689Q mutation on BAZ2A. Consequently, I designed and expressed 
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another mutant carrying the double mutation D1688N/E1689Q, in order to neutralize 
the charge on the 310 helix of BAZ2A. ITC experiments showed that the double mutation 
reduced the binding affinity of BAZ2A towards H3 10-mer up to ~17-fold.  
Table 2.2 summarizes the thermodynamic binding parameters for the complex 
formation of H3 wt 10-mer with the mutants of BAZ2A/B PHD.  
Figure 2.9 shows the ITC binding curves of the titration of H3 10-mer peptide into PHD 
zinc finger of BAZ2A/B. ITC titrations were performed and analysed as described in 
Chapter 6.  Correct folding of the mutants was checked by 1D 1H NMR spectra (A.7 in 
appendix). 
 
 
PROTEIN 
 
KD (µM) 
 
N 
 
ΔH 
(KCAL/MOL) 
 
TΔS 
(KCAL/MOL) 
 
ΔG 
(KCAL/MOL) 
 
BAZ2A PHD WT 
 
48 ±  2 
 
1.29 ± 0.01 
 
 
-7.9 ±0.1 
 
-2.0 ±0.1 
 
-5.90 ±0.02 
 
BAZ2A PHD 
E1689Q 
 
83 ± 7 
 
1.02 ±0.03 
 
-9.6 ± 0.7 
 
-4.0 ± 0.8 
 
-5.57 ± 0.05 
 
BAZ2A PHD 
E1689K * 
 
116 ± 6 
 
1.1 ±0.4 
 
-7.6 ±2.5 
 
-2.2 ±0.4 
 
-5.37 ± 0.03 
 
BAZ2A PHD 
D1688N/E1689Q 
 
810 ± 50 
 
1¥ 
 
-9.0 ± 1.2 
 
-4.8 ± 1.2 
 
-4.22 ± 0.04 
 
BAZ2B PHD WT 
 
 
47 ± 2 
 
1.17 ±0.02 
 
-8.3 ±0.2 
 
-2.4 ±0.2 
 
-5.90 ±0.03 
 
BAZ2B PHD 
E1944Q 
 
660 ± 60 
 
1¥ 
 
-8.5 ±1.1 
 
-4.1 ± 1.1 
 
-4.34 ±0.06 
 
BAZ2B PHD 
E1944K 
 
>1000 
 
N.D. 
 
N.D. 
 
N.D. 
 
N.D. 
 
Table 2.2. Summary of the ITC-based binding parameters for the formation of the complex of 
H3 WT 10-mer peptide with BAZ2A/B PHD mutants 46.  
All the titrations were performed in triplicate, except where differently specified, and values are reported 
as the means ± s.e.m. Temperature of titration was 25°C. 
N.D. = not determined 
¥ N value was fixed at 1. 
* titrations were performed in duplicate. 
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Figure 2.9. Acidic wall on BAZ2A/B PHDs and H3 N-terminal tail recognition.  
ITC binding curves showing integrated ΔH (kcal/mol) values plotted versus the peptide/protein molar 
ratio. H3 10-mer peptide was titrated into wild-type and mutants of BAZ2A PHD (A) and BAZ2B PHD (B). 
Detailed legends for the mutations are reported in each panel. 
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2.5 STUDIES TOWARD ELUCIDATING THE BINDING MODE OF H3 TAIL 
WITH TANDEM PHD-BRD OF BAZ2A/B  
 
 Wang et al. in their work 146 showed that PTMs can affect the secondary structure of 
the histones, for example, acetylation was found to increase the α-helical content of the 
histone tail. In light of this and of the outcomes of the work herein presented, it might 
be theorised that also the secondary structure of the histone proteins could play a role 
in epigenetic regulation. Indeed, the structural rearrangement of the N-terminal histone 
tails, through either induction or destabilization of the helicity, could constitute a further 
layer of regulation for the epigenetic process, beyond or in cross-talk with PTMs 
recognition. 
Indeed, there are examples in literature reporting how the helical folding of the H3 
peptide is important for the simultaneous recognition of different region of the H3 
histone by two adjacent reader domains. For example, this is the case of the PHD zinc 
finger and Tudor domain of UHRF1, where the helical conformation assumed upon the 
binding to the PHD is essential for the recognition of methylated K9 by the Tudor domain 
147. Another example is the simultaneous recognition of the unmodified K4 and acylated 
K14 on H3 by the double PHD zinc finger of MOZ or MORF; for both proteins the helical 
folding of H3 is found to be critical for the binding mode 58, 145 . 
 
These observations, coupled to the results presented so far in this chapter, motivated 
further work aimed to shed new light and understanding of the combinatorial readout 
in the context of the combined PHD zinc finger and bromodomain tandem module (PHD-
BrD) of BAZ2A/B proteins. Since it was previously shown that the adjacent bromodomain 
in both BAZ2A/B recognizes K14ac on H3 45, 136, it is reasonable to postulate that the 
helical fold of H3 could play a role in the simultaneous recognition of both unmodified 
K4 and acetylated K14, respectively, within the same histone tail by PHD and 
bromodomain. This hypothesis would be consistent with data obtained so far showing 
that the two domains are not interacting 45 but would rather come close, facing each 
other, to bind the related PTMs without necessarily showing any interactions between 
themselves, as proposed by the SAXS data in antecedent work 45.  
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In order to investigate on the potential cooperative effect of the combinatorial readout 
of the tandem module of BAZ2A/B, I performed ITC experiments. Tandem modules of 
both proteins were expressed. BAZ2B PHD-BrD, upon purification, showed a good level 
of purity to be used in biophysical experiments, as reported in the SDS-page of figure 2. 
10. In contrast, BAZ2A PHD-BrD showed to be more unstable and prone to degradation 
as evidenced by SDS-page gel and gel filtration profile, therefore  this was not pursued 
for biophysical experiments.  
 
 
 
Figure 2.10. Gel filtration elution profile and SDS page gel of BAZ2A and BAZ2B PHD-
BrD tandem. 
 
A 20-mer peptide, resembling the H3 tail and carrying the acetylation mark on K14 
(ARTKQTARKSTGG-Kac-APRKQL), was synthetized and purified (details in Chapter 6.3) 
and used as a tool for structural investigation. With these molecules in hand, I set to 
perform ITC experiments, titrating the peptide into the tandem protein (Chapter 6.4). A 
summary of the thermodynamic parameters measured by ITC is reported in Table 2.3 
and raw data are shown in figure 2.11. 
 
Protein KD (µM) N ΔH (kcal/mol) TΔS (kcal/mol) ΔG (kcal/mol) 
BAZ2B 
Tandem 
27.5 ± 1.3 1.62 ± 0.01 -6.5 ± 0.1 -0.25 ± 0.03 -6.2 ± 0.1 
 
Table 2.3. Summary of thermodynamic binding parameters.  
ITC-based binding parameters for complex formation between 20-mer H3K14ac peptide and BAZ2B 
PHD-BrD tandem. Error values reported on KD, N, and ΔH are generated by the Origin program and 
74 
 
reflect the quality of the fit between the nonlinear least-squares curve and the experimental data.  
 
 
Figure 2.11. ITC binding curve if H3K14ac 20-mer vs BAZ2B PHD-BrD tandem. 
ITC binding curve of H3K14ac 20-mer titrated into BAZ2B is shown in black and the relevant reference 
titrations (peptide into buffer) in green, in the upper panel. The integrated ΔH (kcal/mol) values are 
plotted versus the peptide/protein molar ratio and shown in the lower panel. 
 
Stoichiometry value N ~ 1.6 can be explained considering the model in figure 2.12 and 
admitting a binding mode intermediate between the two states A and B, with a 
prevalence of the state B being populated at higher peptide concentration. 
 
Figure 2.12. Two-state model of binding. 
Cis (A) or trans (B) mode of binding of the PHD-BrD tandem. 
 
In case of 1:1 binding event (case A) where the two reader domains from the same 
tandem protein simultaneously recognize hallmarks on the same peptide, an increase 
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of affinity due to a cooperative effect is expected. In our case the KD value did not report 
any significant increase in binding potency compared to the binding between the single 
domain and the 10-mer peptide (KD ~47 µM) 46 and more importantly no significant 
increase in the heat signal value was observed (ΔH ~-8.3 kcal/mol for the PHD and ΔH ~-
6.5 kcal/mol for the tandem module).  
The high energy required to bring close the individual domains PHD and BrD may 
account for the marginal energetic gain of the binding of the tandem to the H3K14ac 20-
mer. Indeed, the long unstructured linker between the two may favour a binding in trans 
mode (case B in figure 2.12) and constitute an energetic barrier to the cis binding mode. 
Analysis of the profile of the ITC shows the presence of a shoulder at the end of the each 
peak that might be accounted for a structural rearrangement event happening during 
the binding of the PHD-BD tandem to the H3K14ac 20-mer peptide. The model built in 
figure 2.13 can be representative of the orientation that the two domain may assume 
upon binding.  
 
 
 
Figure 2.13. Proposed cis model for the binding of BAZ2B to the H3 histone tail. 
 
Conversely, there are examples in literature of cooperative binding of PHD-BrD tandem 
(TRIM24 or TRIM33) showing enhanced affinity for the H3 peptide with the double 
marks compared to the binding of a single domain for the single-mark peptide 62. All 
these observations pointed toward a prevailing of state B where the two reader domains 
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might separately bind the two marks on two different histone molecules. However, 
reasonable population of state A (cis recognition) at the early titration points of the 
curve cannot be excluded, indeed the cis recognition mode (figure 2.13) may still happen 
inside the cell. 
 
In order to further gain insights on the binding mode, several crystallization attempts 
were performed with the goal to co-crystallize the complex PHD-BrD BAZ2B tandem - 
H3K14ac 20-mer, however these has remained inconclusive to date. The difficulty to co-
crystallize this system could be justified assuming the promiscuous binding mode that 
leads to a heterogeneous complex intermediate between state A and B as in figure 2.11. 
 
Nevertheless, the evidence to support the binding mode of the PHD-BD tandem of 
BAZ2A/B for histone H3 remains preliminary and requires further investigation. 
2.6 DISCUSSION 
 
This study centred on the molecular recognition mode of the H3 N-terminal tail by PHD 
zinc fingers of BAZ2A and BAZ2B. The major findings of my work was the solution of the 
crystal structure of the complex of BAZ2A PHD with H3 peptide which led to the 
discovery of the peptide helical binding mode. These findings motivated investigation of 
crystal structures available in the PDB of PHD domains with bound histone peptides. 
These analyses led to the realisation that PHD domains binding histone tails in a helical 
fold, as the case of the PHD of BAZ2A/B, are characterized by the presence of an acidic 
patch, containing Asp, Glu or both residues, on the loop or helical turn just before the 
first β-strand of the PHD 46. The importance of this acidic patch was confirmed by 
mutagenesis experiments. I was able to show that indeed inversion or neutralization of 
the negative charge(s) led to a drop or complete loss of binding. Further work 
investigating artificial mutations on K4 or Q5, to Ala or Gly, to stabilize or disrupt, 
respectively, the peptide helicity, revealed an increase or decrease in binding affinity, 
consistent with the hypothesis that histone tail helicity plays a central role in the 
molecular recognition. These mutagenesis approaches on either the acidic wall patch of 
histone tail themselves could provide rapid and straightforward ways to identify other 
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reader domains that might recognize H3 in helical fold, prior to committing to detailed 
structural studies. The results of this study were recently published in Biochem J. 46 
 
The observations from this work have led to speculation that the helicity of the histone 
tail could represent an additional layer of regulation within the epigenetic processes. 
There are several studies which describe the importance of the helicity on H3 to 
guarantee the combinatorial readout of neighbouring domains. In this context, an 
investigation of the role of the secondary structure of the histone tail H3 upon 
recognition by the PHD-BD tandem of BAZ2B was conducted. The model here proposed 
seems to be compatible with a trans recognition mode of the histone tail on the 
nucleosome. According to this model,  one protein,  using two distinct reader domains 
(PHD and bromodomain) could bring closer two different nucleosomes through the 
binding of each domain to a distinct H3 tail. Although this data point toward a prevalent 
trans mode hypothesis of binding, the cis mode cannot be excluded, especially 
considering a recent work published by Kostrhon et al., about the role of the linker on 
BAZ2B-histone interaction 148. The authors found that the linker may negatively regulate 
the binding of the BrD to H3K14ac in the context of the tandem. This work has also 
opened another interrogative on the importance of the function of the long linker 
between two domains. Indeed, it is possible that the long linker region between the two 
reader domains acts as a scaffold to recruit partner proteins, leading to the formation 
of a larger complex. In this context, pull-down experiments followed by mass 
spectrometry analysis could help to elucidate this question. 
 
Finally, the disclosure of this structural work has implications for drug discovery. Indeed, 
the PHD zinc finger still remain a class of reader domain poorly targeted and 
characterized by perceived lower druggability when compared to other reader domain 
families such as bromodomains. Taking advantage of the knowledge gained to date,  the 
use of peptides able to stabilize the helical conformation e.g. stapled peptides 149, 150 or 
the use of a pharmacophore able to mimic the helical motif 151 in the histone pocket, 
could be a valid approach to design and develop chemical probes able to disrupt the 
Histone-PHD interaction in BAZ2A and BAZ2B PHD.  
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CHAPTER 3. 
PROBING THE LIGANDABILITY OF THE PHD ZINC FINGER 
DOMAIN OF BAZ2A AND BAZ2B  
3.1 MOTIVATION OF THE WORK 
 
The aim of the work presented in this chapter is to explore the ligandability, i.e. their 
propensity to bind to small molecules, of two epigenetic reader domains: PHD of BAZ2A 
and BAZ2B. The ultimate goal of this project will be the development of chemical probes 
able to selectively bind these reader domains and which could be used as tools to 
investigate the activity and biological function of BAZ2A and BAZ2B proteins. 
 
Targeting the PHD of BAZ2A/B has been shown to be challenging to date because of 
their shallow binding sites. Preliminary efforts in the lab with a fragment screening 
approach, involving high-throughput screening by biolayer interferometry (BLI) and 
differential scanning fluorimetry (DSF), had remained inconclusive. To view this in a 
different light, it was decided to adopt an alternative approach, performing a virtual 
screening and further biophysical validation, in order to aid assessment of the 
ligandability of these reader domains. 
 
In this chapter, I will introduce the biophysical validation and structural characterization 
which I performed to validate some of the fragment hits previously identified by in silico 
screening. The two main techniques used were NMR and X-ray crystallography. The first 
one allowed a primary validation and estimation of a KD of binding, while crystallography 
confirmed the hypothesis of binding formulated by NMR. Despite the high similarity 
between the two PHD proteins, some differences in the binding modes were observed. 
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3.2 CRYSTAL STRUCTURE OF THE TRIPEPTIDE ‘ART’ BOUND TO THE PHD 
OF BAZ2A 
 
The alanine scan on the H3 10-mer peptide (discussed in Chapter 2) highlighted that the 
first three residues ART of the H3 histone tail are essential for the binding to the PHD 
domain of BAZ2A/B 46. In order to elucidate the binding mode of this key N-terminal 
region of the H3 tail, I solved the crystal structure of the PHD of BAZ2A in complex with 
the tripeptide ‘ART’. The complex was obtained by soaking overnight crystals of BAZ2A 
PHD in a solution containing the reservoir and supplemented with 20 mM ART peptide. 
The structure was solved following the same procedure used for PHD BAZ2A in complex 
with H3 10-mer peptide. Crystallographic data are summarized in Table 3.11. 
Inspection of the structure led to the observation that three of the four protomers in 
the ASU (chains A, B and D) showed an extra electron density to fit the tripeptide ART. 
This is in contrast with the complex with H3 10-mer, in which only two chains (A and D) 
were binding to the peptide 46. This can be rationalized as the short ART peptide 
occupies a smaller area and could have greater access than the H3 10-mer peptide 
through the solvent channels. Chain A and D are solvent exposed, while chain B and C 
are partially occupied by contacts with an adjacent asymmetric unit. 
The analysis of the structure highlighted the hot spots of binding, reported in figure 3.1. 
The terminal amino group of A1 was found interacting through H-bonds and 
electrostatic interactions with the carbonyl of the backbone of P1714, E1715 and G1716. 
The carbonyl group of R2 was interacting with the N-H of L1693 while the N-H group of 
R2 is in contact with a structural water molecule, W1, located between the carbonyl of 
L1693 and the side chain of D1695. The hydroxyl group on the side chain of T3 is found 
to interact with the backbone carbonyl in E1689. The peptide is amidated at the C-
terminus and the amidic nitrogen displays interaction with the backbone carbonyl of 
L1691 and D1688 
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Figure 3.1 Complex of PHD of BAZ2A with H3 3-mer peptide. 
(A) Surface representation of the crystal structure BAZ2A PHD (wheat) in complex with ART (green sticks) 
tripeptide. Highlighted in sticks protein residues interacting with the peptide. (B) Fo-Fc map for the 3-mer 
peptide is in grey and countered at 3σ. 
 
The side chain of R2 seemed to be influenced by the crystal contacts present in the 
pocket. Because this residue was highlighted from the alanine scanning as an important 
residue for the interaction with the protein, the expectation was to find the guanidinium 
group interacting in a well-defined region of the binding site, making stable contacts. 
Instead, I observed that in the ART chains modelled in the histone pocket of protomers 
A and D, the electron density was clearly defined only up to the Cβ atom of the side 
chain, indicating that the rest of the residue does not make strong interactions. 
Moreover, in protomers A and D, it was observed that the carbonyl group of C1694 and 
C1697 make crystal contacts with the side chain of K1676 of chain C belonging to an 
adjacent ASU (figure 3.2 A). The presence of this contact in this position could generate 
electrostatic repulsion to the guanidinium group, which would be destabilized from the 
expected position interacting with the carbonyl from L1693 and the side chain of D1695.  
Protomer B has the histone pocket partially blocked, but despite this, clear electron 
density was observed and a molecule of ART tripeptide was built in. Modelling of the 
ART motif in this pocket showed that while the backbone was found in the expected 
position, the side chain of R2 was satisfactorily modelled in a way to make crystal 
contacts with the 310 helix and β-strand of another protomer belonging to an adjacent 
ASU (figure 3.2 B). In particular, I observed H-bonds formation between the guanidinium 
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group of R2 and the carbonyl group of L1691 and D1688 of the histone pocket of an 
adjacent ASU. Because the presence of this crystal contact, no peptide was observed in 
chain C. 
 
 
 
 
Figure 3.2. Crystal contacts between adjacent ASU. 
(A) Chain D of one ASU is reported as wheat cartoon. In stick the two residues making crystal contacts 
with K1676 in chain C form the adjacent ASU. (B) R2 of the H3 3-mer peptide in complex with protomer B 
making crystal contacts with protomer C of the adjacent ASU. 
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3.2.1 Superposition of H3 10-mer complex with H3 3-mer complex 
 
Superposition of the structures of BAZ2A PHD in complex with H3 10-mer and in complex 
with H3 3-mer (Figure 3.3) showed that the binding mode for the first three residues is 
retained in both structures, as expected, since they are critical to anchor the whole H3 
tail to the PHD finger.   
 
 
 
Figure 3.3. Superposition of BAZ2A PHD in complex with H3 10-mer peptide (PDB: 
5T8R) and H3 3-mer peptide. Superposition of the crystal structure of BAZ2A PHD (wheat) in 
complex with ART (green sticks) tripeptide and H3 10-mer peptide (cyan).  Highlighted in sticks protein 
residues interacting with the peptides.  
 
The ART motif occupies an area that seemed adequate to accommodate fragment-like 
molecules. This observation would suggest that it might be possible to target the histone 
pocket of the PHDs with drug-like small molecules.  
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3.3 IDENTIFICATION OF DRUGGABLE POCKETS AND HITS FROM IN 
SILICO SCREENING 
 
Using the FTMap software [2], Dr. Xavier Lucas identified two potential druggable 
pockets in the PHD of BAZ2A/B. The first pocket was the histone binding pocket 45, 46, 
perceived as druggable from the software, and here defined as pocket one. This is 
primarily acidic (figure 3.4). A second pocket was also found as druggable; this is located 
on the opposite side of the first pocket, on the rear of the protein (Figure 3.4). This 
second pocket is primarily basic and enriched with aromatic residues such as tryptophan 
and histidine. 
 
 
 
Figure 3.4. Pockets perceived as druggable from FTMap on BAZ2A PHD. 
Interaction maps identified from FTMap software on PHD of BAZ2A. In green the FTMap of the histone 
pocket and in purple the FTMap of the second pocket. 
 
In silico fragment screening was performed by Dr. Xavier Lucas using a virtual library of 
~1,200 fragment-sized commercially available compounds. The final selection was 
trimmed by choosing only fragments that conformed to a set of criteria: calculated 
solubility in water (> 10 mM), chemical complexity (no more than two stereogenic 
centres), molecular weight (prioritizing lower number of heavy atoms) and fragments 
with opportunities for chemical modification.   
Visual inspection of the virtual screening results led to 35 interesting candidates. 
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Amongst these, 15 fragments were selected from the in-house library, while additional 
four compounds from the virtual library were purchased (Table 3.1), for validation. 
 
Table 3.1. List of fragments selected by in silico screening. 
Chemical structure of the 19 fragments selected from virtual screening. 
 
3.4 NMR VALIDATION 
 
3.4.1 (15N-1H)-HSQC validation 
 
The pool of fragments identified in this first pilot screening was, in first instance, 
validated by (15N-1H)-heteronuclear single-quantum correlation (HSQC). This technique 
was chosen because it is one of the most sensitive to low-affinity interactions 152. 
Moreover, it can provide information on the  region of binding through chemical shift 
mapping. The small size of both proteins (6.5 kDa) allowed to generate high quality (15N-
1H)-HSQC spectra of PHD of BAZ2A and BAZ2B, which resonances were previously 
assigned 46.  
15N -labelled protein was incubated with 5 mM of each fragment at final concentration 
of 1.25% (v/v) of d6-DMSO. Spectra of proteins incubated with fragment were then 
overlaid with the spectrum of the apo form of the protein, obtained in presence of 
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matching 1.25% d6-DMSO. Fragments showing chemical shift perturbation (CSP) in at 
least one peak, as in Figure 3.5, were considered binders. Those that did not show any 
relevant shift were discarded from the analysis. Fragment 4 was also discarded because 
not soluble in the presence of protein even at low concentrations as 500 µM. 
 
Figure 3.5. Example of CSPs induced upon fragment addition to PHD of BAZ2B. 
Overlay of (15N-1H)-HSQC spectra recorded on the apo form of 15N-BAZ2B PHD (blue) and upon addition of 
fragment (red). Arrows represent the direction of the shift of the peaks.  
 
Amongst this small pool of fragments, seven compounds showed binding towards the 
PHD of BAZ2A and eight fragments showed binding to BAZ2B; most binders were 
common to the two PHDs, with just few fragments selectively binding BAZ2A or BAZ2B. 
Table 3.2 summarizes the results of this primary validation step. 
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Table 3.2. List of fragments selected by in silico screening. 
Chemical structure of the 19 fragments selected from virtual screening, highlighting those validated by 
HSQC. In red fragments found as communal hits for both PHDs BAZ2A/B. In blue are fragments binding 
only to PHD of BAZ2B, and in green fragment binding only PHD BAZ2A. 
 
CSPs were plotted for each residue on a histogram and mapped on the structure of 
BAZ2A/B PHDs by colouring residues in red for the strong shifts and in orange for the 
medium shift.  All those shifts reporting intensities lower than 𝛥𝛿̅̅̅̅ + σ were considered 
as weak and coloured in grey. An example is shown in figure 3.6. 
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Figure 3.6. Examples of chemical shift perturbation induced on BAZ2B PHD upon 
addition of fragment. 
Chemical shift differences induced on BAZ2B PHD upon addition of fragment 3 (upper panel) and 7 (lower 
panel) were plotted against the amino acid sequences of BAZ2B. The histograms, on the right, group the 
shifts according to their intensities: strong shift (Δδ > 𝛥𝛿̅̅̅̅ + 2σ) and intermediate shift (Δδ > 𝛥𝛿̅̅̅̅ + σ). The 
CSPs observed were mapped on BAZ2B PHD structures (PDB: 4QF3) by colouring residues with red and 
orange (respectively strong and medium shift). In the upper panel there are highlighted residues 
belonging to the histone pocket. In the lower panel, it is reported an example of shifts observed in the 
second pocket of the protein (180° rotation from the histone pocket). 
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Figure 3.7 A-C. Heat maps of CSPs projected on BAZ2A/B PHD. 
CSPs observed with the fragments reported in the middle column were mapped on BAZ2A (PDB: 4QF2, 
left) and BAZ2B (PDB: 4QF3, right) PHD structures by colouring residues with red and orange. Red is 
representative of strong shifts (Δδ > 𝛥𝛿̅̅̅̅  + 2σ). Orange is representative of intermediate shifts (Δδ > 𝛥𝛿̅̅̅̅  + 
σ). A, B and C respectively shows CSPs of BAZ2A and BAZ2B with Fr3, Fr5 and Fr8. The protein is illustrated 
with the histone pocket in frontal view. 
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Figure 3.7 D-E. Heat maps of CSPs projected on BAZ2A/B PHD. 
CSPs observed with the fragments reported in the picture (middle column) were mapped on BAZ2A (PDB: 
4QF2, left) and BAZ2B (PDB: 4QF3, right) PHD structures by colouring residues with red and orange. Red 
is representative of strong shifts showing Δδ > 𝛥𝛿̅̅̅̅  + 2σ. Orange is representative of intermediate shifts 
with Δδ > 𝛥𝛿̅̅̅̅  + σ. Panel D and C respectively shows CSPs of BAZ2A and BAZ2B with Fr17 and Fr19. The 
protein is illustrated with the histone pocket in frontal view. 
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Figure 3.7 F-I. Heat maps of CSPs projected on BAZ2A/B PHD. 
CSPs observed with the fragments reported in the picture (middle column) were mapped on BAZ2A (PDB: 
4QF2, left) and BAZ2B (PDB: 4QF3, right) PHD structures by colouring residues with red and orange. Red 
is representative of strong shifts showing Δδ > 𝛥𝛿̅̅̅̅  + 2σ. Orange is representative of intermediate shifts 
with Δδ > 𝛥𝛿̅̅̅̅  + σ. In panel F, G and H the rear view of the protein is reported. In F, CSPs of BAZ2A and 
BAZ2B interacting with fragment 18. In G and H, it is reported only BAZ2b PHD interacting respectively 
with Fr 7 and Fr 11. In panel I, frontal view of BAZ2A PHD with CSPs from the interaction with Fr 14.  
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Fragment 3 (1H-imidazo[4,5-b]pyridine-2-amine) and 8 (2-amino-1,3-benzothiazole-6-
sulfonamide). 
A first difference between the two proteins raised up from the different intensities of 
the CSPs of Fr 3 and Fr 8. CSPs of both fragments were much more pronounced in BAZ2B 
than BAZ2A.   
Interestingly, Fr 3 and Fr 8 present a highly similar scaffold. They both contains two 
condensed aromatic systems, respectively a 1H-imidazo[4,5-b]pyridine and a 
benzothiazole, carrying an amino group on the azole derivative. Remarkably, a previous 
study, reported by Miller et al. 57, identified the same 2-amino benzothiazole fragment 
as a binder of Pygo PHD. This amino group, in this particular position, seems to be the 
driving force of the binding. Indeed, it was noticed that also Fr 15 contains a similar 
scaffold constituted of two condensed aromatic ring (an indazole) which also carry an 
aromatic –NH2 group but on the phenyl ring. Fr 15, conversely to Fr 3 and Fr 8, did not 
show any CSPs.  
Fr 8 contains a sulphonamide motif which is capable of binding to metals. This functional 
group of the molecule could potentially interfere with the PHD zinc finger chelating the 
zinc ions within the protein. This possibility was eventually discarded since the CSPs, 
projected on both PHDs, display a defined cluster of residues in the region of the histone 
pocket. Nevertheless, in BAZ2A PHD, some of the residues adjacent to one of the zinc 
ions are characterized by intense shifts, suggesting potential interference in that region 
of the protein (figure 3.7 C). X-ray crystallography will prove invaluable for elucidating 
the binding mode of this fragment.  
 
Fragment 5 (4-(4-chlorophenyl)-4-hydroxypiperidine) 
Fr 5 was one of the ligand that produced the most intense shifts in both proteins, 
although the mapping appears to be different between the two PHDs (Figure 3.7 B). It 
contains amine and hydroxyl groups that could act as HBDs and a clorophenyl ring which 
could be involved in aromatic stacking. From in silico modelling, Fr 5 is supposed to bind 
to the histone pocket and the CSPs reported for BAZ2B PHD seems to be in agreement 
with the prediction. For BAZ2A, CSPs do not identify a specific cluster of binding and 
some peaks were also disappearing upon titrations. This observation could indicate a 
level of non-specific binding. 
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Fragment 7 (2-amino-4-methylbenzamide) and fragment 11 (thiochroman-4-one). 
Fr 7 and Fr 11 selectively showed CSPs only for the PHD of BAZ2B. Mapping of the shifts 
identified as potential region of binding the second pocket on the rear of the protein 
(Figure 3.7 G and H). The similar scaffold between the two compounds may account for 
the analogous response detected by HSQC. Indeed, both fragments contain a phenyl 
ring (likely involved in van der Waals interactions and π-π interactions) and a carbonyl 
group that could act as hydrogen bond acceptor. 
 
Fragment 14 : 4-methoxy-5,6,7,8-tetrahydropyrido[4,3-b]pyrimidine 
Fr 14 showed weak shifts only for PHD of BAZ2A, located in the region of the histone 
pocket (Figure 3.7 I), while the in silico prediction reported potential binding also for 
BAZ2B PHD. 
 
Fragment 17: 3-amino-2 methyl-N-((1-methyl-2-(thiophen-2-yl)piperidin-3-
yl)methyl)butanamide 
This molecule presents a larger molecular weight compared to the other fragments 
tested. It presents a peptidomimetic scaffold and for this reason was predicted to bind 
to the histone pocket. In BAZ2B showed a cluster of shift related to the histone pocket, 
although a very intense shift is also reported for K1955 on the rear of the protein (Figure 
3.7 D, right side). In BAZ2A, the sequence of shifts registered does not define a proper 
pocket, making any hypothesis of binding difficult (Figure 3.7 D, left panel). However, it 
must be noted that this molecule presents four chiral centres that will generate a 
racemic mixture of 16 diastereoisomers. In this case, we might have different scenarios 
where more than one species is potentially binding the protein (generating non-specific 
binding that could account for the CSPs trend observed in BAZ2A) or the binding can be 
specifically determined by one single diastereoisomer. 
 
Fragment 18: N-(benzo[b[thiophen-3-ylmethyl)-2-ureidoacetamide 
Fr 18 also presents a peptidomimetic scaffold. It contains many possible groups for 
binding, including three amines, two carbonyls, and a benzothiophene group. In both 
proteins the CSPs target the second pocket located on the back of the protein (figure 3.7 
F). In this case, we could assume that the binding might be driven from the 
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benzothiophene group. 
 
Fragment 19: 2-amino-1-(6,7-dihydrothieno[3,2-c]pyridine-5(4H)-yl)ethan-1-one 
This fragment has a small region with peptidomimetic characteristic plus a thiophene 
group that could be useful to catch hydrophobic interactions. By HSQC it was found to 
bind both proteins in the histone pocket, as expected. Residues reporting shifts are the 
hotspots of binding for H3 peptide, on the first β-strand of the PHD 46, as shown in Figure 
3.7 E. 
 
Impurities associated with fragments can often cause binding interference, in particular 
there are works from the literature suggesting how metals coming from the synthesis 
may influence  the hits of binding 134 153. The effect of metals can be prevented using in 
the assay chelating agents as EDTA. Unfortunately, this precaution was not achievable 
in our NMR validation experiments since the proteins under investigation contain two 
structural zinc ions and the addition of EDTA would have caused denaturation of the 
domains. 
 
3.4.2 Validation by ligand-observed NMR 
 
Considering the low MW of the target protein, it was deemed interesting to investigate 
if it was possible to monitor protein-ligand interactions by ligand-observed NMR 
techniques. For this study, I tested some of the fragments already validated by HSQC: Fr 
3, Fr 5, Fr 7, Fr 8 and Fr 11. As model of study I chose BAZ2B PHD because this protein 
gave more pronounced CSPs with fragments in the HSQC experiments. 
WaterLOGSY showed low positive signal upon protein addition for Fr 3, Fr 5 and Fr 7 
(figure 3.8), while for Fr 8 and Fr 11 no change in response was detected. In contrast, in 
the STD spectra recorded, for all the fragments, upon protein addition, no fragment 
signal was detected. CPMG spectra were initially recorded with relaxation delays of 60 
ms. In this condition no relevant signals were detected. A trial of different relaxation 
time was attempted. Six different spin-lock time were applied: 40, 120, 160, 320, 640 
and 1280 ms. Majority of the fragments did not show any response despite the changes. 
Instead Fr 3 and Fr 8 generated sensible CPMG spectra only with specific spin-lock time. 
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Fr 3 with delay at 320 and 640 ms while Fr 8 only at 160 ms (figure 3.8).  
Despite these changes, responses obtained were not convincing to state the viability of 
these techniques towards detecting ligand binding in our model study. So, no further 
investigation by ligand-observed NMR was conducted.  
 
 
Figure 3.8. Ligand-observed NMR performed for PHD BAZ2B with fragments.  
CPMG and WaterLOGSY spectra of fragments that gave positive responses. In blue fragment alone, in red 
fragment upon protein addition. 
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Table 3.3. Ligand-observed NMR test. 
Five selected fragments, validated by protein-observed NMR, tested by ligand-based NMR. Crosses 
indicate negative response detected and ticks indicate positive response detected. 
 
 
3.5 DIFFERENTIAL SCANNING FLUORIMETRY (DSF) 
 
DSF was next used as an orthogonal technique to confirm binding already observed by 
HSQC-NMR.  Prior to testing the fragment by DSF, the best conditions to perform the 
assay were evaluated.  
 
3.5.1 Identification of screening conditions 
 
Previous experiments in the lab had tested the stability of the PHD BAZ2A/B in different 
buffers at different pH. It was chosen to perform the fragment validation using a buffer 
condition where the Tm was as close as possible to 37 °C, in a way to resemble conditions 
close to the physiological one. Buffer containing 100 mM MES at pH 6.0 was considered 
suitable. The buffer concentration was kept high in order to ensure good buffering 
capacity in the presence of high fragment concentrations. In addition, the effect of 
DMSO and NaCl on protein stability was evaluated. A first screening was performed with 
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both proteins PHD BAZ2A/B testing two different salt concentrations and different 
percentage of DMSO up to 5% v/v (figure 3.9). 
It was observed that the increase of DMSO did not affect the stability of the proteins, 
indeed, the Tm remained in the same range. The increasing concentration of salt showed 
a more pronounced variation of the Tm, with protein stabilisation already observed at 
50 mM NaCl (figure 3.9). Eventually, it was chosen to perform the screening at 100 mM 
MES pH 6.0, 5% (v/v) DMSO and 50 mM NaCl, in order to guarantee stability of the 
protein and high solubility of the fragments at all the concentrations, without increasing 
the ionic strength which could prevent the binding of the fragment to the pocket (figure 
3.9).  
 
97 
 
 
Figure 3.9. Optimization of DSF conditions prior to performing the fragment screening. 
Conditions screened for the optimization are listed on the right side. Derivative of the melting profile of 
PHD of BAZ2A and PHD of BAZ2B are reported. The asterisk individuated the conditions selected for the 
screening: 100 mM MES, 50 mM NaCl and 5% DMSO. 
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3.5.2 Fragment screening 
 
Eight fragments identified by HSQC NMR as positive hits were tested by DSF. The H3 10-
mer peptide that is known to bind the PHDs was used as positive control and tested at 
500 μM. Each fragment was tested at three concentrations: 3, 5 and 15 mM. 
Table 3.4 reports the results of the screening. 
 
 
 
Table 3.4. Summary of ΔTm calculated by DSF. 
Summary of the ΔTm calculated by DSF for each protein upon addition of 3, 5 and 15 mM of fragment. 
On the left the chemical structure of the fragments tested and already validated by HSQC. 
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The majority of the fragments showed a stabilization of the protein with positive ΔTm, 
increasing at increasing fragment concentration, as expected for genuine reversible 1:1 
binding. 
Fr 14, which was expected to bind only BAZ2A PHD based on the NMR data, was in fact 
found to stabilize both proteins by DSF. 
 
 
Figure 3.10. DSF melting curves. 
DSF melt curves of BAZ2A and BAZ2B PHDs (black) in presence of H3 10-mer peptide (purple) and 3 mM 
Fr 17 (cyan) on the left side. On the right side, DSF melting curves of BAZ2A/B PHD in presence of 
increasing concentrations of Fr 5. Data are reported as relative fluorescence units (RFU) vs temperature 
(°C). 
 
Examples of some DSF melting curves are reported in figure 3.10. In black the protein 
alone, in purple the protein in presence of the H3 10-mer peptide (used as control) and 
in cyan the protein in presence of the Fr 17, in a shifted position intermediate between 
the protein alone and the complex protein- peptide, as expected. On the left are shown 
thermal melting profiles of the protein alone and in presence of the three increasing 
concentration of a fragment that stabilize the protein. In this case, the observed shift 
increases with the increasing of the fragment concentration. The highest shift is always 
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registered in presence of 15 mM of fragment (darker green).  
Fr 7 was tested only for the PHD of BAZ2B since it did not show any shifts for BAZ2A PHD 
in the previous NMR validation. As reported in Fig. 3.11 and in Table 3.4, it destabilizes 
the protein with a ΔTm of -0.9 at 3 mM fragment and -1.9 with 5 mM fragment. It has 
been proven, from previous studies reported in literature, that also ligands that 
destabilize the protein can be real binders 133. Fr 18 also showed a negative ΔTm for PHD 
BAZ2A while for BAZ2B no detection was possible. Fr 18 precipitated at concentration 
higher than 3 mM, generating high fluorescence already at low temperatures, and not 
detectable signal. 
Figure 3.11 reports melting curves generated by destabilization of the protein upon 
binding with Fr 7. DSF curves appear to be flatter than the curves of the protein alone. 
 
 
Figure 3.11. DSF melting curves with Fr 7. 
DSF melt curves relative to the destabilizing Fr 7 in complex with BAZ2B PHD. Relative fluorescence (RFU) reported 
against temperature. In black curve of the protein alone, in light blue protein in presence of 3mM Fr 7 and in dark 
blue protein in presence of 5 mM Fr 7. 
 
Fr 3 and Fr 8  did show intrinsic fluorescence signal in any of the three concentrations 
screened. This effect could be explained by either aggregation of the protein in presence 
of fragment, aggregation of fragment itself or possible interactions between the 
fragment and the SyproOrange probe.  
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3.6 DETERMINATION OF BINDING CONSTANT KD 
 
3.6.1 Estimation of binding constant by (15N-1H)-HSQC  
 
One of the crucial step during fragment screening in drug discovery is the determination 
of binding constants. The purpose is to rank the fragments for further optimization and 
lead selection. 
In this study, it was decided to use Chemical Shift Perturbation (CSP) analysis to 
determine the binding constants since the domains studied have a low molecular weight 
and yielded to good quality HSQC spectra. Given that fragments are generally weak 
binders (KD >10-5 M), our expectation is to observe shifts in the fast exchange regime 
(kex >> Δω). This means that we should be able to detect the binding within the NMR 
scale time and following the variation of the chemical shifts during addition of increasing 
concentrations of compound, it would be possible to extrapolate information about the 
binding constant.  
Conditions of the assay were changed compared to the NMR validation step. Buffer 
concentration was increased up to 50 mM H2PO4-/HPO4- in order to improve the 
buffering capacity also at high fragment concentration (till 5 mM). No salt was added to 
limit potential screening away of electrostatic interactions. Some of the fragments 
showed higher solubility and were directly dissolved in the NMR buffer; other fragments 
were previously dissolved in DMSO. It was noticed that up to 5% DMSO no substantial 
differences in the chemical shift were observed in the HSQC spectrum compared to the 
apo form. Consequently, as reference was used the spectrum of the apo form of the 
protein.  
Due to the low 15N -labelled proteins availability, titrations were performed adding 
known ligand volumes to the protein samples, in order to limit the protein consumption. 
The added volume was kept low (no more than 5 μL), using a high fragment stock 
concentration, to minimize the errors on the fitting due to the protein dilution. Protein 
concentration was kept at 100 μM which is the lowest concentration still yielding good 
quality spectra, with sharp and defined peaks. Fragments were titrated in a range 
between 0.5 and 5 mM, according to the solubility limits of the compounds. 
Concentrations higher than 5 mM were not used to prevent potential aggregation either 
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of the protein or of the compound, to avoid changes in pH of the solution that may alter 
the signals and confuse the analysis as well as other artefacts associated with high 
compound concentrations.  
All the fragments identified by HSQC were titrated versus the protein where CSPs were 
previously observed at the singleton screening.  
The titration pattern observed, confirmed that most fragments follow the fast exchange 
regime, as expected, since the affinities are in the mM range. Indeed, the majority of the 
peaks, affected by binding, move smoothly from the unbound to the bound form, with 
the exception of few peaks disappearing or broadening (potential indication of non-
specific binding or intermediate exchange). 
The analysis of the spectra and KD estimation were performed using the CcpNMR 
software 154, which allows to calculate the weighted shift changes Δδ at different ligand 
concentration and KD value for each residue of the protein. Indeed, for each fragment, 
it is possible to extrapolate a KD for each single residue of the protein, but only those 
residues giving meaningful shifts (Δδ > Δ𝛿̅̅̅̅ + σ) were accounted for the calculation of the 
overall KD , since  involved in binding . The final KD is then calculated, for each fragment, 
as mean of KD values derived from CSPs of those residues showing Δδ > Δ𝛿̅̅̅̅ + σ. An 
example representative is reported in Figure 3.12. In table 3.5 there is a summary of the 
KD  of binding, estimated by HSQC, for the hits previously validated. 
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Figure 3.12. Fr 17 binding to PHD of BAZ2B. 
(A) Overlay of the spectra of PHD of BAZ2B upon addition of different fragment concentrations. (B) 
Histogram of CSPs plotted for each residue of the protein. (C) Plot of Δδ (ppm) versus ligand/protein ratio 
of the residue Gly1955 of BAZ2B. In red the experimental values, in blue the theoretical values. Chemical 
shifts reported in different colour at different concentrations: blue, no fragment; red, 1 mM Fr 17; green, 
3 mM Fr 17 and purple, 5 mM Fr 17.  
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Fragment structure KD (mM) BAZ2A PHD KD (mM) BAZ2B PHD 
Fr 3  
NT 
 
4.3 ± 1.3 
(LE 0.36) 
Fr 5  
4.7 ± 1.9  
(LE 0.23) 
 
>16 
(LE 0.17) 
Fr 8  
NT 
 
4.4 ± 0.7 
(LE 0.23) 
Fr 14  
9.3 ± 1.6  
(LE 0.23) 
 
NT 
Fr 17  
10.8 ± 2.1  
(LE 0.13) 
 
3.4 ± 0.3 
(LE 0.16) 
Fr18  
9.2 ± 2.6  
(LE 0.15) 
 
 
2.3 ± 0.5 
(LE 0.2) 
 
Fr 19  
 
NT 
 
 
9.4 ± 1.8 
(LE 0.2) 
  
Table 3.5. Summary of KD estimation by HSQC NMR and ligand efficiency (LE). 
KD are calculated as mean ± s.e.m. of single KD extrapolated from CSPs. In brackets, ligand efficiency in 
(kcal/mol)/heavy atom. NT = not tested. 
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In the first HSQC validation screening, Fr 3 and Fr 8 were individuated as possible binders 
of both proteins. During the titration it was observed that, while for BAZ2B increasing 
Δδ were observed at increasing of fragments concentration, for BAZ2A only one residue 
was showing Δδ, displaying also not relevant changes upon titration.  Consequently, Fr 
3  and Fr 8 were not further investigated for KD evaluation towards BAZ2A. 
Fr 7 and Fr 11 showed toward BAZ2B a trend similar to Fr 3 and Fr 8  towards BAZ2A. 
Indeed, upon titration low intensity shifts were observed so they were discarded from 
the analysis because considered either non genuine or too weak binders.  Details of the 
overlay of the spectra are reported in figure 3.13.  
Fr 14 showed CSPs only against the PHD of BAZ2A, so was exclusively titrated against 
this protein. Analysis of the KD values highlighted a first difference between the two 
proteins: values are higher for BAZ2A PHD than BAZ2B, implying a lower affinity for 
BAZ2A (Table 3.5). 
At this stage, very little information is gained about the binding mode of these fragments 
but CSPs allowed to formulate hypothesis on the potential region of binding (figure 3.6 
A-I).  
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Figure 3.13. HSQC spectra. 
Spectra reporting the HSQC titration of PHD of BAZ2B with Fr 7 (upper panel) and Fr 11 (lower panel). 
Meaningful shifts are observable only after high fragment concentration above 5 mM. 
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3.6.2 Surface Plasmon Resonance (SPR) 
 
Another orthogonal technique was chosen with the intent to validate the binding 
affinities of this pool of selected fragments and compare with values obtained by NMR. 
Considering the number of fragments to evaluate, it was decided to use surface plasmon 
resonance (SPR). Kinetic and equilibrium binding parameters can be determined by SPR 
using a minimal amount of both protein and fragments. In the cases of genuine 
reversible binding ligands, KD values can be obtained and are found to correlate quite 
well with KD  determined by other methods  
 
3.6.2.1 Assay development: choice of the immobilization method 
 
The first step was to set up the conditions of work for the assay and optimize the choice 
of immobilization of the protein. 
There are different ways to immobilize a protein onto the surface of a chip: non covalent 
methods with high affinity interactions as, for example biotin/streptavidin, or covalent 
binding via free amine or thiol coupling. One of the most popular way of immobilization 
is the use of the streptavidin/biotin affinity, requiring as further step only the 
biotinylation of the protein. The risk associated with the choice of biotinylation is the 
generation of heterogeneous product with random orientation of the protein and 
consequently impaired function. Indeed, the main concern about the biotinylation of 
our PHDs is that these proteins are very small domains (~60 aa) containing only three or 
five Lys located in proximity of the two potential binding pockets. In this way, upon 
biotinylation and binding of the protein to the streptavidin coated surface, the PHD 
pockets could results as partially blocked from steric hindrance and with restricted 
access for the fragments. In addition, to support this theory there were results from 
previous fragment screening with BLI, using biotinylated protein, that did not lead to 
any interesting results for hits later confirmed by protein-observed NMR.  
To obviate these issues, I decided to adopt an alternative strategy immobilizing the 
protein to the surface of the chip using the 6His affinity tag and stabilizing the binding 
through a capture coupling 155. The aim of this approach is to expose both pockets, to 
control the steric orientation and to warrant a stable surface with higher binding 
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capacity. The 6His tagged constructs of PHD of BAZ2A and BAZ2B were found not 
soluble. Suitable for our purposes was, instead, the usage of the soluble construct of 
6His-SUMO-PHD, that is purified prior to protease cleavage to release the tag (see 
Method 6.1.6). The main concern arising from the usage of this tag is that SUMO (MW 
~12 KDa) may itself interact with small molecules. In order to account for this potential 
interactions and to compensate for any matrix effect due to interactions of the 
fragments with the surface of the chip, a reference cell was set up, containing the 6His-
SUMO tag alone to be subtracted to the actual data obtained during the data 
experiment (figure 3.14). 
 
 
Figure 3.14. Schematic representation of the protein immobilization onto the sensor 
chip. 
(A) Representation of the surface of the sample cell with 6His-SUMO-PHD protein immobilized onto the 
chip. In blue 6His-SUMO and in wheat the PHD. (B) Representation of the reference cell with the only 
6His-SUMO protein immobilized. In green is depicted the analyte. 
 
3.6.2.2 Assay set up 
 
Proteins were immobilized using a Ni-NTA chip. I mainly followed the protocol reported 
in the paper from Kimple et al. 155. The surface of the chip, constituted of 
carboxymethylated dextran pre-immobilized with nitrilotriacetic acid (NTA), was first 
regenerated with an EDTA solution to remove all potential contaminants, subsequently, 
a Ni2+ solution was injected to bind the surface. The surface was then activated with a 
coupling solution EDC/NHS and then the tagged protein was allowed to chelate the 
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metal ions. Ethanolamine was injected in the final step to block uncoupled primary 
amines on the surface. The capture coupling has the further purpose to stabilize the 
surface avoiding loss of protein over the course of the experiment. 
The sensorgram obtained for the immobilization process of BAZ2A/B PHD is reported in 
Figure 3.15. 
 
 
Figure 3.15. Sensogram showing the different steps for protein immobilization.  
The sensor chip was first regenerated, and subsequently allowed to bind Ni2+ at the surface. The surface was then 
activated with the coupling solution EDC/NHS and then it was allowed the tagged protein to chelate the metal ions. 
Ethanolamine was injected in the final step to block uncoupled primary amines.  
 
3.6.2.3 Analysis 
 
Prior to the testing fragments, as positive control to guarantee that the immobilized 
protein was actually active, the H3 10-mer peptide was used 46. As negative control was 
used one of the fragments, from the in silico screening (Fr 1) that did not show any shift 
by HSQC NMR. H3 10-mer peptide and Fr 1 were both tested in three different 
concentrations in dilution 1:2 starting from 500 µM (10~fold KD [1]). Responses detected 
are reported in the plot in figure 3.16 and are the difference between sample cell minus 
reference cell and further subtraction of the nearest blank. Peptide titration was 
repeated at the end of the assay to check the stability of the response over the time.   
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For each point the relative Rmax was extrapolated. Rmax  corresponds to the maximum 
binding capacity, in RU, of the protein bound on the surface. Rmax was calculated using 
the following formula, assuming that the protein is binding to one molecule of analyte 
(peptide or fragment): 
 
𝑅𝑚𝑎𝑥 =
𝑅𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒∗𝑀𝑊𝑎𝑛𝑎𝑙𝑦𝑡𝑒
𝑀𝑊𝑝𝑟𝑜𝑡𝑒𝑖𝑛
   
 
where the Rbaseline is representative of the amount of PHD present on the surface of the 
chip and is calculated as the difference between the baseline of the surface containing 
the 6His-SUMO-PHD and the reference cell containing 6His-SUMO protein alone; 
MWanlayte is the molecular weight of the peptide or fragment and MWprotein is the 
molecular weight of the PHD of BAZ2A/B. 
 
 
Figure 3.16. SPR response to H3 10-mer peptide and Fr 1. 
Plot of the SPR response detected for H3 10-mer peptide (green) and negative control (Fr 1, blue) towards 
BAZ2B PHD. Three concentrations tested are reported in µM on the x axis. In grey, for comparison, are 
reported the relative Rmax. 
 
As shown in Figure 3.16, for 500 μM peptide the experimental RU at the beginning of 
the titration is slightly above the Rmax while the other two points are within the admitted 
range. This effect could be explained by dimerization of the peptide at high 
concentration and in presence of DMSO. The negative control showed low response as 
expected. 
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Subsequently, both proteins were screened with those fragments previously validated 
by HSQC: Fr 3, Fr 5, Fr 7, Fr 8, Fr 11, Fr 18 and Fr 19 reported in table 3.3. Six different 
concentrations were injected, in a dilution 1:2 starting from 900 µM, for each fragment. 
Higher concentration of 900 µM was avoided in order to reduce mass transport effects 
due to a high concentration. 
Fr 17 was not included due to availability issues at the time of the experiment.  
The first observation from the analysis of the sensorgram was the low response detected 
for all the fragments, that does not allow a proper analysis. Responses detected were in 
the same range of the negative control. In figure 3.17 were plotted the RU/Rmax (%) for 
each concentration of each compound. This plot is informative of the fraction of 
maximal activity observed for each compound.  
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Figure 3.17. SPR responses upon fragment injections. 
Histograms of the response detected by SPR for each fragment at different concentrations. In the upper 
panel the response versus BAZ2A PHD and in the lower panel the responses versus BAZ2B PHD. Fragments 
are grouped by colour as reported in the legend.  
 
The responses detected were very low in RU but for some fragments it was still possible 
to observe a trend of increasing response at increasing concentrations. This is the case, 
for example, of Fr 19 towards both BAZ2A/B PHD, however the maximum active fraction 
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was lower than 10% of the expected one. Also Fr 3 in BAZ2B showed a concentration 
dependent response for the first three injections. 
An interesting case was Fr 18 that for both proteins showed negative responses at high 
fragment concentration. Responses relative to Fr 18 were taken out of the analysis since 
towards both proteins were observed high negative response that would have masked 
responses of the other fragments. This event could be caused from the bulk-effect, due 
to the presence of precipitated compound flowing through the cells. The refractive index 
is dependent from the bulk properties of the buffer and the presence of small particulate 
or too high density of the solution could generate a negative response. Despite the 
several studies about SPR, there is no available literature able to explain this 
phenomenon.  
 
The low responses showed in the sensograms seem to suggest different potential 
scenarios:  
1) the interaction of the fragments with the PHD proteins is comparable to the 
interaction with the protein in reference cell; 
2) the fragments either do not bind at all, or bind too weakly to the PHD domain to 
generate a measurable signal 
3) the similarity in responses between data and reference cell could be determined from 
the partial degradation of the tagged protein 6His-SUMO-PHD into 6His-SUMO, still 
bound onto the surface, and PHD alone. In this situation the surface of data and 
reference cell would be exactly the same justifying the zero response. This last 
assumption is further supported by mass spectrometry analysis for BAZ2A protein that 
detected three species in solution: 6His-SUMO-PHD, the 6His-SUMO and PHD alone 
(figure A.6 in Appendix), suggesting instability of the protein and degradation over the 
time. 
Another phenomenon to consider is the binding of some of the fragments to the Ni2+ on 
the surface of the chip. Indeed, this interaction may generate interferences which could 
lead to unreliable response in the assay. In particular, amongst the pool of fragments 
tested, Fr 8 (Table 3.1), which carries the sulphonamide group, could be capable of metal 
chelation on the surface of the chip and interference with the assay. 
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3.6.2.4 Limitations of the assay and alternatives 
 
These data taken in account together suggest a main limitation of the usage of the SPR 
assay to detect fragment binding. It is possible that fragments under investigation bind 
too weakly to be adequately detected in the assay. In addition, the construct required 
for the immobilization of the protein (6His-SUMO-PHD) showed to be unstable and thus 
could be unsuitable for detection of reliable responses. Therefore, another strategy 
should be addressed in future. A potential alternative would be the usage of a tag that 
allow a stable immobilization, simultaneously warranting the right orientation of the 
protein, exposing both pockets. The AviTag would be an attractive choice. AviTag is a 
sequence of 15 amino acids (GLNDIFEAQKIEWHE) that can be enzymatically biotinylated 
on the single Lys residue present in the tag sequence using the enzyme biotin ligase 
(BirA), in presence of biotin and ATP 156, 157. This peptidic sequence can be inserted by 
inverse PCR mutagenesis 157. The advantage is the selective biotinylation of the Lys on 
the AviTag, preventing derivatization of lysine residues that could affect protein activity. 
In this way it would be possible to immobilize the protein on the surface of the chip in a 
controlled manner, exposing all the potential binding sites, as expected. The more 
general advantage of this methodology is that the usage of this tag could be applied to 
other high-throughput screening that requires a stable and oriented immobilization of 
the protein. 
3.7 ALPHALISA COMPETITION ASSAY 
 
One of the limitations of the chemical shift mapping is that it may be difficult to 
distinguish whether it arises from specific or non-specific binding since broadening and 
change in intensity of the peaks could be caused from either non- specific binding or 
intermediate exchange. In this context, application of an orthogonal functional 
technique, such as competition AlphaLISA assay, could provide additional information 
useful to elucidate the binding mode of the small molecules.  
In order to test if the identified hits were able to bind the PHDs BAZ2A/B in the histone 
pocket, I developed a competition assay using the AlphaLisa bead-based technology.  
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3.7.1 Assay development 
 
The assay was set up using the streptavidin donor beads and the anti-FLAG acceptor 
beads. Proteins were biotinylated in order to bind the donor beads. For this assay, the 
usage of biotinylated protein does not constitute a limitation since the signal observed 
is considered to arise from the fraction of active protein on the bead surface. Even if this 
fraction is low, it must be sufficient to generate a signal that will be still appropriate to 
perform competition studying by fragments.   
The peptide H3 10-mer AA mutant 46 was chosen for the assay and synthetized with the 
additional Flag epitope at the C-terminus (ARTAATARKS-DYKDDDDK), in order to be 
recognized by the anti-FLAG acceptor beads. The binding of the FLAG tagged peptide  
was confirmed for both PHDs BAZ2A/B by ITC (Table 3.6 and figure 3.18) and the 
obtained KD correlated well to those obtained for the H3 10-mer AA mutant (BAZ2A KD 
~12 µM and BAZ2B KD ~ 2.6 µM)46. 
 
 
Protein 
 
KD (µM) 
 
N 
 
ΔH 
(kcal/mol) 
 
TΔS 
(kcal/mol) 
 
ΔG 
(kcal/mol) 
 
BAZ2A PHD 
 
 
5.9 ± 0.08 
 
1.27 ± 0.002 
 
-7.16 ± 0.01 
 
-0.03 ± 0.02 
 
-7.13 ± 0.01 
 
BAZ2B PHD 
 
 
1.7 ± 0.05 
 
1.29 ± 0.002 
 
-8.3 ± 0.01 
 
-0.5 ± 0.02 
 
-7.8 ± 0.02 
 
Table 3.6. Summary of thermodynamic binding data for FLAG peptide. 
ITC-based binding parameters for complex formation between FLAG peptide and BAZ2A/B PHD.  
Error values reported on KD, N, and ΔH are generated by the Origin program and reflect the quality of the 
fit between the nonlinear least-squares curve and the experimental data. Errors reported on T∆S and ∆G 
were propagated from the errors of KD and ∆H.  
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Figure 3.18. Raw ITC experiments with the FLAG-peptide. 
Raw ITC binding curves of H3 FLAG peptide into PHD of BAZ2A (left) and BAZ2B (right) are reported in the 
upper panel. The integrated ΔH (kcal/mol) values are plotted versus the peptide/protein molar ratio and 
shown in the lower panel. 
 
Prior to performing the assay, protein and peptide concentrations were optimized. 
Using 5 µg/mL of both beads, different protein and peptide concentrations were 
screened in order to get the optimal signal over the background range but to avoid the 
hook effect that can occur when in solution there is an excessive amount of protein or 
peptide to saturate all the binding sites, inhibiting the interaction between the beads. A 
first protein/peptide screening did not generate any signal of interaction between 
peptide and protein. This result suggested that something within the assay could 
prevent the binding between protein and peptide, as for example the length of the 
peptide. Indeed, the FLAG tag, immediately adjacent to the H3 epitope could have 
impeded the correct structural organization of the peptide, needed for the binding with 
the protein. In order to overcome this issue, a longer peptide was synthesized carrying 
an extra flexible linker (TGGSGGSG) between the N terminus and the FLAG epitope 
(ARTAATARKS-TGGSGGSG-DYKDDDDK, namely AlphaLISA peptide). Furthermore, DTT 
was removed from the assay since it reduces the disulfide bonds on the M2 epitope of 
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the anti-FLAG beads, needed to recognize the FLAG sequence. Using the long form 
peptide and in absence of DTT, signal was now pleasingly observed (Figure 3.19). A 
peptide concentration of 160 nM was sufficient to produce maximal response.  A 10 nM 
concentration was chosen for both proteins since it gave reasonable signal without 
saturating the system, simultaneously guaranteeing a low usage of protein. 
 
Figure 3.19. Determination of saturation points of acceptor (protein) and donor 
(peptide) in AlphaLisa assay. 
Histograms reporting AlphaLISA response versus peptide/protein concentrations. The hook effect is 
observed increasing the protein concentration. 
(A1) and (B1): BAZ2A/B PHD titrations with six different peptide concentrations.  
(A2) and (B2): peptide titrations with six point protein concentrations of BAZ2A PHD and BAZ2B PHD, 
respectively. 
 
AlphaLisa displacement assay was then set up using 10 nM of protein and 160 nM of 
peptide in 100 mM HEPES buffer supplemented with 0.02 % CHAPS and 0.1% BSA to 
minimize non-specific binding. No salt was added in order to minimize extra 
interferences with the assay. Buffer concentration was kept high to avoid pH changes at 
high fragment concentrations. 
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Validity of the assay was assessed for each protein using the S/B and Z’ factor 158, 
calculated as described in chapter 6.4.4. Table 3.7 summarizes the results. 
 
Protein S/B Z-factor 
BAZ2A PHD ~72 0.79 
BAZ2B PHD ~22 0.43 
 
Table 3.7. S/B and Z-factor for BAZ2A and BAZ2B PHD AlphaLISA assay. 
 
Signal to background (S/B) is large for both proteins. Z-factor is good for BAZ2A since 
over 0.5, which is considered the optimal threshold 158. In BAZ2B the Z-factor is lower 
than 0.5, nevertheless can be considered an acceptable value to state reasonable quality 
of the assay since the range of points used for the analysis is low (four points) and the 
deviation from the threshold is still minimum. 
 
3.7.2 Competition assay with H3 10-mer peptide 
 
Prior to performing AlphaLisa competition assay with the fragment set, a positive control 
experiment was performed. The H3 10-mer wild-type peptide was used as competitor. 
Eight different concentrations of peptide (in serial dilutions 1:5) were tested and IC50 
was obtained from the dose-response curves (figure 3.20 B-C) with the relative 95% 
confidence interval and plotted as LogIC50 in figure 3.20 A. As negative control was used 
one of the fragments, Fr 1, that did not show any shift in HSQC validation. Fr 1 did not 
generate any response in AlphaLISA, as expected. 
 
3.7.3 Competition assay with fragments 
 
Initially, only three concentrations of fragments were tested in order to explore the 
competition response with this assay set up. 
Subsequently, a proper analysis dose-response was performed. Both PHDs were titrated 
against eight different concentrations of each fragment (dilution series 1:5). IC50 values 
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were extrapolated to assess whether fitting of the dose-response curve was possible. 
Fragments were tested according to their availability in the lab (Fr 3, 5, 7, 8, 14 and 18) 
at the time of the experiment and the LogIC50 values of those fragments that gave a 
dose-response curve was plotted in Figure 3.20 D-E. 
 
 
Figure 3.20 A-C. Results from AlphaLISA competition assay. 
(A) Log(IC50) were plotted against H3 10-mer wt peptide. In green the response detected towards BAZ2A 
PHD and in orange towards BAZ2B PHD. (B) and (C) dose-response curve obtained respectively for BAZ2A 
and BAZ2B PHD plus the respective IC50 extrapolated from the curves. 
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Figure 3.20.D-E. Results from AlphaLISA competition assay. 
In panel D, Log(IC50) were plotted against each fragment tested. In green the response detected towards 
BAZ2A PHD and in orange towards BAZ2B PHD. In panel E, raw dose-response curves. ND=not detected.  
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Figure 3.20.F. Results from AlphaLISA competition assay. 
In panel F, raw dose-response curves of Fr 18 and Fr 5. ND=not detected.  
 
Reasonable dose-response curves were detected for Fr 3, Fr 7 and Fr 14 (Figure 3.20 D-
E). Unexpectedly, Fr 7 showed to interfere with the histone in both proteins, despite 
from a first analysis based on the CSPs was identified as potential binder only for BAZ2B. 
Similarly Fr 14, that was supposed to interact only with PHD of BAZ2A, shows 
displacement also for the PHD of BAz2B although with a higher IC50. A likely explanation 
of the phenomena could be either a non-genuine effect due to the high concentration 
of compound in the assay or an allosteric effect on the histone pocket. 
Fr 5 did not seem to affect the interaction for both proteins at any of the concentrations 
tested. This might be indicative of the fact that is either non-specific binder or is binding 
a region of the protein, far from the histone pocket or its affinity is too low to generate 
any effect (figure 3.20 F). 
Fr 18 generated a reasonable response only for BAZ2A PHD and at very high fragment 
concentration (over 1 mM) but the data could not be fitted to extrapolate an IC50 (figure 
3.20 F). This may be representative of the fact that the fragment does not bind the 
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histone pocket (as hypothesized from CSPs) but the signal is decreased at high 
concentration of compound, potentially due to mass effect.  
3.8 SOAKING EXPERIMENTS AND X-RAY STRUCTURAL STUDIES 
 
3.8.1 Inspection of crystal packing 
 
Structures of the apo form of BAZ2A and BAZ2B PHD were previously solved from Dr. 
Cynthia Tallant, a former postdoc in the lab 45. The proteins crystallize in different space 
groups and exhibit different crystal packings, despite crystallizing in the same buffer 
conditions (2.2M Na/K phosphate buffer pH 8.5) (figure 3.21). These differences are 
summarized in Table 3.8. 
 
Figure 3.21. Picture of crystal of BAZ2A PHD (left) and BAZ2B PHD (right). 
Crystals are obtained in 2.2 M Na/K phosphate buffer at pH 8.5 at room temperature. 
 
 
Table 3.8. Space group of crystallization for each protein and relative number of 
protomers per ASU. 
 
Based on the observations reported in table above, I surmised that the two apo forms 
were not suitable soaking systems for the second pocket of the PHDs of both BAZ2A/B. 
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On the other hand, the histone pocket of BAZ2A was considered available to soaking 
because free from crystal contacts.  
 
3.8.2 Solvent test for soaking 
 
Soaking fragments into apo form crystals is one of the methods of choice to obtain 
ligand-protein complex owing to the ease of the process. Despite this, there are some 
limitations when using this approach and several factors to be considered. Indeed, 
crystals may be fragile and not tolerate soaking. Another limitation is represented by 
the solubility of the fragments in the crystallization conditions. It is often found that 
fragments are not soluble in the crystallization conditions and, consequently, some 
organic solvents are needed to increase their solubility but the addition of the solvent 
may destabilize the crystal packing.  
To overcome this issue, the stability of both apo form crystals of PHD of BAZ2A/B was 
tested at different percentage of several solvents. In the first instance, I tested the 
stability in presence of DMSO, since is the most widely used organic solvent to dissolve 
small molecules. Unfortunately even low concentrations as 0.5% (v/v) of DMSO were 
not tolerated as the crystals immediately dissolved. A solvent screening was then 
performed testing the stability of the crystals in a solvent range between 2.5% and 20% 
(v/v). Crystals were incubated at different percentage for at least 1h before to be soaked 
in a higher percentage of solvent. Crystals were found stable in acetone, acetonitrile, 
1,4-dioxane, ethanol and xylitol up to 20% (v/v) of solvent. 
The diffraction pattern of crystals incubated overnight at 20% in the tolerated solvent 
was then assessed, using the appropriate cryoprotectant (20% glycerol). All of the above 
solvents resulted in good diffraction pattern with well-spread and not overlapped spots. 
This was in spite of the overall appearance and morphology of the crystals not being 
preserved after soaking in all cases.  
 
3.8.3 Soaking fragments 
 
The privileged system used for soaking was BAZ2A because of the presence of two 
accessible pockets in the ASU. However, also BAZ2B was soaked since small molecules 
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such as fragments can readily diffuse through solvent channels and bind to small pockets 
of the protein surface, even if partially occluded by crystal packing. It was therefore 
considered of interest at this stage to explore the ligandability of any potential sites on 
the protein surface. 
 
Fr 3 and Fr 8 were soaked into crystals of both proteins even if they showed very nice 
shift only for BAZ2B PHD. The main issue for these fragments was their poor solubility 
in all the solvent tolerated from the crystals. Indeed, they were insoluble in dioxane, 
acetone and acetonitrile at the target soaking concentration of 100 mM. Because of this, 
the actual concentration used in the soaking could only be estimated and it spanned in 
a range between 10 mM and 50 mM. It was not possible to increase the amount of 
compound in the reservoir since when mixed with the crystallization buffer it generated 
crystallization of the components. Before mixing fragment and reservoir, to make a 
homogeneous suspension, the powder was vortexed for few seconds. Soaking was 
performed from 10 to 36 h, but despite the appearance of coloured crystals, no extra 
electron density was observed in any of the data set collected for these two fragments. 
For Fr 3 and Fr 8, because of their low solubility, co-crystallization trials were also 
attempted but unfortunately to no avail. 
 
Fr 7 and Fr 11 were found soluble up to 1 M in 1,4-dioxane, acetonitrile and acetone. 
Soaking was performed only with BAZ2B crystal since CSPs remarkable showed shifts 
only for this protein. For these fragments binding was expected in the second pocket 
that in the crystals is actually involved in crystals contact. If this assumption, based on 
HSQC data, was correct we would have expected to destroy the crystal packing after 
prolonged soaking or in alternative we might have found the ligand to bind in another 
region.  Crystals soaked in a range between 25 mM-200 mM over 10/16 h were still 
showing a good diffraction pattern. However, the data sets collected did not show any 
extra electron density to fit the ligand. This may be indicative of a low binding affinity, 
in agreement with the HSQC data, that upon titration showed very little intensity of 
shifts (Figure 3.13). 
 
Fr 14 was partially soluble in water at 1 M but once dissolved at 100-200 mM in the 
125 
 
soaking drops generated big crystals with a shape similar to the protein crystals. This 
phenomenon was not reduced using lower concentrations of fragments in the drop or 
changing solvents. BAZ2A crystals upon soaking with Fr 14 were found to colour in 
yellow, potentially suggesting fragment binding, but no electron-density was observed 
for the compound.  
 
Fr 17 was soluble at 100 mM in water but crystals did not tolerate higher concentration 
than 5-10 mM.  Also for this fragment no extra electron density was detected. 
 
Fr 19 was soluble up to 1 M either in water or crystallization buffer and was then soaked 
in crystals of PHD of BAZ2A in a concentration range between 25 mM to 100 mM.  
 
All the crystals, before to be flash-frozen, were cryo-protected in the same soaking 
solution supplemented with 20% glycerol. 
 
3.8.4 Fragment 19 
 
From the soaking of the Fr 19 within BAZ2A PHD crystals, one data set was collected at 
1.9 Å resolution. Inspection of the electron density after data processing led to the 
identification of an extra density in the region of the histone pocket of chain B. 
Unexpectedly, no electron density were visualized in chain A and D (which exhibit 
exposed histone pocket), but only in B and C (where histone pockets are partially 
occluded by crystal contact). This could be in agreement with the fact that in the solvent 
exposed pockets, since the affinity of the fragment is too low, the solvent diffusion is 
too fast and does not lead to any interpretable electron density. Indeed, the two pockets 
of chain B and C are partially occluded and this would reduce the exchange rate leading 
to higher occupancy of the ligand in the pocket. Ligand Fr 19  was then modelled into 
the Fo-Fc map. Several refinement cycles were performed and the summary of the 
crystallographic data is reported in Table 3.11. 
Analysis of the structure (Figure 3.22) allowed identification of important features of 
binding. The aromatic ring of the thiophene is not visible in the electron density 
suggesting that this portion of the molecule is not making stable interaction with the 
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protein. The alkyl ring is only partially visible, with density detected up to the two carbon 
atoms adjacent to the nitrogen. Omit map and polder map calculation 159 did not show 
any further density on this region of the molecule.  
Binding is driven by the amino terminal group of the molecule that is involved in 
hydrogen bonds with the side chain of D1695 and with the carbonyl group of the 
backbone of L1693. Further electrostatic interactions are established with the backbone 
C=O of the G1716 (Figure 3.22 A). Hydrogen bonds are observed also between the 
carbonyl of the ligand and the backbone NH of the backbone of L1693 (Figure 3.22A). 
 
 
Figure 3.22. Crystal structure of the complex of BAZ2A PHD with Fr 19. 
(A) Frontal view of the surface and cartoon representation (wheat) of BAZ2A PHD in complex with Fr 19 
(cyan sticks). Residues of the protein interacting with the ligand are represented as stick and labelled in 
black. (B) Unbiased Fo-Fc electron density map is reported in grey and countered at 3σ. 
 
3.9 FRAGMENT OPTIMIZATION 
 
Analysis of the histone pocket of the fragment-bound structure of BAZ2A PHD with Fr 
19, showed how the particular conformation and structure of Fr 19 did not allow the 
thiophene ring to fulfil the hydrophobic region of the histone pocket (in yellow in figure 
3.23) so this part of the molecule needed further optimization. 
Molecular modelling studies were performed by Dr. Lucas Xavier with the aim to 
improve the binding mode of the fragment. The 2-amino-acetamide region was 
conserved and kept fixed in the conformation identified in the crystal structure (in red 
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in the chemical structure of Fig. 3.23) but flexibility of the molecule was improved 
substituting a tertiary amide with a secondary amide. Docking sought to identify the best 
group to fill the hydrophobic cavity (yellow surface in figure 3.23), for example a phenol 
or thiazole group (Table 3.9). 
 
 
 
Figure 3.23. BAZ2A PHD in complex with Fr 19. 
On the left, surface representation of BAZ2A PHD in complex with Fr 19 (green stick). In red the surface 
of the acidic wall and in yellow the surface of the hydrophobic pocket. On the right, chemical structure of 
Fr 19 showing in red the portion of the molecule which was conserved during the optimization. 
 
In order to further stabilize the aromatic ring in the pocket we sought to catch hydrogen 
bonds with the side chain of the residue D1688 on the acidic wall (Fig. 3.23) introducing 
either a phenol or aniline group (Table 3.9). 
Fr 20-23 were purchased and tested by biophysical techniques. 
 
 
Table 3.9. Chemical structures of fragments obtained upon optimization of Fr 19. 
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3.9.1 HSQC and KD determination 
 
All four fragments were first validated by singleton HSQC. Then, systematic titrations 
were performed in order to estimate a KD of binding. These optimized fragments were 
all soluble in water and NMR buffer, with the exception of Fr 20 soluble in water only at 
100 mM. Titrations were performed up to 5 mM as for the previous fragments. Figure 
3.24 A-B reports a summary of the extrapolated KD  for each protein and heat map 
obtained from CSPs. In red the strong shifts (above Δ𝛿̅̅̅̅ + 2σ) and in orange the 
intermediate shifts (above Δ𝛿̅̅̅̅ + σ).  
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Figure 3.24.A. CSPs and KD estimation for the binding of fragments analogue of FR 19 
to BAZ2A PHD 
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Figure 3.24.B. CSPs and KD estimation for the binding of fragments analogue of FR 19 
to BAZ2B PHD. 
CSPs reported for the optimized fragments (left column) were mapped on BAZ2A (PDB: 4QF2, panel A) 
and BAZ2B (PDB: 4QF3, panel B) PHD structures.  
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Fr 20, 21 and 23 shows clear concentration depending shifts without any effect on the 
intensity or shape of the peaks, in agreement with the expected fast exchange. Fr 22 
showed a different behavior.  A defined cluster of residues located in the histone pocket 
was observed in BAZ2B, as expected, and the intensities of shifts were comparable to 
those of the other fragments. In BAZ2A, the fragment showed less intense shifts 
involving residues randomly distributed over the protein surface. This behavior could 
point toward non-specific binding.  
 
3.9.2 X-ray structural studies 
 
In order to gain further insight into the binding mode of these fragments, soaking 
experiments were performed. Fr 21, 22 and 23 were found soluble in water.  
Fr 20 was not soaked due to availability issues at the time of the experiments. Fr 22 was 
soaked in a range between 10-50 mM in reservoir for 10-24 h but upon inspection of 
structures, no electron density was detected to fit the ligand. 
 
3.9.2.1 Fragment 21 
 
Fr 21 was soaked at 10-20 mM in buffer crystallization for 10-24h. Higher concentration 
led to immediate dissolution of the crystals, while longer soaking time (above 24h) were 
tolerated by the crystals but destroyed the diffraction pattern. Inspection of the 
structures following data processing led to the identification of extra electron density 
only for BAZ2B PHD crystals.  
This was the first structure of BAZ2B PHD solved with a ligand bound and the first 
structure of a PHD with a fragment bound in the histone pocket.  
Structure was obtained upon soaking of the crystal for 1 day at 20 mM concentration of 
Fr 21. Crystals soaked for less than 24 h did not show any fragment bound. 
Crystallographic data are reported in Table 3.11. 
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Figure 3.25. Crystal structure of BAZ2B PHD in complex with Fr21. 
(A) Crystal structure of BAZ2B PHD (pale green surface) in complex with Fr 21 (purple sticks). Residues 
interacting with Fr 21 are drawn in sticks. Oxygen, nitrogen and sulphur are respectively reported in red, 
blue and yellow. (B) Planar representation of the interactions of the fragment with BAZ2B. In Angstrom 
the distance of the hydrogen bond. HBA stands for hydrogen bond acceptor and HBD for hydrogen bond 
donor, relatively to the residue on the protein. In (C) and (D), the Fo-Fc map in grey contoured respectively 
at 2σ and 3.5σ. 
 
Hotspots of the interaction between BAZ2B and Fr 21 are reported in fig. 3.35 A and B. 
These are in agreement with the hotspots identified by HSQC titration (Figure 3.24). The 
amino terminal group of the molecule is involved in H-bonds with the side chain of 
D1950 and the carbonyl group of L1948, while the carbonyl of the amide group of Fr 21 
is making hydrogen bond with the NH of L1948. The above interactions are conserved 
with those observed in the BAZ2A-Fr 19 structure (further discussed below). The NH of 
the amidic group of the molecule may be involved in electrostatic interactions with the 
carbonyl group of the G1971. The thiazole group was modelled with the sulphur atom 
133 
 
pointing towards the beta strand of the PHD since Fo-Fc map showed density up to 3.5 
σ level (figure 3.25 D). The aromatic group is located just above the hydrophobic pocket, 
making interactions with the side chains of L1947 and I1968. 
 
Superposition of BAZ2B-Fr 21 with BAZ2A-Fr 19. 
 
Figure 3.26. Superposition of the crystal structure of BAZ2B PHD in complex with Fr 21 
and BAZ2A PHD in complex with Fr 19.  
Superposition of the crystal structure of BAZ2B (cartoon, in palegreen) in complex with Fr 21 (violet sticks) 
and BAZ2A (cartoon, in wheat) in complex with Fr 19 (cyan, sticks). Oxygen, nitrogen and sulphur are 
respectively reported in red, blue and yellow. The arrow indicates the rotation of the 2-amino acetamide 
plane. 
 
Superposition of the complex BAZ2B-Fr 21 and BAZ2A-Fr 19 (Figure 3.26) highlighted 
that the binding mode is mainly conserved between the two proteins, indeed, they are 
involved in hydrogen bonds with the same set of residues. The introduction of a 
secondary amide with Fr 21 stabilizes the interaction of the aromatic group with the 
hydrophobic pocket. A major difference is the 2-amino acetamide plane which is 
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oriented in a different manner in the two fragments, making an angle of 69.7° between 
the two. In Fr 21 all the torsion angles lie on the same plane of the aromatic ring, 
consistent with extensive delocalization of the π system. This particular structural 
orientation favours the electrostatic interaction of the NH of the amide of Fr 21 with the 
backbone carbonyl of G1971, while the corresponding conserved residues in BAZ2A 
(G1716) point towards the amino terminal group of Fr 19 (Figure 3.26).  
The orientation of the ligand could be influenced from the different position of the loop2 
in the two proteins. Indeed, the measured distance between the Cα of the two 
conserved residues G1971 (BAZ2B) and G1716 (BAZ2A) is 2.5 Å. Also the hydrophobic 
pocket has a more open conformation in BAZ2B due to the residues I1968 pointing 
outside of the protein, instead the correspondent V1713 in BAZ2B points toward the 
protein itself (Figure 3.26). 
Another scenario that may influence the conformation adopted from Fr 21 in BAZ2B is 
the presence of a crystal contact. Indeed, in the pocket we observe the presence of the 
side chain of D1941, from an adjacent ASU that, through electrostatic interaction with 
the carbon of the amide of Fr 21, could help the stabilization of the small molecule in 
that particular position (figure 3.27). 
 
Figure 3.27. Crystal contact with adjacent ASU. 
Crystal contact between the carbon of the carbonyl group in Fr 21 and the oxygen of the side chain of 
D1941 of an adjacent ASU. 
 
Superposition of BAZ2A-H3 3-mer with BAZ2B-Fr 21. 
 
Analysis of the superposition of the complex of BAZ2A with H3 ART and Fr 21, can 
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underline interesting features that may be of importance towards the elucidation of the 
binding mode and to assist future optimization of the leading fragment. The overall area 
occupied by the fragment is comparable with the area occupied by the backbone of the 
H3 tripeptide. Interestingly, the fragment in BAZ2B adopt a different orientation from 
the tripeptide ART. The NH2 group of Fr 21 displaces the water molecule W1, located 
between the side chain of D1950 and the carbonyl of L1948 (Figure 3.28). This water is 
necessary for the binding with the peptide, as described in Chapter 2 (Figure 2.2). The 
carbonyl group of Fr 21 is involved in H-bond with the backbone of L1948, in a similar 
fashion to the carbonyl of R2. The thiazole group is in proximity of the hydrophobic 
region occupied by the methyl group of the side chain of T3. 
 
Figure 3.28. Superposition of the crystal structure of BAZ2B PHD in complex with Fr 21 
and BAZ2A PHD in complex with ART. 
Superposition of the crystal structure of BAZ2B PHD (cartoon, in pale green) in complex with Fr 21 (violet 
sticks) and BAZ2A PHD (wheat cartoon) in complex with ART tripeptide (grey sticks). Oxygen, nitrogen and 
sulphur are respectively reported in red, blue and yellow. Water W1 is reported as red dot. 
 
3.9.2.2 Fragment 23: structural studies of binding mode 
 
Fr 23 was soluble in water up to 1 M concentration. Soaking fragments up to 50 mM and 
up to 24 h was well tolerated from crystals of BAZ2A and BAZ2B which both assumed a 
136 
 
brown colour typical of the fragment solution (figure 3.29). 
 
Figure 3.29. Appearance of crystals of BAZ2A/B after 24h soaking with Fr 23.  
Crystals of BAZ2B PHD in (A) and of BAZ2A PHD in (B).  
 
Structures of PHD of BAZ2A/B were solved as described in chapter 6.5 and refinement 
statistics are reported in the Table 3.11. 
Inspection of the electron density identified the ligand presence in the histone pocket 
of both PHDs. Extra electron density in the histone pocket of two chains, B and C was 
observed for BAZ2A protein, and in one chain for BAZ2B protein. In figure 3.30 and 3.31, 
the fragment bound structure of BAZ2A and BAZ2B with Fr 23 solved at 2.7 Å resolution.  
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Figure 3.30. Crystal structure of BAZ2A PHD in complex with Fr 23.  
(A) Crystal structure of BAZ2A PHD (pale green surface) in complex with Fr 23 (pink sticks). Residues 
interacting with the fragment are drawn in sticks. (B) Planar representation of the interactions of the 
fragment with BAZ2A. Distance of the hydrogen bonds are in Å . HBA stands for hydrogen bond acceptor 
and HBD for hydrogen bond donor, relatively to the residue on the protein. (C) Fo-Fc map in grey countered 
at 2σ. 
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Figure 3.31. BAZ2B PHD in complex with Fr 23.  
A) Crystal structure of BAZ2B PHD (pale green surface) in complex with Fr 23 (pink sticks). Residues 
interacting with the fragment are drawn in sticks. (B) Planar representation of the interactions of the 
fragment with BAZ2B. In Å the distance of the hydrogen bonds. HBA stands for hydrogen bond acceptor 
and HBD for hydrogen bond donor, relatively to the residue on the protein. (C) Fo-Fc map in grey countered 
at 2σ. 
 
Figures 3.30 and 3.31 highlights the hotspots of the interaction, which show to be 
consistent between the two proteins and in agreement with the heat map obtained 
from HSQC titration of both proteins (figure 3.24). The amino group on the aromatic ring 
points towards hydrogen bond formation with the backbone of E1689 in BAZ2A and of 
E1944 in BAZ2B, while we expected to catch interactions with the side chain. The fact 
that we are not able to observe this interaction in the crystals does not mean that is not 
happening in solution, indeed, the particular crystal form adopted could be a limitation 
that does not allow the movement of the side chain towards the aniline group.   
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Figure 3.32. Superposition of the crystal structure of Fr 23 bound to PHD BAZ2A/B. 
Superposition of the crystal structure of BAZ2B (cartoon, in palegreen) in complex with Fr 23 (pink sticks) 
and BAZ2A (cartoon, in palegreen) in complex with Fr 23 (orange, sticks). The arrow indicates the different 
orientation of the terminal amino group. 
 
Key differences are observed in the binding mode of the two proteins. Firstly, the 2-
amino acetamide planes assume a different orientation. In Fr 23 bound to BAZ2B the 
torsion angle of the acetamide plane is planar to the aromatic ring, while in Fr 23 bound 
to BAZ2A the torsion angle is clockwise rotated of 46° compared to the plane of the ring. 
This rotation  is needed to retain the hydrogen bond with the protein despite the 
aromatic ring being pushed further by the presence of V1713 in a closer conformation 
in BAZ2A than BAZ2B (Figure 3. 32). Indeed, the orientation of the 2-amino acetamide 
plane in Fr 23 bound to BAZ2A is retained also in Fr 19 in complex with BAZ2A (figure 
3.33). 
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Figure 3.33. Superposition of the crystal structure of Fr 23 and Fr 19 bound to PHD 
BAZ2A. 
Superposition of the crystal structure of BAZ2A (wheat cartoon) in complex with Fr 23 (pink sticks) and Fr 
19 (cyan sticks) showing that the 2-amino acetamide retains the orientation in both fragments 
(highlighted by red dashed circle). 
 
This difference in the torsion angle accounts for some differences in the binding mode 
between the two proteins. The H-bond distances in BAZ2B are shorter and we observe 
an electrostatic interactions between G1971 and the amide of the ligand (figure 3.32 
and 3.31), while in BAZ2A, the correspondent glycine residues is involved in electrostatic 
interactions with the N-terminal  amino group of the ligand (figures 3.30 and 3.32).  
 
Comparison between binding mode of Fr 23 and ART peptide 
 
The superposition of the complex of BAZ2A with Fr 23 and ART peptide (Figure 3.34) 
revealed molecular details previously highlighted in the superposition with Fr 21, in 
figure 3.28.   
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Figure 3.34. Superposition of complex of BAZ2A with Fr 23 and ART tripeptide. 
Superposition of the crystal structure of BAZ2A PHD (wheat cartoon) in complex with Fr 23 (pink, sticks) 
and ART tripeptide (grey sticks). Waters are reported as red dots and bond distance with black dashes. 
 
3.9.2.3 Summary of the crystallographic data 
 
Table 3.10 summarizes the number of structures obtained for each fragment and 3-mer 
peptide and the number of ligands found in each asymmetric unit. Table 3.11 A and 3.11 
B display the crystallographic data of the structures solved. 
 
Protein Protomers 
in ASU 
ART 3-mer  
peptide bound 
Fr19 
bound 
Fr21 
bound 
Fr23 
 bound 
BAZ2A PHD 4 3/4 2/4 X 2/4 
BAZ2B PHD 2 X X 1 1 
 
Table 3.10. Summary of the peptide and fragment bound structures and number of 
ligand for each ASU. ‘X’ denote no fragment or peptide bound. 
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Data collection BAZ2A-ART BAZ2A-Fr 19 BAZ2A-Fr 23 
Space group P43212 P43212 P43212 
Cell dimensions    
a, b, c (Å) 73.4, 73.4, 99.7 72.1, 72.1, 99.2 72.8, 72.8, 99.6 
α, β, γ (°) 90, 90 , 90 90, 90 , 90 90, 90 , 90 
Resolution (Å) 46.03 (2.0) 45.34 (1.9) 45.2 (2.7) 
Unique 
observations 
19049 21069 7841 
Completeness 99.9 99.3 100 
Redundancy 8.6 (9.0) 3.8 (4.0) 12 (12.3) 
CC1/2 0.99 (0.78) 0.99 (0.83) 0.99 (0.95) 
I/σI 15.5 (2.1) 14.3 (2.6) 10.7(3.7) 
Refinement    
Rwork/Rfree 19.6/23.5 20.3/23.7 17.4/22.4 
B factor (Å2) 35.3 36.7 62.7 
Rmsd bond (Å) 0.011 0.01 0.005 
Rmsd angle (°) 1.6 1.7 0.75 
Ramachandran 
statistics 
   
Allowed (%) 0.5 0.5 2.5 
Favoured (%) 99.5 99.5 97.5 
Outliers (%) 0 0 0 
 
Table 3.11.A. Crystallographic data of the BAZ2A PHD structures. 
In parentheses data relative to highest resolution shell. 
 
 
 
 
 
 
143 
 
Data collection BAZ2B-Fr 21 BAZ2B-Fr 23 
Space group P212121 P212121 
Cell dimensions   
a, b, c (Å) 38.3, 45.4, 65.0 37.8, 45.5, 64.8 
α, β, γ (°) 90, 90 , 90 90, 90 , 90 
Resolution 65.04 (1.95) 64.83 (2.7) 
Unique 
observations 
8453 3349 
Completeness 97.7 (87.1) 100.0 (100.0) 
redundancy 5.8 (4.9) 5.6 (5.9) 
CC1/2 0.99 (0.91) 0.96 (0.56) 
I/σI 18.1 (1.3) 5.3 (1.9) 
Refinement   
Rwork/Rfree 18.5/23.8 22.6/29.9 
B factor (Å2) 34.1 67.7 
Rmsd bond (Å) 0.02 0.014 
Rmsd angle (°) 1.88 1.73 
Ramachandran 
statistics 
  
Allowed (%) 2.7 5.5 
Favoured (%) 97.3 94.5 
Outliers (%) 0 0 
 
Table 3.11.B. Crystallographic data of the BAZ2B PHD structures. 
In parentheses data relative to highest resolution shell. 
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3.10 DISCUSSIONS 
 
In this chapter, I presented extensive biophysical and structural validation of six out of 
19 fragments identified from an in silico screening. The KD and potential region of binding 
were determined for some of the fragments using CSPs. One of the validated fragments, 
Fr 19, led to a co-crystal structure with BAZ2A PHD, although the electron density did 
not cover the entire small molecule. This first fragment-bound structure identified a key 
recognition site at the histone binding pocket, consistent with the chemical shift 
perturbation data observed by HSQC NMR. 
 
These co-crystal structures guided further optimization of the fragment in order to 
improve the binding mode, by purposefully targeting the hydrophobic region of the 
histone pocket and the acidic wall. Four fragments were designed as outcome of this 
optimization and their binding mode was further characterized by HSQC and X-ray 
crystallography. Two of these fragments were successfully soaked in BAZ2A and BAZ2B 
PHD. I solved the structure of Fr 21 with BAZ2B and Fr 23 with both BAZ2A and BAZ2B 
PHDs. All fragments bound to the same conserved hotspots, in agreement with the 
HSQC data. Analysis of these structures led to the identification of similarities and 
differences in molecular recognition between the two proteins, as well as similarities 
and differences in binding mode between the fragments and the histone peptide.  
 
In summary, this work furnishes a blueprint for the development of future improved  
ligands of this family of PHDs: BAZ2A and BAZ2B. All fragments recapitulate a conserved 
hotspot at the histone binding site, which however is not explored by the histone tail. It 
therefore may be possible to combine information from the two binding modes e.g. by 
merging features of the two types of molecules, to enhance the yet moderate binding 
affinity of these compounds. Further exploration of the peptide binding features could 
contemplate a rational design to take advantage of the important histone tail helicity 
revealed in the previous Chapter, for example by linking our identified fragments with 
synthetic scaffolds able to mimic or recapitulate those alpha helical features. Such 
approaches could aid the development of novel chemical probes disrupting the 
interaction between BAZ2A/B PHD finger domains and histone H3, which could 
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ultimately provide new chemical tools to interrogate the still elusive molecular 
structure, activity and biological function of these proteins. 
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CHAPTER 4. 
STRUCTURAL STUDIES AND DE-ORPHANIZATION OF 
PHD-BROMODOMAIN TANDEM MODULES 
4.1 MOTIVATION OF THE WORK 
 
PHD finger- bromodomain tandem modules characterise several chromatin-associated 
proteins and are generally known to interact with histone proteins. Mutations 
associated with their loci are often linked to tumorigenesis and genetic disorders 39, 55. 
Since their involvement in the development of human disease, these reader domains 
are regarded as potential targets for drug development 36, 43, 70. 
This chapter focuses on the identification of the histone binding partner of the PHD 
finger – bromodomain of BAZ1B and TRIM66 with the aim to elucidate, at molecular 
level, the basis of this interaction. Although it is known from literature that both proteins 
are involved in diseases 108, 115, 116, 140, the structure-function properties of their PHD-
bromodomain modules remain elusive, and no information have been gained yet about 
their substrate binding partner. Indeed, if it is possible to associate binding of an 
acetyllysine residue on a histone tail to the bromodomain, the binding partner of the 
PHD zinc finger is less predictable since these domains can recognise a much broader 
range of substrates and PTMs 46. Moreover, it was noticed that these two tandem 
modules are both present at the C-terminus of the protein but the linker inter-
connecting the two reader domains is substantially different in length, suggesting a 
potential different histone recognition mode for the two tandems (either in cis or trans). 
The main goal of the work here presented is to provide structural information and 
elucidate the molecular recognition features of these domains. In doing so, we aim also 
to develop a platform of biophysical and structural assays to assist the future design of 
small molecules able to target these reader domains. The future ambition will be to 
furnish a chemical scaffold that could be further developed either into an inhibitor or 
into a probe useful to investigate the biological function of the proteins themselves. 
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4.2 BAZ1B ALSO KNOWN AS WSTF 
 
The strategy adopted to study the PHD-BrD tandem module of BAZ1B was to dissect the 
tandem in the two individual reader domains, PHD zinc finger and bromodomain, which 
were investigated first as independent units. Here, there are described the efforts 
toward crystallization of BAZ1B PHD, which however proved unsuccessful, and several 
attempts to identify the histone binding partner of this PHD finger. 
 
4.2.1 Insights into deorphanization of PHD of BAZ1B 
 
The BAZ1B PHD construct (figure 4.1) was designed based on the constructs of PHDs of 
the same BAZ family, previously studied in the lab (BAZ2A/B). It was cloned into the 
pCri11b plasmid which allows expression of BAZ1B PHD fused, at its N-terminus, with a 
6His-SUMO tag. The expression of the BAZ1B PHD was performed in BL21(DE3) E.coli 
strain and the purification followed four steps, described in details in the Experimental 
section.  
The first step was a Ni2+ affinity chromatography, followed by overnight cleavage of the 
His6-SUMO tag and a further step of affinity chromatography for the tag removal. At this 
point, pooled fractions from the previous step were dialyzed to reduce the salt 
concentration in the buffer, and the protein was further purified using anion exchange 
chromatography.  The last polishing step was size exclusion chromatography (SEC) in 
buffer supplemented with 20 µM ZnCl2 to assure native conditions to the sample, given 
the protein chelates two zinc ions (figure 4.1). The final yield obtained was 10 mg per 
litre of culture and the right MW was confirmed by ESI-MS (figure A.1 Appendix). 
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Figure 4.1 Purification of PHD zinc finger domain of BAZ1B. 
(A) Amino acid sequence of PHD of BAZ1B. Highlighted in orange the Cys and in blue the His residues 
belonging to the conserved motif Cys4-His-Cys3 that coordinates the two zinc ions. (B) Gel filtration 
elution profile of PHD of BAZ1B. In blue, the protein absorbance. (C) SDS-page: from left to right the 
fractions under the peaks with the protein ladder on the right.  
 
 
1D proton NMR spectrum provided a rapid evaluation of the protein folding.  
 
 
Figure 4.2 1D NMR spectrum of PHD of BAZ1B. 
In A and B the details of the two most interesting regions of the spectrum. 
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In a spectrum of folded protein, the signal is scattered on a large range of chemical shifts 
and the peaks appear sharp and narrow because the protons are constrained in a 
specific conformation and the environment of each proton is influenced by the tertiary 
structure of the protein. In an unfolded spectrum we would see a set of peaks not so 
widely dispersed and with a broad shape; the reason is that in an unfolded protein the 
protons can experiment different environments and the signal is just an average of 
them.  
The most meaningful part of the spectrum is the region indicated with A in fig. 4.2. It 
represents the amide protons region, between 7-10 ppm, which also contains aromatic 
protons. In B there is the aliphatic region. In Fig. 4.2, the signals are well spread on all 
the spectrum and the peaks are sharp, so it is possible to infer that the protein is folded. 
 
4.2.1.1 Crystallographic efforts to solve the apo form structure of PHD of BAZ1B 
 
The NMR structure of the apo form of PHD of BAZ1B was already available when I started 
my PhD. Despite this, it was deemed important to obtain a crystal structure of the apo 
protein since it could have been used, in soaking experiments, to study, at molecular 
level, interactions with its potential binding partner.  
Several crystallization screening were performed using sparse matrix and grid screens at 
4°C and 20°C with different concentration of proteins, in a range between 3 and 14 
mg/mL. Crystallization drops were visually inspected and most of them resulted in 
precipitate or clear drops. It was noticed that in the PACT screen (Qiagen), upon 
examination, all drops were clear, suggesting the protein is highly soluble in these 
conditions and saturation was not achieved. Two conditions were chosen to perform 
some buffer exchange experiments. Indeed, there are examples, in literature, showing 
how conditions that increase the solubility of the protein can be beneficial to induce 
crystallization 160. Two conditions were chosen from the screening:  C7 (200 mM NaCl 
and 100 mM Tris pH 8) and D7 (200 mM NaCl and 100 mM HEPES at pH 7) where drops 
appeared to be extremely clear. The PHD of BAZ1B was buffer-exchanged in these two 
empirically identified enhanced-solubility buffers, concentrated to 12 mg/mL and 
rescreened against the PACT conditions. The outcome was the formation, after few 
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days, of microcrystals in many drops of the plate. In order to decrease the nucleation 
points, the protein/crystallization buffer ratio was decreased, but also in this case no 
hits were obtained.  
 
4.2.1.2 In situ proteolysis and optimization of the construct 
 
A factor that can influence the rate of success of the crystallization process is the choice 
of construct. Indeed, it is important to avoid the presence of flanking regions which 
might constitute an entropic and steric barrier toward the formation of crystal packing. 
Indeed, analysis of the crystal structures of the homologous PHD of BAZ2A and BAZ2B, 
previously solved in our lab 46, showed that the flexible N-terminal tails of these PHDs 
become ordered in the crystal packing. These N-terminal tails are important for the 
formation of homodimeric anti-parallel β-sheet contacts in the crystal packing. 
However, it may be that for PHD of BAZ1B, this hypothetic flexible extension are an 
obstacle for the crystallization process. 
An in situ preotelysis 161 approach for crystallization was attempted to potentially 
overcome the problem of having flexible tails in the protein. Minimal traces of protease 
were added to the crystallization drops in the screen (protease/protein ratio~1/5000 ). 
The choice of the protease was guided by the cleavage site and by enzyme availability. 
Papaine was the elected one, with the cleavage site that includes a sequence like XX-
hydrophobic-X -R/L- X(excluded V), where X is a generic amino acid. Eventually, also this 
method did not lead to any crystallization hit. 
Next, it was decided to design a new construct removing the first four N-terminal 
residues (His-Met -Ala-Glu) by quickChange PCR. The protein was expressed and purified 
following the same protocol used for the previous construct, and concentrated to 7 
mg/ml. Crystal screen PACT, PegIon, Morpheus and JCSG+ were performed at 20°C. 
Inspection of the plates identified only formation of microcrystals and precipitate, apart 
from few clear drops. No improvement in the generation of crystal hits was observed 
for this shorter construct. 
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4.2.1.3 Matrix microseeding screening experiments (MMS) 
 
The crystallization process for the PHD zinc finger of the protein BAZ1B has been very 
challenging and despite the several conditions screened, the crystallization drops 
inspected so far resulted in precipitate, microcrystals or clear drops. In light of these 
results, it was decided to adopt another approach: matrix microseeding screening 
experiments (MMS). It consisted in the usage of crystal seeds, that are small pieces of 
larger crystals from which it is possible to grow a new crystal, added to the ordinary 
crystallization screens 162, 163 and not only in the optimization step. To understand how 
microseeding could help in the crystallization process, it is helpful to refer to the diagram 
of the crystallization process in figure 4.3, adapted from Stewart et al. 164. Crystallization 
is a process influenced by several factors: precipitants, protein concentrations, 
temperature, etc. In a simplistic case, we can interpret this phenomenon as dominated 
by two main factors: protein concentration and precipitant concentration (figure 4.3).  
 
Figure 4.3. Phase diagram of the crystallization process. Figure adapted from Stewart et al.164 
Schematic phase diagram reporting four main areas: undersaturated, metastable, labile and precipitation 
zone. The arrows are vectors representative of the water evaporation process in the vapor diffusion setup. 
The initial and ending points of the arrow are representative of the initial and final conditions of the 
process. Thick arrows delineate the process of crystallization of those conditions that overcome the 
metastabile zone ending up in the labile zone. Dashed arrows represent conditions that end up in the 
metastabile zone, while thin arrows depict conditions for which no crystals are observed because too high 
(precipitation) or too low (undersaturation) concentration of the components. 
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At high concentration of both components, precipitation is occurring and protein is 
aggregating in an amorphous way. Lowering one of the two components, we fall in 
either nucleation (labile) zone or the metastable zone. The nucleation zone is where 
nuclei form and crystals will grow. The ideal situation is the formation of a few nuclei so 
the majority of the protein present can increase the size of the nucleus giving proper 
single crystal. In the metastable zone, crystals are only allowed to grow but there are no 
conditions for the nucleation to initiate. If a seed is added in the metastable zone, it will 
grow larger giving a crystal. The line between the metastable and labile zone is 
representative of the solubility of the protein. Instead, in the undersaturated zone, 
conditions stay clear and no crystals can grow. Difficult in crystallizing often comes when 
the nucleation zone (labile zone) is very small and there are really few conditions that 
can lead to the formation and growth of these nuclei. In situation like this, the addition 
of seeding in the metastable zone can assist the crystal formation.  
In literature, there are several cases of proteins where the MMS method performed 
even with homologous proteins, has notably increased the number and types of hits 
where little or no nucleation is normally observed 162, 165, 166.  
 
I decided to perform MMS using cross-seeding with seed of the homologous PHDs of 
BAZ2A and BAZ2B 46, 167. Crystallization screenings were set up following the protocol 
from Douglas Instruments (http://www.douglas.co.uk). For the preparation of the 
microseeds stock the Seed Bead kit provided by Hampton Research was used, following 
the instructions of the manufacturer. Unfortunately, also random microseeding 
screening did not provide any interesting hit for the PHD of BAZ1B, but only 
microcrystals and precipitate. 
 
4.2.1.4  Lysine methylation 
 
A potential barrier to the crystallization of BAZ1B PHD could be the high flexibility of 
some regions of the protein that might be detrimental to the formation of a well-
ordered crystal lattice, as for example the sequence comprising residues 1192-1198 that 
is enriched in K residues and is shown to be highly flexible in the NMR structural 
ensemble (Figure 4.4).  
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Figure 4.4. NMR ensembles of BAZ1B PHD. 
Cartoon representation in orange of the NMR ensembles of the PHD of BAZ1B. In sticks are reported the 
residues belonging to the area highlighted in red on the protein sequence and enriched of lysine.  
 
Protein surface engineering by chemical modifications is an interesting approach for the 
reduction of the protein surface entropy due to the mobility of solvent-exposed 
residues. Indeed, it is a procedure that requires less time and labor compared to the 
more classical surface entropy reduction by mutagenesis 168, 169. A method that has 
proven to be successful on proteins refractory to the crystal formation, is the chemical 
modification of highly entropic residues, as for example, methylation of solvent exposed 
lysine 168. 
Lysine methylation of the PHD of BAZ1B was performed following the protocol from 
Walter et al. 168. The MALDI-TOF mass spectrometry confirmed that all the Lysine 
residues were dimethylated and this was a clear signal that all of them were on exposed 
surface (figure A.3 in Appendix). The dimethylated BAZ1B PHD was purified and 
concentrated to 14 mg/mL. Several crystal screening were performed in sparse matrix 
and grid screens at 4°C, 15°C and 20°C. Unfortunately, no evidence of crystal formation 
was observed.  
 
All these failures in the crystallization of the apo form of the PHD of BAZ1B motivated 
the choice to focus the next efforts on the identification of a possible histone binding 
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partner for this PHD. Indeed, the discovery of a binding partner might have been crucial 
for the formation of a stable complex, more liable of crystallization.  
 
4.2.1.5 Identification of the histone binding partner of BAZ1B PHD 
 
Sequence alignment of the PHD of BAZ1B with the PHDs of BAZ2A/B suggests that the 
binding of BAZ1B PHD to the unmodified histone H3 is conserved, since the majority of 
the residues in the region that binds the histone (circled with the red box in figure 4.5) 
are conserved. Moreover, it was noticed from the alignment that this domain lacks of 
the hydrophobic cage typical of the methyllysine PHD binders 45. In order to validate this 
hypothesis, an ITC titration was performed but no meaningful binding was detected 
towards the wild type H3 21-mer peptide. 
 
Figure 4.5. Sequence alignment of the BAZ1B PHD with BAZ2A/B PHD. 
Sequence alignment was performed using Jalview Software 170. Red arrows highlight the Cys4-His-Cys3 
conserved motif of the PHD. The red box is highlighting the residues of the β-strand of the PHD that are 
involved in histone binding. Conserved residues are coloured in blue. 
 
BLI experiments were next performed in order to investigate if PTMs on the histone tail 
could be necessary for the binding to the PHD of BAZ1B.  
BAZ1B PHD protein was screened against a library of 94 different peptides resembling 
the N-terminal tails of H3 and H4 histones, containing several PTMs. BLI response are 
reported in figure 4.6. 
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Figure 4.6. BLI responses of BAZ1B PHD towards H3/H4 peptide library.  
Biotinylated peptides were immobilized on the surface of the BLI tips while the protein was in the well. 
Highest response detected are shown in red (0.27 nm for H4 K12me2), lowest responses in green (0.04 
nm for the unmodified tail H4 11 -31 aa). Intermediate response are in orange. (A-B) BLI responses of PHD 
of BAZ1B towards H3 tails. (C) BLI responses for the H4 N-terminal tail. (D) Legend for the post 
translational modifications associated to the H3/H4 tails. 
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Results showed strong binding preference for the unmodified H4 tail, indeed, in the 
picture is visible a strong red cluster in correspondence of H4 and its derivatives. 
Additional modifications, especially acetylation in position H4K5, H4K8 and H4K12, 
decrease the binding with the exception of the di-methylation in position K12. 
Furthermore, the response increases again with the methylation on the K20 (H4K20me). 
Another interesting observation comes out from the sequence pattern around H4K5, K8 
and K12; indeed, they share  common motifs as: GRGK5GG, K5GGK8LG and GLGK12GG. 
Acetylation on the Lys in this position was observed to reduce the binding response. 
In agreement with the ITC results, no binding was detected for unmodified N-terminal 
H3 tail. This is in marked contrast with the PHD fingers of BAZ2A and BAZ2B 45. However, 
the binding response of BAZ1B for H3 histone slightly increases as a result of tri-
methylation in position K9, and acetylation or tri-methylation in position K14.  
Simultaneously, PHD of BAZ2B was used as positive control against the same peptide 
library; conditions set up of the experiments were identical. The results obtained for 
BAZ2B PHD were equivalent to those previously obtained in the lab 45, as expected. This 
allowed comparison of the binding responses between the two proteins. Although the 
intensities of the BLI responses were comparable, remarkable differences were 
observed in the shape of the binding curves, which can be informative of the type of 
binding. With BAZ2B PHD, the sensorgrams, after the initial fast rise, reached 
immediately a stable plateau and the dissociation step went back to the initial baseline 
(figure 4.7, upper panel).  Sensorgrams of BAZ1B PHD showed a biphasic nature with an 
initial fast rise followed from a slower rate of binding that does not reach saturation 
(figure 4.7, lower panel). The biphasic character of the curves in BAZ1B was also 
reflected in the dissociation step, where the initial fast decay was followed by a slower 
rate without reaching the baseline (figure 4.7 B). This trend is representative of non-
ideal heterogenous binding that could be indicative of non-specific binding of BAZ1B 
PHD to the histone peptides 171.  
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Figure 4.7. Raw BLI sensorgrams obtained for BAZ1B and BAZ2B PHD. 
Raw BLI responses for BAZ2B PHD (upper panel) and for BAZ1B PHD (lower panel) towards 94 different 
biotynilated peptides loaded on the sensor tip. Responses are reported in nm on the y axis over the time 
on x axis. 
 
The results obtained from this high-throughput assay were subsequently validated by 
protein-observed NMR, as detailed below. 
 
4.2.1.6 NMR backbone assignment of BAZ1B PHD 
 
To further study the interactions between BAZ1B PHD and its potential binding partners 
identified in the BLI screening it was decided to use protein-observed NMR experiments. 
The first step was to assign the HSQC resonances of BAZ1B PHD. Assignment of the PHD 
of BAZ1B was available in literature 172 but it was here decided to perform our own 
assignment since we used a longer construct. To this purpose, double labelled 15N/13C 
PHD of BAZ1B was expressed. The level of isotopes enrichment in the expressed protein 
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was determined by electrospray ionization mass spectrometry (figure A.2 in Appendix) 
and estimated to be over 95%. Next, sequence-specific backbone assignments were 
obtained from the identification of intra- and inter-residue connectivities in a series of 
double and triple resonance spectra: 15N/1H HSQC, 15N/13C/1H HNCO, HNCACB, 
HN(CO)CACB. All the backbone amide protons were assigned with the exception of 
prolines and the N-terminal His (not observable since the terminal NH3+ group 
exchanges with the solvent) (figure 4.8).  
 
 
Figure 4.8. HSQC spectrum of BAZ1B PHD with the backbone assignment. 
Assigned peaks are labelled in black with the name of the amino acid. 
 
4.2.1.7 CSPs experiments using histones derived peptides 
 
To confirm the validity of the results of the BLI experiments, and eventually describe the 
region of BAZ1B PHD of binding of the histones, chemical shift perturbation (CSP) 
experiments were performed using histones derived peptides. A set of four 20-mer 
histone peptides derived from the unmodified N-terminal tail of H2B, H2A, H3 and H4, 
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was synthesized. Prior to inserting any specific modification on the histone tail, we 
tested unmodified histone peptides by CSPs. The reason for this was that in BLI the 
highest response was detected for the unmodified H4 peptide, consequently, it was 
expected to be the stronger binder amongst the series. 
 (15N, 1H)-HSQC spectra were recorded on 15N labelled PHD of BAZ1B with increasing 
concentration of 20-mer peptide. Δδ were calculated at the highest ratio using the 
CcpNMR software 154 and plotted for each protein residue on a histogram. CSPs obtained 
for each peptide were projected onto the BAZ1B structure (PDB: 1F62) by colouring each 
residue according to the intensity of the shift registered (figure 4.9).  
Within the series of the four peptides, highest shifts were reported for H4 and H2A 
(figure 4.9 A and 4.9 B) that share conserved sequences in the first ten residues (figure 
4.10). 
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Figure 4.9. Characterization of the interaction between H2A N-terminal tail and PHD 
of BAZ1B in solution by NMR. CSPs induced by 20-mer histone peptides projected onto NMR 
structure of BAZ1B (PDB:1F62). CSPs are reported in ppm and grouped according to the intensity of shift. 
(A-D) CSPs induced by the H4, H2A, H3 and H2B peptides. 
 
Figure 4.10. Sequence alignment of the 20-mer N-terminal H2A and H4 histone 
peptides. Alignment was performed with Jalview software 170 . Residues 100% conserved are highlighted 
in blue. 
 
The CSPs map of BAZ1B were compared to the CSPs map obtained for BAZ2A/B PHD. 
Although the intensities observed were less intense compared to the homologous 
protein, the hotspots of interaction were conserved (figure 4.11).  
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Figure 4.11. CSPs induced by histone peptides on BAZ2A PHD and BAZ1B PHD. 
(A) CSPs induced by titration of H3 10-mer on BAZ2A PHD and projected of the structure of BAZ2A PHD 
(PDB: 4QF2). (B) CSPs induced by titration of H4 21-mer on BAZ1B PHD and projected of the structure of 
BAZ1B PHD (PDB: 1F62).The residues involved in the strongest and medium shifts are respectively 
coloured in red and orange. In yellow weak shifts and grey all the other residues with no significant shifts. 
 
To further investigate and validate the reliability of these interactions, isothermal 
titration calorimetry (ITC) experiments were performed. H2A and H4 peptides were 
titrated against PHD of BAZ1B. H2A and H4 peptide were tested against PHD of BAZ1B 
at two different concentrations. Initially at 1.5 mM peptide versus 60-100 uM protein 
but since the signal detected was too low, it was decided to increase the peptide 
concentration up to 3 mM for H2A and 2.5 mM for H4 versus 100 uM protein; in this 
case the buffer concentration was increased up to 100 mM HEPES in order to avoid 
buffer mismatch due to changes in pH. The only visible result observed was the change 
from exothermic to endothermic reaction but no binding was detected. Also reduction 
of the temperature of the experiment did not improve the heat of binding. 
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4.2.1.8 Histone array screening 
 
To further explore the possibilities of binding of this PHD towards histone peptides, it 
was decided to use a modified histone array to screen for modifications on the N-
terminal histone tails of H3, H4, H2A and H2B that could influence the binding.  
Prior to testing the PHD of BAZ1B, a positive control was tested using the 6His -G9a tudor 
domain, following the manufacturer instructions (figure 4.12 A-B). The amount of 
protein suggested for the assay is in the range between 10 nm to 1 µM. In our case, the 
choice of the concentration of BAZ1B to use was directed from previous considerations 
on the HSQC that showed very weak affinities. It was chosen to use 400 nM, an 
intermediate value, in order to catch also low affinities without generating high 
background. From the array, no interactions were spotted. The array appears dominated 
by a strong background, with the appearance of few spots showing no reproducibility 
within the duplicates, suggesting no specificity of binding for any histone peptide (figure 
4.12 C-D). 
 
Figure 4.12 A-D. Histone peptide array. 
(A) and (C) Images of the ECL detection of the incubation of the histone array duplicates, respectively, 
with the positive control G9a and with BAZ1B PHD. (B) and (D) Distribution of the spots intensities within 
the histone array duplicates. In (B) results relative to G9a control and in (D) relative to PHD of BAZ1B. 
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4.2.1.9. PHD zinc finger of BAZ1B: does it bind any histone tail? 
 
The PHD zinc finger is known to preferentially recognise the histone tails of the 
nucleosome. Despite this, there are few examples in literature, reporting that this 
domains could also recognise DNA 173 or have a mere function of structural support to 
the adjacent domain 174, without recognising any histone tail. Indeed, PHD zinc finger 
are often found in proximity of another reader domain, for example a BrD, as in the case 
of BAZ1B. Interesting is the example reported from Zeng et al. 175, describing the case of 
PHD of TRIM28 that does not recognize any histone tail but is essential for the structural 
and functional integrity of the tandem domain, as well as the case of the PHD of the CBP 
protein 174.  
 
Based on the unsuccessful attempts at characterizing histone tail binding, and on the 
observations above, it was decided to expand the structural and biophysical studies by 
including the adjacent bromodomain in our protein constructs. It was hoped that this 
could help to understand if the two domains within the PHD-BrD tandem module of 
BAZ1B may play a role within each other.  
 
4.2.2 Bromodomain and tandem constructs of BAZ1B 
 
4.2.2.1 Bromodomain of BAZ1B 
 
Sequence alignment of BAZ family bromodomains showed that the acetyllysine binding 
motif is conserved (figure 4.13) 45, 136. In the literature, it is reported that the 
bromodomain of BAZ1B binds in a promiscuous way  all the acetyllysine on H3, without 
showing preference for any mark 37.    
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Figure 4.13. BAZ bromodomains alignment. 
Sequence alignment of bromodomains of BAZ family was performed using Jalview Software 170. Colors 
legend: in blue hydrophobic residues; in red positively charged residues; in magenta, negatively charged 
residues; in green polar residues; cysteine in pink; glycine in orange; proline in yellow and in cyan aromatic 
residues. The green arrow highlights the asparagine residue involved in the recognition of Kac. The 
conservation graph on the bottom is representative of the level of conservation of the residues. 10 is the 
highest score and is reported as ‘*’. 
 
In order to verify this hypothesis, expression and purification of the bromodomain of 
BAZ1B was attempted. Constructs of different length were cloned into pET28a plasmid. 
The His tag was chosen as purification tag since the His-SUMO tag has a molecular 
weight comparable with the one of the BrD.  I first attempted the purification of a short 
construct BrD(residues 1343-1444) including only the residues strictly predicted to be 
part of the bromodomain organization, in order to create a construct prone to 
crystallization. Phyre2 server  was used for the structural prediction of the domain 176, 
while the IUPred server 177, 178 confirmed that this region is highly structured. 
A first expression trial was performed using the BL21 E.coli strain and induction of the 
protein with 0.5mM [IPTG] at two different OD600 ~1 and ~ 2. After induction, cells were 
incubated overnight at 20°C and then spun down, re-suspended in lysis buffer (20 mM 
Tris-HCl, 5mM Imidazole, 2 mM TCEP, 500 mM NaCl pH 8) and lysed with the French 
Press. Three fractions were analysed by SDS-PAGE: the total, which includes the cell 
suspension after cell lysis, the soluble and insoluble fractions, obtained after spinning 
down the lysate. Results of this first expression trial are reported in figure 4.14. 
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Overexpressed protein runs on the expected position on the lane, according to its MW 
(~ 12.7 KDa) but it was found only in the total and insoluble fractions.  
 
Figure 4.14. Expression trial at two different OD600 of induction for BrD(1343-1444)  of 
BAZ1B. 
Expression trial of BrD(1343-1444) of Baz1B after induction at OD600 ~1 on the left and at OD600 ~ 2 on the 
right. “P-Ind” stands for “pre-induction fraction”. “Tot” is the fraction of the lysate straight after lysis. 
“Ins” represents the insoluble fraction. “Sol” stands for the soluble fraction. 
 
In an attempt to improve the solubility of the construct, BAZ1B BrD was co-expressed 
with the chaperon GroEL. This approach has been widely used in the last few years to 
increase folding and solubility of recombinant proteins, and reducing their aggregation. 
In addition to GroEL co-expression several changes were introduced into the expression 
and lysis process to maximize the protein solubility. Following induction of protein 
expression with 0.5 mM of IPTG the cell culture was incubated for 16 h at a lower 
temperature 16 °C. Furthermore, the lysis buffer was supplemented with 1 M NaCl (to 
help the solubility of the protein) and 10% glycerol (to stabilize and prevent protein 
aggregation) 179. Finally, cells lysis was performed with a milder process through 
sonication. Unfortunately, also this optimized expression and lysis process did not yield 
soluble BAZ1B Brd. 
 
Next, the addition of surfactants and a denaturing agent was tested to improve the 
solubility of this construct. Tween 20 and Triton X-100 were used as detergent  
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Mild detergents can assist the protein solubility without disrupting native interaction 
but interacting with hydrophobic portion of the protein sustaining its miscibility in 
water. Urea was used as denaturing agent. Urea is known to destabilize the protein 
conformation through direct interactions with polar residues and peptide backbone but 
also altering the water structure and dynamic 180. Therefore, the elimination of urea, 
should lead to the refolding of the protein, in presence of stabilizing agent. This 
approach is preferentially chosen in those cases where it is possible to check the quality 
of the refolding process of the protein, for example, testing the activity of the protein or 
its binding with a known partner. Otherwise, the scepticism on the use of this method 
is mostly due to the possibility of generating a refolded non-functional protein.  
Protein was next expressed in BL21 strains and lysed using a mild method with the 
lysozyme. As protocol, I followed the one reported by EMBL website (www.embl.de). 1 
mg/mL of lysozyme was added to the lysis buffer with 5 mM EDTA to enhance the 
activity of the lysozyme. Cell were incubated for 2h at 4°C under agitation. Subsequently, 
the addition of 6 M urea, 0.2% Tween 20 and 0.2% Triton X-100 was tested but no 
improvement of solubility was observed. 
To improve the solubility of the protein, I designed two other constructs expanding the 
number of amino acids at the N- and C-terminus. IUPred software 177, 178, which 
estimates the disorder tendency in proteins, helped to decide which region to choose to 
increase the solubility of the construct. The 6His-SUMO tag, which is known to increase 
the solubility of the constructs, could not be used since its MW is comparable with the 
one of the bromodomain and this would make more difficult to check the quality of the 
samples by SDS page gel. 
BrD(1321-1449) and BrD(1310-1449) were obtained by cloning strategy using the same 
plasmid as above. 
The expression of these two constructs was tested in two different E.coli strains, 
BL21(DE3) and Rosetta. Induction was performed at OD600 0.8 and with 0.5 mM IPTG. 
Cells were incubated overnight at 16°C. After this, cells were spun down and pellet was 
re-dissolved in 20 mM Hepes at pH 8.5, 1 M NaCl, 1 mM DTT supplemented with 10% 
glycerol. The calculated pI for BrD(1310-1449) is 7.2 (Protparam calculation 181), this 
motivated to use a buffer at pH 8.5. Results of the expression trial are reported in figure 
4.15. 
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Figure 4.15. Expression trial for the longer constructs of BAZ1B Bromodomain. 
Expression trial of construct BrD(1321-1449) on the left and BrD(1310-1449), on the right. Total (tot) and 
soluble (sol) are reported. Circled in red the potential bands of BrD(1310-1449) (MW 17.4 KDa). No 
spotless bands for BRD22. 
 
For BrD(1321-1449) no spotless bands are detected in the expected MW; for BrD(1310-
1449), a band that may correspond to the MW of our construct could be observed, that 
was present in both total and soluble fraction with the same intensity (red circle). 
However, the level of expression is very low in these conditions since is comparable to 
the background protein of the strain used. In order to verify if the band highlighted is 
really relative to the bromodomain construct of BrD(1310-1449), scaling up of the 
expression is needed with further optimization of purification conditions. 
 
4.2.2.2. Expression trial of the PHD-BrD tandem modules of BAZ1B 
 
Following these trials for the individual BrD of BAZ1B, it was decided to move to express 
also the full tandem module PHD-BrD.  
A PHD –BrD construct of BAZ1B(1321-1449) was sub-cloned in pCRi11b plasmid in order 
to express the protein as 6His-SUMO tagged protein. In this case, the different MW 
between protein and affinity tag allows to differentiate them on the SDS page.  
Expressing this construct under identical conditions employed for the other PHD-BrD 
tandem constructs did not lead to soluble protein. It was therefore decided to undertake 
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a more systematic approach. After initial incubation at 37°C, the induction was induced 
with two different IPTG concentrations: 0.1 mM and 1 mM. Overnight incubation was 
performed at three different temperatures: 37°C, 25°C and 16°C. Expression was 
checked at different time: after 2h, after 4h and after overnight incubation. Following 
cell lysis by sonication, fractions representative of different conditions were loaded on 
a SDS page gel to induction of protein expression. As reported in picture 4.16, the lanes 
are all similar to the pre-Induction lanes and no overexpressed band is showing in any 
of them at the expected MW (~43 KDa). 
 
 
Figure 4.16. SDS-page gel of expression trial for PHD-BrD BAZ1B. 
Expression trial of the tandem construct of BAZ1B in BL21 E.coli. Each lane is labelled with the condition 
of expression. No bands are detected in the expected region at ~43 KDa. 
 
This test was performed using  BL21(DE3) E.coli strain. Further trials were carried out 
using the Rosetta strain and, more importantly, C41(DE3) 182 strain that is known to help 
the expression in case of toxic proteins  that are easily degraded in other strains. Also in 
this case, no overexpression of the target protein was observed. Sequencing analysis 
confirmed that the region of the gene after the T7 promoter is preserved, so the lack of 
expression could not be related to an issue with the DNA quality of the plasmid.  
 
In summary, it has proven challenging to identify and characterize the structure and a 
putative binding partner of BAZ1B PHD. It also proved so far to be mostly unsuccessful 
to express soluble protein constructs of BAZ1B tandem and BrD domains. Due to time 
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constraints, it was decided during my PhD to redirect efforts in other directions. In light 
of the results obtained, future plans should consider alternative expression systems as, 
for example, insect cell that are useful when protein cannot be expressed in E.coli cause 
a better folding or crucial post translational modification are needed. Xiao et al. were 
the only group reporting expression of the PHD-BrD tandem of BAZ1B and, specifically, 
in insect cells, although still yielding a very low amount of soluble protein 105. 
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4.3. TANDEM CONSTRUCT OF TRIM66 
 
In parallel to the study on the elucidation of the histone binding partner for BAZ1B 
tandem modules, I investigated on the PHD-BrD tandem module of the TRIM66 protein. 
In this protein, differently from BAZ1B, the two reader domains within the tandem were 
located very close to each other likely suggesting cooperativity or interactions between 
them, in the recognition mode of a potential binding partner. It was therefore decided 
to express TRIM66 as a tandem PHD-BrD module. 
 
Four different PHD-BrD tandem constructs of TRIM66 were subcloned in the expression 
vector pET28a, inserting the TEV protease cleavage site, and expressed as hexahistidine 
tagged protein. Amongst the four constructs, the one that showed higher solubility was 
selected for the biophysical assays, T66(966-1159). Its gel filtration chromatogram is 
reported in figure 4.17. The elution is observed at the expected volume, according to its 
MW ~22.5 KDa.  
 
Figure 4.17. Gel filtration chromatogram of TRIM66 PHD-BrD and SDS-page gel. 
Chromatogram of the gel filtration of TRIM66 PHD-BrD in green. On y axis, absorbance at 280 in mAu. On 
x axis, volume in mL. The column used for the gel filtration was a Superdex 75 26/600 (GE Healthcare). 
16% SDS-page gel showing the bands of TRIM6, in the expected region (MW~22.5 KDa). 
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Next, a DSF screening was performed to identify the buffer conditions that provide the 
highest stabilization of the protein. Most suitable conditions were found in a pH range 
between 7.0 and 8.5 in Hepes, Tris and phosphate buffer. 
 
4.3.1 TRIM66 PHD-Bromo binds amino terminal tail H3 
 
4.3.1.1 PHD zinc finger 
 
The sequence alignment of the PHD domains of the TRIM family  proteins highlighted 
that, the histone binding region is highly conserved for TRIM24, TRIM33 and TRIM66 
(red circles in figure 4.18), with the exception of TRIM28 which is known it does not 
recognize any histone tail 175. In addition, the aromatic residue that is signature of 
specific methyllysine recognition at position 9 (K9me) is conserved (green arrow in figure 
4.18), while the aromatic cage typical of the H3K4me3 reader is not present. PHD of 
TRIM24 and TRIM33 were already known to recognize the H3 histone tail 51, 62, herein 
the alignment suggested that also the PHD of TRIM66 might be capable of binding to the 
H3 tail. 
 
 
 
Figure 4.18. Alignment of the PHD zinc finger domain within the TRIM family.  
Sequence alignment made by Jalview 170 of the PHD fingers within TRIM family. Cys  and His of the 
conserved motif of the PHD zinc finger are highlighted by the red arrows. The conserved H3 histone-
binding motif is circled with the red box. The green arrow and green box highlight the aromatic residues 
conserved through TRIM33, TRIM24 and TRIM66. In blue residues 100% conserved through the TIF1 
family. 
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To test our hypothesis of binding based on the sequence alignment, a 10-mer peptide 
resembling the unmodified N-terminal tail of H3 (ARTKQTARKS) was synthetized and 
tested by ITC. Titration confirmed binding of the PHD-BrD of TRIM66 to the H3 histone 
tail reporting a KD of 6 µM. Modifications on K4 and K9 were tested and showed a 
decrease of binding that in the case of K9 was less pronounced than in K4 (figure 4.19). 
Indeed, acetylation of K4 led to KD of binding affinity of 130 µM while acetylation on K9 
moderately affected binding, increasing KD up to 10 µM. I decided to test also the effect 
of methylation on both K4 and K9. 10-mer peptides were synthetized with both mono 
and double methylation on K4 and K9. It was not possible to synthesize the peptide 
containing try-methylated lysine since the required amino acid could not be purchased  
at the time of the experiment. Summary of the thermodynamic data is reported in Table 
4.1. ITC titrations showed how methylation on K4 sensibly reduced the affinity of binding 
(table 4.1).  In contrast, double methylation at position K9 was tolerated (table 4.1).   
 
 
Figure 4.19. Raw ITC-binding curves of the H3 10-mer peptides titrated into PHD-BrD 
of TRIM66. 
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Peptide 
 
KD (µM) 
 
N 
 
ΔH 
(kcal/mol) 
 
TΔS 
(kcal/mol) 
 
ΔG 
(kcal/mol) 
H3 wt 10-mer 5.8 ± 0.6 1.3 ± 0.1 -4.3 ± 0.7 2.9 ± 0.6 -7.2 ± 0.1 
H3K4ac 10-
mer 
131 ± 19 1.3 ± 0.1 -4.0 ± 0.4 1.3 ± 0.5 -5.3 ± 0.1 
H3K9ac 10-
mer 
10.7 ± 0.9 1.3 ± 0.0 -4.0 ± 0.1 2.7 ± 0.1 -6.9 ± 0.1 
H3 K4me 10-
mer 
23 ± 1.1 1.7 ± 0.01 -3.06 ± 0.01 3.26 ± 0.01 -6.32 ± 0.01 
H3K4me2 10-
mer¥ 
31.3 ± 0.2 1.32 ± 
0.03 
-2.63 ± 0.07 3.5 ± 0.1 -6.14 ± 0.04 
H3K9me2 10-
mer 
6.5 ± 0.1 1.5 ±0.1 -4.0 ± 0.01 3.08 ± 0.01 -7.08 ± 0.01 
H3 wt 21-mer 10.2 ± 1.2 1.56 ±0.02 -4.13 ± 0.03 2.68 ± 0.03 -6.81 ± 0.01 
H3K9ac 21-
mer¥ 
5.6 ± 0.3 1.50 ± 
0.01 
-3.83 ± 0.03 3.33 ± 0.05 -7.2 ± 0.1 
H3K14ac 21-
mer¥ 
5.1 ± 0.5 1.52 ± 
0.02 
-3.06 ± 0.05 4.1 ± 0.1 -7.2 ± 0.1 
H3K18ac 21-
mer 
2.9 ± 0.5 1.7 ± 0.1 -6.5 ± 0.1 1.1 ± 0.1 -7.5 ± 0.1 
H3K14acK18ac 
21-mer 
2.6 ± 0.3 1.3 ±0.1 -8.5 ± 0.4 -0.8 ± 0.3 -7.6 ± 0.1 
H3K23ac 30-
mer 
0.72 ± 
0.01 
1.31 ± 
0.01 
-4.67 ± 0.02 3.71 ± 0.02 -8.38 ± 0.01 
H3K27ac 30-
mer 
1.2 ± 0.1 1.61 ± 
0.02 
-3.35 ± 0.02 4.72 ± 0.04 -8.06 ± 0.02 
 
Table 4.1. Summary of the ITC-based thermodynamic binding parameters for complex 
formation between TRIM66 PHD-BrD and different H3 peptides.  
Titrations were performed at 25 ⁰C in triplicate or duplicate, except where differently specified, and values 
reported are the means ± s.e.m.  
¥ = titrations were performed only once and the errors are calculated by MicroCal ORIGIN software. 
 
A model of the structure prediction of Trim66 was generated using Rosetta server 183 
and aligned in Pymol with the PDB structure of Trim33 in complex with H3K9me3 (PDB: 
3U5O) (figure 4.20 and 4.21). Structure of TRIM33 in complex with H3 histone showed 
that H3K4 is involved in hydrogen bond with TRIM33 through the side chain of D885 and 
D889 plus the carbonyl of N887, at the N-terminus of the domain. From the 
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superposition shown in figure 4.20, Trim66 is predicted to preserve the same set of 
binding with the conserved N969 and D971 while the D885 of Trim33 is replaced by I967 
in Trim66. The presence of this hydrophobic residue could justify why additional 
methylation on K4 are not completely detrimental and the binding is still retained, 
although with lower affinity (KD 23 µM for K4me and KD 31 µM for K4me2). Instead, the 
presence of an acetylation mark, which neutralizes the charge on the lysine side chain, 
showed a remarkable loss of binding (KD 130 µM). 
 
Figure 4.20. Superposition of TRIM33 and prediction model of TRIM66. 
Zoom in on the interaction between the K4 of the histone peptide and the superposition of the predicted 
model of TRIM66 (white cartoon and sticks) with the crystal structure of TRIM33 (pink cartoon and sticks) 
in complex with H3K9me3K14acK18ac peptide (cartoon and orange sticks). Each residue is labelled 
according to the colour of the protein which it belongs.  
 
Hypothesis on the mode of binding of H3K9me2 towards TRIM66 PHD-BrD were using 
the same superposition with the Rosetta model of TRIM66. As reported in the alignment 
in Figure 4.18, the aromatic cage required for the methyllysine binding is not conserved 
in the TRIM PHDs but the presence of W889 in TRIM33 is able to coordinate the K9me3 
on H3 through the cation-π recognition. In TRIM66 the aromatic residue is replaced by 
F972 and the Q894 in TRIM33 is substituted by V977 that can assist the coordination of 
the methyllysine (figure 4.21). A study published by Gallivan and Dougherty 54 suggested 
that the Trp is more suited to form a cation-π recognition than Phe or Tyr. This may 
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account for the lower binding affinity showed from TRIM66 than TRIM33 toward the 
H3K9me2 histone. Taking in account these observations, it would be also interesting to 
investigate potential methylation occurring on the R8 and how can affect the interaction 
to the PHD, since methylated arginine are more favoured in the cation-π recognition 
than Lys. 
 
Figure 4.21. Superposition of TRIM33 and prediction model of TRIM66. 
Zoom in on the region of binding of H3K9me3 and TRIM33 (cartoon and stick in pink). W889 involved in 
the cation-π recognition is drawn as stick. Superposition of the complex TRIM33 (pink cartoon) with 
H3K9me3 peptide (orange) and the predicted model of TRIM66 (grey cartoon).  
 
4.3.1.2 Bromodomain 
 
Sequence based alignment of the bromodomains within the TRIM family implied that 
also TRIM66 BrD is an acetyllysine reader since the F/N residues in the binding of the 
Kac are conserved (green arrow in figure 4.22). 
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Figure 4.22. Sequence alignment of bromodomain of TRIM family. 
Sequence alignment of the bromodomain of TRIM family. Highlighted in blue are the residues 100% 
conserved. The F/N residues known to recognize Kac are conserved only for TRIM24, TRIM33 and TRIM66, 
while TRIM28 does not show any conservation. Indeed, TRIM28 does not recognize any Kac 175.  
 
In first instance, 10-mer peptides were synthesized, containing a single Kac, to identify 
any specificity of binding. Tested peptides were containing K9ac, K14ac, K18ac, K23ac, 
K27ac and K36ac in the middle of the sequence, expecting that the BrD would have 
engaged a unique acetyllysine residue.  No significant binding was detected with any of 
these peptides. Therefore, I decided to synthesize longer peptides carrying the same 
Kac, in order to investigate for any potential cooperative effect. H3K9ac 21-mer and 
H3K14ac 21-mer did not show any change of binding  when compared to the H3 21-mer 
wt (Table 4.1 and figure 4.23) and, more importantly no relevant variation in  the heat 
signals were observed. H3K18ac 21-mer reduced the KD to 3 µM compared to the 
unmodified peptide (KD ~ 10.2 µM ) with an associated ΔH of -6.5 kcal/mol (figure 4.23). 
This increment of the heat signal could account for a cooperative effect during the 
binding of the two reader domains to the double marks on the peptide: the unmodified 
region from the PHD and the K18ac from the BrD. Double acetylation H3K14acK18ac did 
not improve the binding affinity compared with the single acetylation on K18ac, 
although a further increase in absolute value of ΔH was observed (ΔH ~-8.5 kcal/mol, 
figure 4.23 and Table 4.1). These data would suggest that the binding is mainly driven 
by the acetylation on K18, while K14ac alone seems do not play any relevant role, but in 
combination with K18ac could mediate cooperativity of binding. It could be speculated 
that, admitting a linear binding mode of the unmodified H3 peptide to the PHD of 
TRIM66, it might be that the K14ac is located too far from the BrD pocket of the same 
molecule of TRIM66 for being able to bind it (Figure 4.21). Analogous situation was 
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reported for TRIM33 51. Remarkable increment in affinity were detected upon titration 
of TRIM66 with 30-mer peptides carrying respectively K23ac and K27ac, with KD 
decreasing to 0.6 µM and 1.1 µM, respectively. For these peptides no changes in ΔH 
were observed compared with shorter and unmodified peptides (Table 4.1 and figure 
4.23). 
 
Figure 4.23. Raw ITC-binding curves of the H3 21-mer and 30-mer peptides titrated 
into PHD-BrD of TRIM66. 
 
4.3.2 Crystallization efforts to gain molecular insights of histone 
recognition 
 
To understand the molecular basis of H3 recognition by the PHD-BrD of TRIM66, I 
wanted to solve the structure of this tandem module either in the apo form and/or in 
complex with the cognate histone. A crystal structure of the apo form might have been 
useful to perform soaking experiments in the case the histone pockets of PHD and 
bromodomain were free from crystal contacts. Crystallization screening of sparse matrix 
and grid screen were set up with two different constructs of TRIM66 tandem at different 
concentration of protein in a range between 5 and 24 mg/mL. Crystallization drops were 
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visually inspected and most of them resulted in precipitate or microcrystals formation. 
Few drops that showed interesting formation were attempted to be optimized. 
For example, in the Morpheus screening two similar conditions were identified that led 
to microcrystals (figure 4.24). 
 
 
 
Figure 4.24. High magnification pictures of crystallization drops.  
Crystallization drops from Morpheus screening reporting microcrystals from apo TRIM66 PHD-BrD at 
20°C. On the bottom of the figures details of the crystallization conditions. 
 
Conditions within the two drops have high similarity of components. In both cases the 
pH is in the range found as the most stable for the protein and far from the theoretical 
pI (~5.8). Low MW PEGs were used as precipitant, which increase the molecular 
crowding inducing separation of the macromolecules from the solution, in combination 
with 20% of an organic solvent (glycerol or ethylene glycol) that reduces the dielectric 
constant of the solvating medium. In this context, the presence of  divalent salts helped 
the protein to avoid copious precipitation keeping it in the salting-in region. In order to 
push the conditions towards the ideal conditions for crystallizations, few parameters 
were changed. Different concentrations of protein were explored between 10 and 4 
mg/mL simultaneously to different concentration of the divalent salts.  
Also the effects of pH and protein concentration were tested. Four different pH were 
explored (8.1, 8.3, 8.5 and 8.7). One of these conditions led to the formation of a drop 
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containing a tiny crystal, still too small to be harvested and shot on the X-ray generator 
(figure 4.25). 
 
Figure 4.25. Magnified view of the tiny crystal obtained from optimization. Conditions 
are described on the right of the figure. Protein concentration used of TRIM66 PHD-BrD was 10.6 mg/mL. 
 
Also the effect of the concentration of the PEG8000 and ethylene glycol was explored, 
keeping constants all the other conditions and the protein concentration. This led to the 
generation of few drops with tiny crystals, bigger than microcrystals, but still too difficult 
to be harvested (figure 4.26). 
 
Figure 4.26. Magnified view of the tiny crystal obtained from optimization.  
Microcrystals obtained upon optimization at room temperature of crystallization condition for TRIM66 
PHD-BrD apo form. Conditions used are detailed right below the picture.  
 
Crystallization plates were set up also with the tandem module in complex with H3 wild-
type 10-mer peptide (protein/peptide ratio 1:3), withH3K14ac 21-mer peptide 
(protein/peptide ratio1:1.5 and 1:2) and H3K18ac 21-mer at different protein/peptide 
180 
 
ratio. Figure 4.27 illustrates some of the hits identified for TRIM66-H3 10-mer peptide 
complex  in JCSG+ screen. 
 
Figure 4.27. Magnified view of the microcrystal or quasi crystals obtained from G2 in 
JCSG+. Conditions used are described below the picture. 
 
In the scale up to larger drops in the optimization grid the amount of protein was reduce 
to 8mg/mL from the initial 14.6 mg/mL of the small drop of the screening. This is needed 
to compensate the loss of protein that is generally occurring in the small drops since in 
small drops at the interface drop/air lot of protein is lost so the real concentration is 
lower than the theoretical one. Optimization tested different precipitant concentrations 
between w/v 8% and 22% at pH of 7.0, 7.2, 7.5 and 7.8, but only precipitation was 
observed. 
Interesting formation resembling quasi crystals or small crystals were observed for the 
complex of the tandem with H3K14ac 21-mer peptide in the JCSG+ plate (condition H1, 
figure 4.23). In this condition the pH 5.5 was found very close to the calculated pI. As 
precipitant there was only magnesium formate. The influence of the temperature seems 
to be relevant in increasing the size of the formations (figure 4.28). 
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Figure 4.28. Magnified view of the microcrystal or quasi crystals obtained from H1 in 
JCSG+. 
Microcrystals and quasi crystals observed at 4°C (left) and room temperature (right) for the complex PHD-
BrD TRIM66 with H3 10-mer peptide. 
 
In the optimization process different conditions were explored to expand the range of 
the precipitant concentration between 100 and 600 mM, keeping the pH constant. It 
was observed that microcrystals were bigger at increasing concentration of precipitant 
but still too small to be harvested on a loop. Keeping constant the protein/peptide ratio 
at 1:3, three different protein concentrations were used: 9mg/ml, 15 mg/mL and 20 
mg/mL. Different pH conditions were tested in presence of low precipitant 
concentration (0.2 mM or 0.3 mM) and with the addition of 5% glycerol and 8- 20% w/v 
PEG3550 to assist the precipitation. Also the effect of addition of higher NaCl (1-2 M) 
concentration was tested but no crystal formation was observed. No success was gained 
even testing different drop size and protein/reservoir ratio as well as the addition of Al’s 
oil (1:1-paraffin:silicon oil) which should decrease the rate of the vapor diffusion and 
consequently the formation of the nuclei. 
An additive screening was also performed using as starting condition the one in figure 
4.23, with the aim to identify  a reagent able to perturb sample-sample and sample-
solvent interactions in a way to induce crystalline formations. Also a matrix 
microseeding experiment (MMS) was performed using as seed the quasi crystals in 
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condition H1 of JCSG+ (figure 4.23). In both cases, only microcrystals formed which 
would have required further optimization. 
Observation of the drops through all the sparse matrix screening, highlighted that 
microcrystals or quasi crystals formations were mainly present in all the condition with 
pH close to the calculated pI of the protein (~5.8). In contrast, at pH < 5.5 protein 
precipitation was consistently observed. Small MW PEGs and Mg(HCOO)2 , MgCl2, 
NH4AcO, NaCl and Mg(AcO)2 were the favourite overall precipitants. These 
considerations could lead future works towards the development of a 96-well screening 
containing all the precipitants listed above plus those with similar properties, in order 
to explore a more selective range of reagents and their effect on the protein using 
different pH and concentrations range. 
In summary, high-affinity binding partner histone peptides were identified for the PHD-
BrD tandem of TRIM66. However, unfortunately, no suitable crystals could be grown for 
the protein either apo or in presence of peptide. 
4.4 DISCUSSIONS 
 
In summary, in this chapter, I have presented a preliminary study on the histone 
recognition of the PHD-BrD tandem module of two chromatin-binding proteins: BAZ1B 
and TRIM66. 
 
Deorphanization studies performed on the single PHD domain of BAZ1B, using BLI, 
protein observed NMR and ITC experiments, did not reveal specificity of binding towards 
any histone peptide tested. The presence of a lysine residue (Lys1998) in BAZ1B PHD 
domain located in a key hydrophobic patch for histone binding was hypothesized to be 
responsible for the lack of specificity. For this reason, future work on this reader domain 
should focus towards the elucidation of the potential influence of this lysine within the 
histone pocket. To address this point, mutagenesis experiments on both proteins 
BAZ2A/B and BAZ1B are warranted. 
 
From literature, we have also learnt that some PHDs can have a role of structural support 
within tandem epigenetic domain unit 175. To further investigate on the mutual 
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relationship within the two reader domains, it was decided to express also the 
bromodomain construct and the tandem construct of BAZ1B. Work done so far has only 
led to the identification of a potential soluble construct for BAZ1B BrD, but its expression 
will need to be further optimized. The tandem module did not show any expression in 
E. coli. Therefore, an alternative approach must be undertaken, as for example, the 
expression either in insect cells, already reported in literature 105, or in mammalian cells. 
The presence of the long linker (108 AA) between the two domains could be detrimental 
to the formation of a stable tandem construct and could require further stabilization 
through the binding to another partner. Indeed this linker, as for the long linker in 
BAZ2A/B, could act as a scaffold for the recruitment of potential binding partner. Pull-
down experiments, using the single domains and the tandem constructs, could help to 
elucidate preferential binding partners for the PHD-BrD of this chromatin-associated 
protein.  
 
The protein TRIM66, in contrast to BAZ1B and BAZ2A/B proteins, has the two readers, 
PHD and bromodomain, located very close to each other, with only a short spacer 
between them. PHD sequence alignment within the TRIM family allowed formulating 
hypotheses of binding that were confirmed by ITC experiments. Indeed, TRIM66 
recognizes unmodified H3 tail and seems to tolerate methylation in position K9, 
presumed to be the result of cation-π recognition with residue F972. Studies on the 
specificity of binding of the bromodomain have shown preference of binding for the 
acetylation in position K18 and K23 and the binding was favoured in case of the longer 
peptides. It was observed that different length of the peptides can impact on the binding 
affinity. For this reason, in order to properly identify whether TRIM66 BrD has 
preferential mark recognition, the tested peptides should all have comparable lengths.   
 
The results presented provide a preliminary investigation of histone binding recognition 
to TRIM66, which have nevertheless laid out a direction of investigation to be pursed 
and raised new questions. It will be interesting to analyse in future the contribution of 
binding of double marks on the same histone tail, as for example, K9me3 in combination 
with K18ac or K23ac. Structural insights at atomic level will be crucial to elucidate the 
binding mode and rationalize the observations of binding from the ITC experiments. 
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Crystallization results to date have not led to suitable single protein crystal, and further 
studies could move towards the crystallization of the complex between TRIM66 tandem 
and the identified peptides that showed higher binding affinity, to ensure full saturation 
and stability of the protein-peptide complex. If structural information will not be 
achieved by crystallography, either protein-observed NMR or computational studies 
could be a valid alternative to gain information into the molecular recognition of TRIM66 
and its histone partner.  
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CHAPTER 5. 
5.1 CONCLUSIONS AND FUTURE DIRECTIONS  
 
To date, despite the numerous progress achieved on the understanding of the  
mechanism beyond the epigenetic regulation, still more need to be accomplished 
toward a complete overview of epigenetics and how they relate to diseases.  
In this context, the intense research in the identification of chemical probes able to 
tackle specific domains of chromatin-associated proteins could furnish valid tools to 
interrogate epigenetics and new chemical scaffolds to drug the epigenome. 
Currently, important successes have been achieved in the discovery of inhibitors valid 
to target histone-modifying enzymes and reader domains 70. Most of these molecules, 
are largely used as chemical probes to study biology. However, in addition to their use 
as chemical tools, a few epigenetic inhibitors have already been approved from the FDA 
as drugs, while others have also successfully entered clinical trials 80 . The majority of 
the reader domains successfully  targeted to date are bromodomains 30, 184 or few 
methyllysine binders, as MBT and chromodomains 83.  
PHD zinc finger reader domains have been linked to several disease states, so they are 
also emerging as attractive candidates in epigenetic drug discovery.  However, so far, 
only two systematic studies to assess their ligandability have been reported 56, 57. The 
paucity of information about the ligandability of these reader domains, which could sets 
aside important disclosures, motivated this work. 
 
In the first part of my thesis project, I aimed to elucidate the binding mode of the PHD 
of BAZ2A and BAZ2B towards their histone binding partner and to probe the ligandability 
of these domains with small fragments. I initially solved the crystal structure of the PHD 
of BAZ2A in complex with the H3 histone tail. This allowed the identification of the 
helical conformation of the H3 peptide upon binding with the PHD.  Further work 
performed within the Ciulli Lab helped to define the helicity of the H3 peptide as an 
essential feature of the histone tail binding mode. This was further confirmed by the 
structure of the PHD of BAZ2A in complex with the double alanine mutant H3 peptide, 
which increases the peptide binding affinity.  It was further observed that the helical 
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conformation in H3 was induced by a short helical turn preceding the β-strand of the 
PHD. This observation combined with biophysical analysis was essential to lead to the 
identification of a subclass of PHD characterized by an acidic patch on the helical turn, 
responsible for inducing helicity in the H3 peptide. The structural importance of this 
acidic patch was corroborated by mutagenesis experiments, which inverted or abolished 
the charge on the helical turn, inducing a considerable reduction of affinity for the 
histone tail. Together, these findings from my PhD work and the work of others in the 
group have contributed to the realization that a subclass of PHD fingers have the ability 
to recognize the histone tail specifically in helical conformation. This suggests that the 
secondary structure of the histone tails could constitute a further level of regulation in 
the epigenetic processes.  
In a second part of the project, I investigated the ligandability of the PHD zinc finger of 
BAZ2A and BAZ2B. Using HSQC NMR, as a main technique for monitoring fragment 
binding, I performed a biophysical validation of 19 chemical hits identified by in silico 
screening (performed by collaborator Dr. Xavier Lucas within the group). Nine hits were 
confirmed as potential binders and KD of binding and LE were provided using CSPs 
analysis. One hit led to a fragment bound structure with partial electron density. The 
binding mode of this fragment  was used as scaffold to further improve affinity of binding 
for the fragment. This study identified four hits, all validated by NMR. I solved the 
structure of the PHD of BAZ2A in complex with one of these optimized fragments and of 
BAZ2B with two of these optimized fragments.  
To the best of our knowledge, these are the first crystal structures of PHD fingers solved 
in complex with fragments binding to the histone pocket. Comparison of the structures 
highlighted some differences in the binding mode of the same fragment towards the 
two different proteins. These observations can be used to guide future design towards 
expansion of these hits, in a way to enhance potency and provide some selectivity of 
binding within the same family. Furthermore, fragment optimization could take 
advantage of the importance of the helicity to increase binding affinity. Indeed, the 
linkage of these fragments with a synthetic scaffold able to mimicry a helical pattern 
could be beneficial in future to increase the affinity of the small molecule. 
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This work is an example of how structural information obtained by using synthetic 
peptides that recapitulate the binding epitope of a natural partner, can be combined to 
fragment screening to gauge future optimization of small molecules. 
 
In the last part of the project, I performed initial investigation toward elucidating the 
binding mode of the PHD-BrD tandem module of two proteins: BAZ1B and TRIM66. 
These two proteins are both involved in important epigenetic pathways related to 
diseases, justifying and motivating the interest in studying them.  
For the PHD of BAZ1B, conversely to our expectations, our data suggest that the domain 
alone does not bind to histone tails. The PHD-BrD tandem module did not express in 
E.coli cells suggesting the requirement to express it in a superior system, like insect cells 
or mammalian cells. Studies on the tandem module would allow investigation on the 
mutual relationship between the two domains and on the effect of the linker. Indeed, 
this linker could positively or negatively influence the recognition mode with a potential 
binding partner. 
On the other side, in this work, the tandem module of TRIM66 showed preferences of 
binding for the unmodified H3 10-mer peptide and H3K9me2, presumably ascribable to 
the PHD finger. In this tandem, which contains a short linker between the two reader 
domains, cooperativity of binding was observed for the longer peptide form and in the 
presence of acetylation on H3K18ac and H3K23ac. Further investigation is warranted in 
order to explore other meaningful PTMs and to gain insights on the molecular basis of 
the interactions. Nevertheless, to date, this work provide the first report to our 
knowledge characterizing in detail the binding between the TRIM66 and the histone tails 
and establishing the fundamentals blueprints to further proceeding to investigate on 
this interaction. 
 
In conclusion, the work here presented demonstrated that PHD zinc fingers remain 
challenging targets to small-molecules but they can also be perceived as a class of 
ligandable reader domains. This expands the view of what is considered nowadays as a 
suitable target in the epigenetic field, proposing new reader domains as appealing and 
affordable target for the drug discovery community. The disclosed structures of these 
bound fragments together with the information gained about the binding mode of the 
188 
 
PHD fingers with their natural binding partners, have provided important new 
knowledge that could seed future optimization of these newly identified chemical 
scaffolds, aiming towards the generation of potent and selective chemical tools 
targeting PHD zinc finger domains. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
189 
 
CHAPTER 6.  
MATERIALS AND METHODS 
 
All the reagents used were purchased by Sigma Aldrich, unless differently specified. 
6.1 MOLECULAR BIOLOGY METHODS 
 
6.1.1 Plasmids 
 
Plasmids for the expression of the PHD zinc finger and tandem module PHD zinc finger -
Bromodomain (PHD – BrD) of both proteins BAZ2A (Uniprot code: Q9UIF9) and BAZ2B 
(Uniprot code Q9UIF8) were previously generated in the group by Dr. Cynthia Tallant 
using the pCri11b plasmid 45. Each construct was expressed with a 6His tag fused with 
small ubiquitin like modifier (SUMO)-1 tag at the N terminus of the protein (details of 
the constructs in Table 6.1). 
The cDNAs encoding for the PHD zinc finger and Bromodomain tandem of human BAZ1B 
(Uniprot code Q9UIG0) was synthetized by Invitrogen (Thermo Fisher Scientific) with 
codons optimized for E. coli expression and supplied into a pMA-T (AmpR) vector. The 
regions of interest were amplified by PCR using specific primers (Table 1, Appendix) that 
introduced the NdeI restriction site at 5’ terminus and the XhoI restriction site at 3’ 
terminus. Constructs were then subcloned into the pCri11b and pET-28(+) plasmids using 
the DNA Ligation kit (TaKaRa), following manufacturer’s guidelines. The TEV cleavage site 
was added to those constructs subcloned in pET-28(+). 
The synthetic gene of TRIM66 (Uniprot code O15016) was purchased from Invitrogen 
(Thermo Fisher Scientific). The cDNA, with codons optimized for E. coli expression, was 
supplied into the pMA-T (AmpR) plasmid. Constructs of different length were obtained 
as described above for BAZ1B constructs and, subsequently, subcloned into pCri11b and 
pET-28a(+) plasmids using the DNA Ligation kit (TaKaRa). Table 2 in Appendix 1 reports 
details of the primers used. 
In Table 6.1 a summary of all the constructs relevant to the described studies is provided. 
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Plasmid ID Protein MW(Da) 
 
Tags/cleavage 
site 
Vector Antibiotic 
CTA007 PHD BAZ2A(1673-1728) 6589 6His-
SUMO/SENP1 
pCri11b Amp 
CTA006 TANDEM BAZ2A(1673-
1899) 
26533 6His-
SUMO/SENP1 
pCri11b Amp 
CTA016 PHD BAZ2B(1928-1983) 6534 6His-
SUMO/SENP1 
pCri11b Amp 
CTA014 TANDEM BAZ2B(1928-
2168) 
28517 6His-
SUMO/SENP1 
pCri11b Amp 
AAM005 PHD BAZ1B(1182-1237) 6624 6His-
SUMO/SENP1 
pCri11b Amp 
AAM006 TANDEM BAZ1B(1185-
1444) 
30439 6His-SUMO/ 
SENP1 
pCri11b Amp 
AAM014 TANDEM BAZ1B(1182-
1443) 
30640 6His-SUMO/ 
SENP1 
pCri11b Amp 
AAM009 BrD BAZ1B(1321-1449) 15408 6His-SUMO/ 
SENP1 
pCri11b Amp 
AAM010 BrD BAZ1B(1310-1449) 16654 6His-SUMO/ 
SENP1 
pCri11b Amp 
AAM015 PHD BAZ1B(1182-1237) 6442 6His/Thrombin
_TEV 
pET28-a(+) Kan 
AAM021 BrD BAZ1B(1338-1444) 12780 6His/Thrombin
_TEV 
pET28-a(+) Kan 
AAM022 BrD BAZ1B(1331-1444) 13593 6His/Thrombin
_TEV 
pET28-a(+) Kan 
AAM007 BrD BAZ1B(1321-1449) 15227 6His/Thrombin
_TEV 
pET28-a(+) Kan 
AAM008 BrD BAZ1B(1310-1449) 16474 6His/Thrombin
_TEV 
pET28-a(+) Kan 
AAM012 PHD TRIM66(970-1018) 
 
5613 6His-SUMO/ 
SENP1 
pCri11b Amp 
AAM013 BrD TRIM66(1041-1150) 13922 6His-SUMO/ 
SENP1 
pCri11b Amp 
AAM011 TANDEM TRIM66(970-
1150) 
20886 6His-SUMO/ 
SENP1 
pCri11b Amp 
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AAM001 TANDEM TRIM66(970-
1150) 
20886 6His/Thrombin
_TEV 
pET28-a(+) Kan 
AAM004 TANDEM TRIM66(966-
1150) 
21340 6His/Thrombin
_TEV 
pET28-a(+) Kan 
AAM002 TANDEM TRIM66(966-
1159) 
22481 6His/Thrombin
_TEV 
pET28-a(+) Kan 
AAM003 TANDEM TRIM66(966-
1168) 
23417 6His/Thrombin
_TEV 
pET28-a(+) Kan 
 
Table 6.1. Summary of the constructs produced in this thesis work. 
pET28-a(+) contains double cleavage site as reported in column four: Thrombin and TEV cleavage sites. 
MW refers to the cleaved domains. 
 
6.1.2 Transformations 
 
Different chemically competent E.coli cell strains were used for the transformation 
process. 
DH5-α strain was used for DNA amplification; BL21(DE3), Rosetta, C41(DE3) and 
ArticExpress(DE3) were used for labelled and unlabelled protein expression. The 
protocol used for transformation was the same for all the strains. Briefly, 100 μL of 
competent cells were thawed on ice. To these 1 μL of plasmid DNA (~100 ng) was added 
and incubated for 10 min on ice. Heat shock was performed for 90 s at 42°C and then 
cooled on ice for 10 min. Cells were subsequently diluted with 300 μL of Lysogeny broth 
(LB) and incubated at 37°C for 1 h, then plated onto LB/agar plates, containing the 
relevant antibiotic, and incubated overnight at 37°C. 
 
6.1.3 Site-directed mutagenesis 
 
Site-directed mutagenesis on PHD of BAZ2A/B were performed by PCR using the Phusion 
DNA Polymerase (Thermo Fisher Scientific) and specific pairs of primers (Table 3, 
Appendix) that introduced the desired mutation 46. The PCR amplification product was 
incubated with Dpn I (New England BioLabs) for 1 h at 37°C, which recognizes and digest 
DNA carrying methylated sites on the parental DNA strands.  The DNA was subsequently 
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transformed in DH5-α E. coli strains. Single colonies were picked to inoculate 5 mL of LB 
plus 100 µg/mL ampicillin and grown overnight at 37°C. The following day, DNA was 
extracted from the bacterial cultures using the QIAprep Spin Miniprep Kit (Qiagen) and 
the presence of the desired mutation was checked by DNA sequencing. 
 
6.1.4 Protein expression 
 
PHD zinc finger and tandem constructs of BAZ2A/B and PHD zinc finger constructs of 
BAZ1B were expressed in BL21 (DE3) cells. Colonies from freshly transformed cells were 
grown in 50 mL LB containing 100 μg/mL ampicillin and incubated overnight at 37°C with 
200 rpm shaking. The following morning a dense culture was obtained and this was 
diluted in order to reach OD600 ~ 0.05 in fresh LB medium supplemented with 100 μg/mL 
ampicillin. The culture was then incubated at 37 °C with 200 rpm shacking until the OD600 
reached ~ 0.6; then the temperature was decreased to 20 °C and protein overexpression 
was induced with 200 µM IPTG (Isopropyl β-D-1-thiogalactopyranoside) under 200 rpm 
shacking for 16 h. Cells were harvested by centrifugation at 4200 rpm for 30 min at 4°C 
using a Beckman Coulter Avanti J-6 MC centrifuge. 
The same protocol was adopted for the expression of the PHD-BrD tandem construct of 
TRIM66 except for the antibiotic used that was kanamycin at 50 μg/mL and for the 
induction that was performed at an OD600 of  ~1 with 300 µM IPTG, decreasing the 
temperature at 16°C. 
 
6.1.5 Isotopically-labelled protein expression 
 
For the expression of isotopically labelled 15N PHD of BAZ2A/B was used a minimal media 
M9 185. M9 media contained:  6.8 g/L Na2HPO4, 3 g/L KH2PO4, 0.5 g/L NaCl, 0.044 g/L 
CaCl2, 0.24 g/L MgSO4, 16 mg/L MnCl2, 5 mg/L FeCl3, 0.5 mg/L ZnCl2, 0.1 mg/L CuCl2 , 
0.1 mg/L CoCl2, 0.1 mg/mL H3BO3 and 0.05 g/L EDTA, 0.04 g/L Na2SO4, 0.24 g/L MgSO4, 
0.044 g/L CaCl2, 0.001 mg/mL Biotin and Thiamine supplemented with 1 g/L (15NH4)2SO4 
(Goss Scientific) as the sole nitrogen source. 
The same minimal media was used for the expression of isotopically labelled 15N/13C PHD 
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of BAZ1B where the sole source of nitrogen and carbon were 1 g/L (15NH4)2SO4 (Goss 
Scientific) and 2 g/L 13C D-glucose (Goss Scientific). 
 
6.1.6 Protein purification 
 
The purification of the 6His-SUMO tagged PHD zinc finger and PHD-BrD tandem of 
BAZ2A/B was performed as previously described 45. Following protein expression, cell 
cultures were harvested by centrifugation and the bacterial pellets was re-suspended in 
Lysis Buffer (20 mM HEPES, 500 mM NaCl, 30 mM Imidazole, 1 mM DTT at pH 8) 
supplemented with 5 mM MgCl2, 0.1 mg/mL of DNAse (Roche) and protease inhibitor 
cocktail tablets (Roche) (1 tablet for 50 mL per lysate). The cellular lysis was conducted 
with a high-pressure homogenizer (French Press) and the lysate was cleared by 
centrifugation at 40000 x g for 40 min at 4°C using a Beckman Avanti J-25 centrifuge. The 
6His-SUMO fusion protein, present in the soluble fraction, was first purified by affinity 
chromatography by loading the clear lysate on a nickel-charged column (HisTrap FF 
crude, GE Healthcare). Then the column was previously washed with 50 mL of lysis buffer 
and the 6His-SUMO protein eluted with lysis buffer containing 500 mM imidazole. The 
eluted protein was incubated with SENP1 protease (0.5 mg/ml) overnight at 4°C to 
cleave the 6His-Sumo tag and at the same time dialyzed to reduce the imidazole 
concentration to ~5 mM. In the second purification step an additional affinity 
chromatography on a nickel-charged column was performed to separate the 6His-SUMO 
tag from the desired protein, collecting the latter in the initial flow through and eluting 
the tag with 500 mM imidazole buffer. Following overnight dialysis in 20 mM Tris, 5 mM 
DTT pH 8.0 to reduce the buffer salinity of the sample, the pool fraction was loaded on 
a cation exchange column (Resource S 6 mL, GE Healthcare) and eluted by increasing the 
ionic strength of the buffer implemented with 500 mM NaCl. All domain protein 
constructs were further purified by size exclusion chromatography (HiLoad Superdex 75 
16/600, GE Healthcare) in 20 mM Tris, 200 mM NaCl and 5 mM DTT at pH 8.0.   
The PHD-BrD tandem constructs of TRIM66 were purified following the same procedure 
described above except for the buffer used for the Ni-affinity chromatography steps, that 
was 50 mM H2PO4-/HPO42- pH 7.5, 500 mM NaCl, 30 mM Imidazole, 7 mM β-
mercaptoethanol, and for the usage of TEV protease (0.1 mg/mL) to cleave the tag. 
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6.1.7 Protein biotinylation 
 
Biotinylation of the PHD domains of BAZ2A/B was performed using the EZ-Link NHS–
PEG4–biotin kit (Thermo Scientific) following the manufacturer guidelines. BAZ2A/B PHD 
was mixed in an equimolar ratio with biotin and incubated at room temperature for 1 h. 
The reaction was performed in a free amine buffer (20 mM HEPES, 100 mM NaCl, 5 mM 
DTT pH 7.5) in order to avoid competing NHS-ester reactions. Unreacted biotin was 
quenched by adding 2 µL of 1 M Tris buffer at pH 7.5. To remove any unreacted NHS-
biotin the sample was run over a PD-10 desalting column (GE Healthcare) into 50 mM 
HEPES, pH 7.5, 150 mM NaCl and 1 mM DTT. 
 
6.1.8 Protein methylation 
 
The PHD zinc finger domain of BAZ1B was methylated following the protocol reported 
from the Oxford Protein Production Facility (OPPF) and the Division of Structural Biology 
at Oxford University [3]. The reaction was a reductive methylation conducted overnight 
at 4°C in 50 mM Hepes pH 7.5, 250 mM NaCl at the protein concentration of ~ 0.85 
mg/mL (130 μM) in presence of dimethylamine-borane complex and formaldehyde. The 
methylated protein was then purified by size-exclusion chromatography using a 
Superdex 75 16/600 column pre-equilibrated in 20 mM Tris-HCl pH 7.5 and 200 mM 
NaCl. The purification step was important for the quenching of the unreacted starting 
material, the separation of the product from the reagents and to further monitor the 
oligomeric state of the protein itself. 
 
6.1.9 DNA and protein concentration 
 
DNA and protein concentrations were determined measuring absorbance at the 
wavelength of 260 nm and 280 nm, respectively. Measurements were performed using 
a Nanodrop Microliter UV/Vis spectrophotometer (ThermoScientific). DNA purity was 
estimated by measuring the A260/A280 ratio and all the samples used had A260/A280 
> 1.7. Protein concentration was calculated using the theoretical extinction coefficient 
predicted by ProtParam 181. 
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6.1.10 Protein analysis 
 
Chromatographic fractions showing absorbance at 280 nm were analysed by SDS-page 
gels with 16% or 20% acrylamide, and visualized using Comassie staining (InstantBlue 
protein stain, Expedeon). Protein identity was confirmed by electrospray mass 
spectrometry analysis (Fig. A1- A5, Appendix). 
 
6.2 NUCLEAR MAGNETIC RESONANCE (NMR) EXPERIMENTS 
 
All NMR experiments were performed using a AV-500 MHz Bruker spectrometer 
equipped with a 5 mm CPQCI-1H-19F /13C/15N/D Z-GRD cryoprobe. 
 
6.2.1 NMR backbone assignment 
 
PHD zinc finger BAZ1B backbone resonance assignment was performed using 2D 
15N(1H)-HSQC and 3D HNCO, HN(CA)CO, CBCA(CO)NH and HNCACB. Spectra were 
recorded on 500 µL sample in a Shigami 5 mm symmetrical tube. The sample contained 
15N/13C PHD of BAZ1B at a concentration of 500 µM in NMR buffer (20 mM H2PO4-/HPO42-  
pH 6.3, 50 mM KCl, 10% D2O and 1 mM DTT).  
Acquisition times for the 3D experiments were: 7-8 ms (13C), 12-16 ms (15N) and 100-127 
ms (1H).  
Acquisition times for the HSQC experiments were: 60 ms (15N) and 120 ms (1H). 
All spectra were acquired and processed with TopSpin (Bruker) and analysed with 
CcpNmr 154.  
 
6.2.2 Chemical shift perturbation (CSP) experiments 
 
(15N-1H)-HSQC spectra were recorded on 200 µL sample, in 3-mm NMR capillary tube, of 
15N-labelled BAZ1B PHD at a concentration of 150 µM in NMR buffer (20 mM H2PO4-
/HPO42- pH 6.3, 50 mM KCl and 1 mM DTT and 20% D2O) in absence or presence of 20-
mer N-terminal histone peptides at increasing concentrations. Spectra were recorded 
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on samples with the following protein : peptide molar ratio 1:0, 1:1, 1:2, 1:4, 1:8 and 
1:10. 
15N(1H)-HSQC spectra of both PHD domains of BAZ2A/B were recorded at sample 
concentration respectively of ~100 µM for BAZ2A and ~150 µM for BAZ2B in 200 µL NMR 
buffer as above (pH 6.9 and 6.5, respectively). Spectra were obtained for each protein 
at increasing concentration of fragment compound in a range between 0.5 mM and 5 
mM. The reference spectrum was recorded on the apo form. 
In chemical CSP experiments the weighted chemical shift difference (Δδweighted) was 
calculated with the following equation:  Δδweighted =  √|ΔδH|2  +  |ΔδN|2 ∗ 0.15     
186, where ΔδH is the change in chemical shift of the proton and ΔδN is the change in 
chemical shift of the nitrogen, which is scaled with a factor 0.15 to account for the 
difference in the range of amide proton and amide nitrogen chemical shifts. The 
chemical shift changes for each backbone amide group were measured from the peak 
detected in the HSQC spectrum recorded on the apo form to the peak located at the end 
of the titration.  
Affinities of compounds for PHD of BAZ2A/B were derived from HSQC CSPs and the 
relative KD were calculated using the equation below 186: 
𝛥𝛿 obs = 𝛥𝛿 max
{𝐾𝑑+𝑃𝑡+𝐿𝑡− √(𝐾𝑑+𝑃𝑡+𝐿𝑡)2−4𝑃𝑡·𝐿𝑡}
2[𝑃]𝑡
  
Where [P]t and [L]t are, respectively, the total concentration of protein and ligand; Δδobs 
is the change observed in the shift from the reference spectrum, while Δδmax is the 
maximum shift change obtained upon saturation and is generally calculated from the 
fitting , since it is not always possible to measure it experimentally. 
For each compound the KD was extrapolated as a median value of 4–7 different 
resonances ± s.e.m. as spread of values measured. 
Acquisition times for the HSQC experiments were: 60 ms (15N) and 120 ms (1H). 
All spectra were recorded and processed with TopSpin (Bruker) and analysed with 
CCPNMR [5]. 
 
 
197 
 
6.2.3 Ligand-observed NMR 
 
CPMG (Carr-Purcell-Meiboom-Gill) 126 experiments were performed with different spin-
lock time before acquisition, as explained in detail in chapter 3.4. WaterLOGSY 125 used 
a standard protocol implying a 20ms Gaussian 180° pulse to invert water signal and 1.2 
sec for NOE mixing time. STD (Saturation Transfer Distance) 124 experiments were 
performed alternating ‘on’ and ‘off’ resonance respectively at 100 ppm and 1 ppm with 
a 40 ms selective Gaussian 180° pulse. All the experiments were performed at 25°C in a 
3-mm capillary tube (Bruker) containing 200 µL of NMR buffer (20 mM HEPES, 50 mM 
KCl, 1 mM DTT at pH 6. 9 for PHD of BAZ2A and 6.5 for PHD of BAZ2B) supplemented 
with 20 µM TSP, 20% D2O and 1 mM fragment in presence or absence of 30 µM protein. 
NMR spectra were processed and analysed using TopSpin software (Bruker). 
6.3 PEPTIDE SYNTHESIS  
 
Peptide synthesis was performed using standard automated solid-phase synthesis on a 
ResPep SL peptide synthesizer (Intavis) in a 24-column set up. The synthetic protocol 
was set up on several cycles of deprotection, washing, coupling and washing. Each cycles 
started with Fmoc deprotection of the N–protected amino acid using 20% piperidine in 
DMF; successively, coupling was performed in two steps with 1 eq of 2-(1H-benzotriazol-
1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and 1 eq of 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxid-
hexafluorophosphate (HATU). To cap any unreacted amino acid, a solution of 5% (v/v) 
acetic anhydride and N-methylmorpholine (NMM) in DCM was used. Washing was 
performed with DCM. The solid support phase was a Rink Amide AM resin (200-400 
mesh). Peptides were cleaved from the resin by incubation of the resin for 3 h with 
cleavage mixture containing 92.5% trifluoroacetic acid (TFA), 5% Triisopropylsilane and 
2.5% water (v/v/v) (1mL of cleavage mixture for 100-150 mg of resin, as suggested by 
the manufacturer). Peptides were separated from the resin using a single-fritted column 
and precipitated in 5 ml of ice-cold diethyl ether. The resulting pellet was washed three 
times with diethyl ether and, subsequently, dissolved in water and lyophilised in a 
centrifugal evaporator (Genevac EZ-2 series, SP Scientific). 
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Amino acids and resin used in the synthesis were purchased by Merck Millipore. 
 
6.3.1 Peptide purification and analysis 
 
Peptides were purified using high-performance liquid chromatography (HPLC) on a 
Gilson Preparative HPLC System with Waters X-Bridge C18 column (100 mm x 19 mm; 5 
μm particle size) at 25 mL/min. Different gradients in a range of 5–25% acetonitrile in 
water with 0.1% TFA were applied for the purification. All the peptides were retained 
and eluted at the beginning of the gradient. Removal of TFA was performed using the 
VAriPure IPE column (Agilent). Absence of TFA was confirmed by 19F NMR spectra. 
Purified peptides were identified and analysed by LC-MS on an Agilent Technologies 
1200 series HPLC connected to an Agilent Technologies 6130 quadrupole LC/MS linked 
to an Agilent dioden array detector. Chromatographic runs were performed with a 
Waters X-Bridge C18 column (50 mm × 2.1 mm, 3.5 µm particle size) or with a column 
Agilent ZORBAX StableBond 80Å C18 (4.6 x 250 mm, 5 μm particle size). The mobile 
phase used was 5-95% water/acetonitrile +0.1% TFA over 3 min or 20 min. 
 
6.4 BIOPHYSICAL ASSAYS 
 
6.4.1 Bio-layer interferometry (BLI) 
 
BioLayer Interferometry (BLI) experiments were performed in an Octet RED384 
instrument (FòrteBio). In the assay, BAZ1B PHD was screened against a library of N-
terminal H3 and H4 derivate peptides carrying multiple post-translational modifications 
and biotinylated at the C-terminus (Altabioscience, Birmingham, UK). Peptides were 
immobilized on Super Streptavidin (SSA) biosensor at a concentration of 5 µM. The 
assays were conducted at 25 °C, in a buffer containing 20 mM HEPES, 200 mM NaCl, 2 
mM DTT and pH 8.0, using BAZ1B PHD at a concentration of 20 µM and 50 µM. The 
experiments were performed in black solid 384-well plate under agitation at 1000 rpm. 
Cycle steps for the analyses included 120 s of biosensor baseline equilibration, 240 s for 
associations in wells containing BAZ1B PHD and 240 s for the dissociations in wells 
199 
 
containing only buffer. Data were processed and analysed on the Octet Data Analysis 
Software, provided by the manufacturer. 
 
6.4.2 Surface Plasmon Resonance (SPR) 
 
SPR experiments were performed using a Biacore T100 instrument (GE Healthcare) at 
20 °C. All the experiments were set up in SPR buffer (10 mM HEPES, 150 mM NaCl, 2 
mM TCEP, 1% DMSO, 0.005% Tween P20 at pH 7.4). 
Protein immobilization onto the sensor chip was performed by injecting a volume of 
66 µL of protein at 0.02 mg/mL concentration on the surface of a chip covered with 
carboxymethylated dextran matrix pre-immobilized with nitrilotriacetic acid (NTA sensor 
chip form GE Healthcare). Prior to protein immobilization, the chip surface was 
equilibrated with 20 µL of a 500 µM Ni2+ solution in order to pre-load the NTA surface 
with Ni2+ metal ion required for the capturing of His-tagged protein. Stabilization of the 
adhesion of the protein onto the chip was guaranteed by a capture coupling protocol 
performed using 30 µL of coupling solution 155. This latter one was made up mixing 
equal volume of NHS and EDC from the Amine Coupling Kit (GE Healthcare, BR-1000-
50).   
Sample data were collected for the 6His-SUMO tagged PHD of BAZ2A/B over six 
fragment concentration points in a 1:2 serial dilution from 900 µM to 28 µM (in SPR 
buffer). Reference data included the response of the 6His-SUMO tag immobilized 
alone and these were subtracted from sample data in order to account for unspecific 
interactions detected by the 6His-SUMO tag alone. Data, whenever possible, were 
processed using the 1:1 fitting model with the Biacore T100 Evaluation Software (GE 
Healthcare), provided from the manufacturer. 
 
6.4.3 Differential scanning fluorimetry (DSF) 
 
Differential scanning fluorimetry (DSF) assays were performed using a CFX96 Touch 
Real-time PCR detection system (Biorad). The assay was performed using a 96-well PCR 
plate. For the pH buffer screening in each well (40 µL reaction) the final conditions were: 
2.5X Sypro Orange (Invitrogen Molecular Probes) and 10 µM protein in different buffer 
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at different pH in a range between 5 and 9. For the fragment screening performed on 
the PHD of BAZ2A/B three different concentrations of compound were tested: 3 mM, 5 
mM and 15 mM in 5% (v/v) DMSO in a buffer containing 100 mM MES, 50 mM NaCl, pH 
6.0. 
The assay was conducted by increasing the temperature from 25 °C to 95 °C at a rate of 
1 °C per minute. Fluorescence was detected at the end of each interval. The melting 
temperature (Tm) for each sample was calculated using the excel spreadsheet “DSF 
analysis” available at ftp://ftp.sgc.ox.ac.uk/pub/biophysics. Fluorescence was plotted at 
different temperatures and fitted into the Boltzmann equation 132, using the 
spreadsheet mentioned above, in order to extrapolate the melting points. Each sample 
was run in triplicate and the Tm values were reported as the mean of three independent 
measurement ± propagated s.d. 
 
6.4.4 AlphaLisa 
 
AlphaLisa competition assays were set up in a 384-well plates (PerkinElmer, USA) in 
100mM HEPES, 50 mM NaCl, 0.1% BSA and 0.02% CHAPS at pH 7.5. In each well were 
initially dispensed solutions of 10 nM protein, 160 nM H3 double mutant peptide 
(described above in Chapter 3.7) and fragment at desired concentration in 4% v/v 
DMSO. Plate was incubated at room temperature for 1 h and then 10 µg/mL (final 
concentration) of Anti-FLAG AlphaLisa acceptor beads and 10 µg/mL of Streptavidin 
donor beads were added to the well under low light conditions. The plate was incubated 
for a further hour at room temperature and subsequently read on a PHERAstar FS plate 
reader (BMG Labtech) using laser excitation at 680 nm and filter set on emission light at 
615 nm. PHD domains of BAZ2A and BAZ2B were tested against eight different fragment 
concentrations in 1:5 serial dilution and IC50 values were extrapolated using the 
GraphPad Prism 6 (GraphPad Software, USA). Validity of the assay was tested using the 
Z-factor and S/B ratio. 
𝑍′ = 1 −
3(𝜎𝑝 +  𝜎𝑛)
𝐼𝑝 − 𝐼𝑛
 
 
𝑆
𝐵 ⁄ =
𝐼𝑝
𝐼𝑛
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Where Ip and In are respectively the mean of the highest signal and of the background 
signal, while σ represent the standard deviation. 
 
6.4.5 Isothermal titration calorimetry (ITC)  
 
Isothermal titration calorimetry (ITC) experiments were performed using ITC200 micro-
calorimeter (GE Healthcare) at 298 K, unless otherwise specified, stirring at 750 rpm. 
The PHD zinc finger and PHD-BrD tandem of BAZ2A/B used for the ITC experiment were 
dialyzed overnight against buffer containing 20 mM Tris, 200 mM NaCl, 1 mM TCEP pH 
8.0, using the a D-tube dialyzer MWCO 3.5 KDa (Millipore). The PHD-BrD tandem of 
TRIM66 was dialyzed against a buffer containing 20 mM Tris, 50 mM NaCl, 1 mM TCEP 
pH 7.5 using D-tube dialyzer MWCO 6-8 KDa (Millipore). 
All ITC experiments were carried out in direct mode titrating peptide solutions (0.9 – 1.5 
mM) into protein solutions (50-120 µM) loaded in the calorimetric cell, performing one 
first injection of 0.4 μL (subsequently discarded during data analysis) followed by 19 
injections of 2 µL at 120 s time intervals.  
For each peptide, a control experiment of titrant into buffer was performed. This data 
was then subtracted from the related titration of ligand into protein. The resulting data 
was then fitted to a single-binding-site model to obtain the stoichiometry n, the 
dissociation constant KD and the enthalpy of binding ΔH using the MicroCal ORIGIN 
software package. Each titration was repeated in either duplicate or triplicate whenever 
possible. KD values reported from replicate titrations were calculated as the mean ± 
s.e.m. from the values obtained in independent measurements. 
 
6.4.6 Modified Histone array 
 
The Modified histone peptide array is a tool that can be used to screen proteins for 
interaction with histone tails and their post-translational modification (PTMs). Each 
array contains up to 384 different peptides resembling the N-terminal tails of the histone 
proteins H2A, H2B, H3 and H4 with a combination of several PTMs such as acetylation, 
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methylation, phosphorylation and citrullination. The array was performed following the 
protocol suggested by the manufacturer (Active Motif). 
The arrays were first blocked with a blocking buffer, containing 10 mM Tris-HCl pH 7.4, 
0.05% Tween 20, 150 mM NaCl and non-fat dried milk, overnight at 4⁰C and then 
incubated with His-tagged protein at room temperature for 2 h (100 nM of His6-tagged 
PHD-BrD tandem Trim66 and 400 nM of His6-tagged PHD of BAZ1B). The array was then 
washed and incubated for 1 h at room temperature with anti-His antibody and 
incubated for 1 h with HRP-conjugated secondary antibody. Eventually, the enhanced 
chemiluminescence (ECL) reaction was performed and the spots visualized on film. All 
the reagents for the experiments were furnished from the manufacturer. The intensity 
of the spots and the graphical analysis of the array were carried out using the Array 
Analyze software (Active Motif). 
 
6.5 PROTEIN CRYSTALLIZATION 
 
6.5.1 Crystallization trials 
 
Several crystallization trials of PHD of BAZ1B and PHD-BrD tandem of Trim66 in free and 
bound state were conducted at 12 °C, 20 °C and 4 °C by the sitting drop vapour diffusion 
method using the 96-well crystallization plate (Hampton Research) and the MOSQUITO 
crystallization robot for the set up. Optimizations of some hits were performed using 
the 24 well crystallization plate in hanging and sitting drop (Hampton Research). More 
details about individual procedures and conditions are available in the result chapters 
4.1 and 4.2.  
 
6.5.2 Soaking experiments 
 
Crystals of BAZ2A and BAZ2B PHD domains were obtained by mixing equal volume of 
protein and crystallisation buffer (2.2-2.4 M Na/K phosphate at pH 8.5) at concentration 
of 6.5–7 mg/ml and 5.5–6 mg/ml was used for BAZ2A and BAZ2B PHD domains, 
respectively. Crystals were left to grow at 20°C for at least two days 45. 
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Crystals of both proteins were soaked with 10–20% of different organic solvents 
(acetone, ethanol, acetonitrile and 1,4-dioxane) at different concentrations of 
fragments (10–200 mM). The soaking process was conducted for varying times, between 
6 to 24 h. Detailed descriptions in chapter 3.9. 
Crystals were also soaked with different concentration of H3 10-mer wt and double 
mutant peptides and H3 3-mer peptide. Peptides were soluble in the crystallization 
buffer and details of the soaking are in chapter 2.1 and 2.2. 
 
6.5.3 Data collection and structure solving 
 
The X-ray diffraction experiments on the crystals were carried out at the beamlines at 
the Diamond Light Source (Didcot, UK) and at ESRF synchrotrons. Data sets were 
acquired at a wavelength of 0.97 Å. Further data set collection was conducted in house 
using the Rigaku M007HF X-ray generator equipped with Varimax Cu-VHF optics, a 
Saturn 944HG+ CCD detector and an AFC-11 4-axis partial χ goniometer. 
BAZ2A PHD crystallized in a tetragonal system (space group P43212) and BAZ2B PHD 
crystallized in orthorhombic system (space group P222) so for both of them in order to 
collect a complete data sets with high multiplicity, I ensured to collect images in a 
rotational range of at least 90°, regardless the spindle axis.  
Images were indexed and integrated using XDS 187, 188 for BAZ2A PHD and iMosflm 189  
for BAZ2B PHD, then scaled and merged using Aimless 190 from the CCP4 package. R free 
flags were copied from the respective apo form pdb model (4QF2 for BAZ2A and 4QF3 
for BAZ2B) used for the refinement. Structures were solved using isomorphous 
refinement with Refmac5 [12] and as pdb model was used the pdb of the apo form.  
The model was manually built against 2Fo-Fc and Fo-Fc maps using Coot 191. Fo-Fc  map 
showed clear electron density to fit the 10-mer peptides, the 3-mer peptide and 
fragments in the histone pocket. Several rounds of refinement were performed using 
Refmac5 with TLS groups generated via TLSMD server 192. Waters were added to the 
model at the latest stages of the refinement process using Coot 191. Residues at the C 
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terminus of the peptide were not visible as well as the very N terminus residues in all 
the protein chains, consequently they were not modelled.  
Modelling of the fragment was performed using the ligand builder in Coot 191. The 
topology files of the fragments, for the refinement, were generated using PRODRG2 
server 193.  
Several cycles of refinement were carried out till R free and R work reached a reasonable 
values, consistent with the resolution of the dataset, and till further refinements were 
no longer improving their values.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
205 
 
CHAPTER 7. 
REFERENCES 
 
[1] Berger, S. L., Kouzarides, T., Shiekhattar, R., and Shilatifard, A. (2009) An operational 
definition of epigenetics, Genes Dev 23, 781-783. 
[2] Bird, A. (2007) Perceptions of epigenetics, Nature 447, 396-398. 
[3] Turner, B. M. (2009) Epigenetic responses to environmental change and their evolutionary 
implications, Philos T R Soc B 364, 3403-3418. 
[4] Bannister, A. J., and Kouzarides, T. (2011) Regulation of chromatin by histone modifications, 
Cell Res 21, 381-395. 
[5] Richmond, T. J. (1999) Hot papers - Crystal structure - Crystal structure of the nucleosome 
core particle at 2.8 angstrom resolution by K. Luger, A.W. Mader, R.K. Richmond, D.F. 
Sargent, T.J. Richmond - Comments, Scientist 13, 15-15. 
[6] Rothbart, S. B., and Strahl, B. D. (2014) Interpreting the language of histone and DNA 
modifications, Biochimica et biophysica acta 1839, 627-643. 
[7] Dhe-Paganon, S., Syeda, F., and Park, L. (2011) DNA methyl transferase 1: regulatory 
mechanisms and implications in health and disease, Int J Biochem Mol Biol 2, 58-66. 
[8] Taverna, S. D., Li, H., Ruthenburg, A. J., Allis, C. D., and Patel, D. J. (2007) How chromatin-
binding modules interpret histone modifications: lessons from professional pocket 
pickers, Nat Struct Mol Biol 14, 1025-1040. 
[9] Yun, M. Y., Wu, J., Workman, J. L., and Li, B. (2011) Readers of histone modifications, Cell Res 
21, 564-578. 
[10] Neilson, C., Santos-Rosa, H., Bannister, A., and Kouzarides, T. (2006) Chromatin 
modifications and their function, Febs J 273, 22-22. 
[11] Allfrey, V. G., Faulkner, R., and Mirsky, A. E. (1964) Acetylation and Methylation of Histones 
and Their Possible Role in the Regulation of Rna Synthesis, Proc Natl Acad Sci U S A 51, 
786-794. 
[12] Yang, X. J., and Seto, E. (2007) HATs and HDACs: from structure, function and regulation to 
novel strategies for therapy and prevention, Oncogene 26, 5310-5318. 
[13] Eberharter, A., and Becker, P. B. (2002) Histone acetylation: a switch between repressive 
and permissive chromatin - Second in review series on chromatin dynamics, Embo Rep 
3, 224-229. 
[14] Lan, F., and Shi, Y. (2009) Epigenetic regulation: methylation of histone and non-histone 
proteins, Sci China Ser C 52, 311-322. 
[15] Bannister, A. J., Schneider, R., and Kouzarides, T. (2002) Histone methylation: Dynamic or 
static?, Cell 109, 801-806. 
[16] Rea, S., Eisenhaber, F., O'Carroll, N., Strahl, B. D., Sun, Z. W., Schmid, M., Opravil, S., 
Mechtler, K., Ponting, C. P., Allis, C. D., and Jenuwein, T. (2000) Regulation of chromatin 
structure by site-specific histone H3 methyltransferases, Nature 406, 593-599. 
[17] Xiao, B., Jing, C., Wilson, J. R., Walker, P. A., Vasisht, N., Kelly, G., Howell, S., Taylor, I. A., 
Blackburn, G. M., and Gamblin, S. J. (2003) Structure and catalytic mechanism of the 
human histone methyltransferase SET7/9, Nature 421, 652-656. 
[18] Zhang, X., Yang, Z., Khan, S. I., Horton, J. R., Tamaru, H., Selker, E. U., and Cheng, X. D. (2003) 
Structural basis for the product specificity of histone lysine methyltransferases, Mol Cell 
12, 177-185. 
206 
 
[19] Herrmann, F., Pably, P., Eckerich, C., Bedford, M. T., and Fackelmayer, F. O. (2009) Human 
protein arginine methyltransferases in vivo - distinct properties of eight canonical 
members of the PRMT family, J Cell Sci 122, 667-677. 
[20] Bedford, M. T. (2006) The Family of Protein Arginine Methyltransferases, Enzymes 24, 31-
50. 
[21] Wang, Y., Wysocka, J., Sayegh, J., Lee, Y. H., Perlin, J. R., Leonelli, L., Sonbuchner, L. S., 
McDonald, C. H., Cook, R. G., Dou, Y., Roeder, R. G., Clarke, S., Stallcup, M. R., Allis, C. D., 
and Coonrod, S. A. (2004) Human PAD4 regulates histone arginine methylation levels via 
demethylimination, Science 306, 279-283. 
[22] Chang, B. S., Chen, Y., Zhao, Y. M., and Bruick, R. K. (2007) JMJD6 is a histone arginine 
demethylase, Science 318, 444-447. 
[23] Mosammaparast, N., and Shi, Y. (2010) Reversal of Histone Methylation: Biochemical and 
Molecular Mechanisms of Histone Demethylases, Annu Rev Biochem 79, 155-179. 
[24] Bedford, M. T., and Clarke, S. G. (2009) Protein Arginine Methylation in Mammals: Who, 
What, and Why, Mol Cell 33, 1-13. 
[25] Trojer, P., and Reinberg, D. (2007) Facultative heterochromatin: is there a distinctive 
molecular signature?, Mol Cell 28, 1-13. 
[26] Rossetto, D., Avvakumov, N., and Cote, J. (2012) Histone phosphorylation: a chromatin 
modification involved in diverse nuclear events, Epigenetics-Us 7, 1098-1108. 
[27] Sakabe, K., Wang, Z. H., and Hart, G. W. (2010) beta-N-acetylglucosamine (O-GlcNAc) is part 
of the histone code, P Natl Acad Sci USA 107, 19915-19920. 
[28] Swamy, M., Pathak, S., Grzes, K. M., Damerow, S., Sinclair, L. V., van Aalten, D. M., and 
Cantrell, D. A. (2016) Glucose and glutamine fuel protein O-GlcNAcylation to control T 
cell self-renewal and malignancy, Nat Immunol 17, 712-720. 
[29] Dehennaut, V., Leprince, D., and Lefebvre, T. (2014) O-GlcNAcylation, an Epigenetic Mark. 
Focus on the Histone Code, TET Family Proteins, and Polycomb Group Proteins, Front 
Endocrinol (Lausanne) 5, 155. 
[30] Muller, S., Filippakopoulos, P., and Knapp, S. (2011) Bromodomains as therapeutic targets, 
Expert Rev Mol Med 13, 1-21. 
[31] Zeng, L., and Zhou, M. M. (2002) Bromodomain: an acetyl-lysine binding domain, Febs Lett 
513, 124-128. 
[32] Smith, S. G., and Zhou, M. M. (2016) The Bromodomain: A New Target in Emerging 
Epigenetic Medicine, ACS chemical biology 11, 598-608. 
[33] MacDonald, N., Welburn, J. P. I., Noble, M. E. M., Nguyen, A., Yaffe, M. B., Clynes, D., Moggs, 
J. G., Orphanides, G., Thomson, S., Edmunds, J. W., Clayton, A. L., Endicott, J. A., and 
Mahadevan, L. C. (2005) Molecular basis for the recognition of phosphorylated and 
phosphoacetylated histone H3 by 14-3-3, Mol Cell 20, 199-211. 
[34] Stucki, M., Clapperton, J. A., Mohammad, D., Yaffe, M. B., Smerdon, S. J., and Jackson, S. P. 
(2005) MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses 
to DNA double-strand breaks, Cell 123, 1213-1226. 
[35] Tamkun, J. W., Deuring, R., Scott, M. P., Kissinger, M., Pattatucci, A. M., Kaufman, T. C., and 
Kennison, J. A. (1992) Brahma - a Regulator of Drosophila Homeotic Genes Structurally 
Related to the Yeast Transcriptional Activator Snf2 Sw12, Cell 68, 561-572. 
[36] Filippakopoulos, P., and Knapp, S. (2014) Targeting bromodomains: epigenetic readers of 
lysine acetylation, Nat Rev Drug Discov 13, 339-358. 
[37] Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J. P., Barsyte-Lovejoy, D., 
Felletar, I., Volkmer, R., Muller, S., Pawson, T., Gingras, A. C., Arrowsmith, C. H., and 
Knapp, S. (2012) Histone recognition and large-scale structural analysis of the human 
bromodomain family, Cell 149, 214-231. 
[38] Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W. I., 
Robson, S. C., Chung, C. W., Hopf, C., Savitski, M. M., Huthmacher, C., Gudgin, E., Lugo, 
207 
 
D., Beinke, S., Chapman, T. D., Roberts, E. J., Soden, P. E., Auger, K. R., Mirguet, O., 
Doehner, K., Delwel, R., Burnett, A. K., Jeffrey, P., Drewes, G., Lee, K., Huntly, B. J. P., and 
Kouzarides, T. (2011) Inhibition of BET recruitment to chromatin as an effective 
treatment for MLL-fusion leukaemia, Nature 478, 529-533. 
[39] Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C. W., Chandwani, R., 
Marazzi, I., Wilson, P., Coste, H., White, J., Kirilovsky, J., Rice, C. M., Lora, J. M., Prinjha, 
R. K., Lee, K., and Tarakhovsky, A. (2010) Suppression of inflammation by a synthetic 
histone mimic, Nature 468, 1119-1123. 
[40] Ferguson, F. M., Fedorov, O., Chaikuad, A., Philpott, M., Muniz, J. R. C., Felletar, I., von Delft, 
F., Heightman, T., Knapp, S., Abell, C., and Ciulli, A. (2013) Targeting Low-Druggability 
Bromodomains: Fragment Based Screening and Inhibitor Design against the BAZ2B 
Bromodomain, J Med Chem 56, 10183-10187. 
[41] Meier, J. C., Tallant, C., Fedorov, O., Witwicka, H., Hwang, S. Y., van Stiphout, R. G., Lambert, 
J. P., Rogers, C., Yapp, C., Gerstenberger, B. S., Fedele, V., Savitsky, P., Heidenreich, D., 
Daniels, D. L., Owen, D. R., Fish, P. V., Igoe, N. M., Bayle, E. D., Haendler, B., Oppermann, 
U. C. T., Buffa, F., Brennan, P. E., Muller, S., Gingras, A. C., Odgren, P. R., Birnbaum, M. 
J., and Knapp, S. (2017) Selective Targeting of Bromodomains of the Bromodomain-PHD 
Fingers Family Impairs Osteoclast Differentiation, ACS chemical biology 12, 2619-2630. 
[42] Schindler, U., Beckmann, H., and Cashmore, A. R. (1993) Hat3.1, a Novel Arabidopsis 
Homeodomain Protein Containing a Conserved Cysteine-Rich Region, Plant J 4, 137-150. 
[43] Musselman, C. A., and Kutateladze, T. G. (2009) PHD Fingers Epigenetic Effectors and 
Potential Drug Targets, Mol Interv 9, 314-323. 
[44] Liu, L. H., Zhen, X. T., Denton, E., Marsden, B. D., and Schapira, M. (2012) ChromoHub: a 
data hub for navigators of chromatin-mediated signalling, Bioinformatics 28, 2205-2206. 
[45] Tallant, C., Valentini, E., Fedorov, O., Overvoorde, L., Ferguson, F. M., Filippakopoulos, P., 
Svergun, D. I., Knapp, S., and Ciulli, A. (2015) Molecular basis of histone tail recognition 
by human TIP5 PHD finger and bromodomain of the chromatin remodeling complex 
NoRC, Structure 23, 80-92. 
[46] Bortoluzzi, A., Amato, A., Lucas, X., Blank, M., and Ciulli, A. (2017) Structural basis of 
molecular recognition of helical histone H3 tail by PHD finger domains, The Biochemical 
journal 474, 1633-1651. 
[47] Lan, F., Collins, R. E., De Cegli, R., Alpatov, R., Horton, J. R., Shi, X., Gozani, O., Cheng, X., and 
Shi, Y. (2007) Recognition of unmethylated histone H3 lysine 4 links BHC80 to LSD1-
mediated gene repression, Nature 448, 718-722. 
[48] Pena, P. V., Musselman, C. A., Kuo, A. J., Gozani, O., and Kutateladze, T. G. (2009) NMR 
assignments and histone specificity of the ING2 PHD finger, Magn Reson Chem 47, 352-
358. 
[49] Shi, X. B., Hong, T., Walter, K. L., Ewalt, M., Michishita, E., Hung, T., Carney, D., Pena, P., Lan, 
F., Kaadige, M. R., Lacoste, N., Cayrou, C., Davrazou, F., Saha, A., Cairns, B. R., Ayer, D. 
E., Kutateladze, T. G., Shi, Y., Cote, J., Chua, K. F., and Gozani, O. (2006) ING2 PHD domain 
links histone H3 lysine 4 methylation to active gene repression, Nature 442, 96-99. 
[50] Li, H. T., Ilin, S., Wang, W. K., Duncan, E. M., Wysocka, J., Allis, C. D., and Patel, D. J. (2006) 
Molecular basis for site-specific read-out of histone H3K4me3 by the BPTF PHD finger of 
NURF, Nature 442, 91-95. 
[51] Xi, Q. R., Wang, Z. X., Zaromytidou, A. I., Zhang, X. H. F., Chow-Tsang, L. F., Liu, J. X., Kim, H., 
Barlas, A., Manova-Todorova, K., Kaartinen, V., Studer, L., Mark, W., Patel, D. J., and 
Massague, J. (2011) A Poised Chromatin Platform for TGF-beta Access to Master 
Regulators, Cell 147, 1511-1524. 
[52] Shi, X. B., Kachirskaia, I., Walter, K. L., Kuo, J. H. A., Lake, A., Davrazou, F., Chan, S. M., Martin, 
D. G. E., Fingerman, I. M., Briggs, S. D., Howe, L., Utz, P. J., Kutateladze, T. G., Lugovskoy, 
A. A., Bedford, M. T., and Gozani, O. (2007) Proteome-wide analysis in Saccharomyces 
208 
 
cerevisiae identifies several PHD fingers as novel direct and selective binding modules 
of histone H3 methylated at either lysine 4 or lysine 36, J Biol Chem 282, 2450-2455. 
[53] Xiong, X., Panchenko, T., Yang, S., Zhao, S., Yan, P., Zhang, W., Xie, W., Li, Y., Zhao, Y., Allis, 
C. D., and Li, H. (2016) Selective recognition of histone crotonylation by double PHD 
fingers of MOZ and DPF2, Nat Chem Biol 12, 1111-1118. 
[54] Gallivan, J. P., and Dougherty, D. A. (1999) Cation-pi interactions in structural biology, P Natl 
Acad Sci USA 96, 9459-9464. 
[55] Baker, L. A., Allis, C. D., and Wang, G. G. (2008) PHD fingers in human diseases: Disorders 
arising from misinterpreting epigenetic marks, Mutat Res-Fund Mol M 647, 3-12. 
[56] Wagner, E. K., Nath, N., Flemming, R., Feltenberger, J. B., and Denu, J. M. (2012) 
Identification and characterization of small molecule inhibitors of a plant homeodomain 
finger, Biochemistry 51, 8293-8306. 
[57] Miller, T. C., Rutherford, T. J., Birchall, K., Chugh, J., Fiedler, M., and Bienz, M. (2014) 
Competitive binding of a benzimidazole to the histone-binding pocket of the Pygo PHD 
finger, ACS chemical biology 9, 2864-2874. 
[58] Dreveny, I., Deeves, S. E., Fulton, J., Yue, B. G., Messmer, M., Bhattacharya, A., Collins, H. 
M., and Heery, D. M. (2014) The double PHD finger domain of MOZ/MYST3 induces 
alpha-helical structure of the histone H3 tail to facilitate acetylation and methylation 
sampling and modification, Nucleic Acids Res 42, 822-835. 
[59] Oliver, S. S., Musselman, C. A., Srinivasan, R., Svaren, J. P., Kutateladze, T. G., and Denu, J. 
M. (2012) Multivalent Recognition of Histone Tails by the PHD Fingers of CHD5, 
Biochemistry 51, 6534-6544. 
[60] Fischle, W., Wang, Y. M., and Allis, C. D. (2003) Binary switches and modification cassettes 
in histone biology and beyond, Nature 425, 475-479. 
[61] Musselman, C. A., and Kutateladze, T. G. (2011) Handpicking epigenetic marks with PHD 
fingers, Nucleic Acids Res 39, 9061-9071. 
[62] Tsai, W. W., Wang, Z., Yiu, T. T., Akdemir, K. C., Xia, W., Winter, S., Tsai, C. Y., Shi, X., 
Schwarzer, D., Plunkett, W., Aronow, B., Gozani, O., Fischle, W., Hung, M. C., Patel, D. J., 
and Barton, M. C. (2010) TRIM24 links a non-canonical histone signature to breast 
cancer, Nature 468, 927-932. 
[63] Ruthenburg, A. J., Li, H. T., Milne, T. A., Dewell, S., McGinty, R. K., Yuen, M., Ueberheide, B., 
Dou, Y. L., Muir, T. W., Patel, D. J., and Allis, C. D. (2011) Recognition of a 
Mononucleosomal Histone Modification Pattern by BPTF via Multivalent Interactions, 
Cell 145, 692-706. 
[64] Ruthenburg, A. J., Li, H., Patel, D. J., and Allis, C. D. (2007) Multivalent engagement of 
chromatin modifications by linked binding modules, Nat Rev Mol Cell Bio 8, 983-994. 
[65] Zhang, X. J., Zhao, D., Xiong, X. Z., He, Z. M., and Li, H. T. (2016) Multifaceted Histone H3 
Methylation and Phosphorylation Readout by the Plant Homeodomain Finger of Human 
Nuclear Antigen Sp100C, J Biol Chem 291, 12786-12798. 
[66] Baud, M. G. J., Lin-Shiao, E., Cardote, T., Tallant, C., Pschibul, A., Chan, K. H., Zengerle, M., 
Garcia, J. R., Kwan, T. T., Ferguson, F. M., and Ciulli, A. (2014) Chemical biology. A bump-
and-hole approach to engineer controlled selectivity of BET bromodomain chemical 
probes, Science 346, 638-641. 
[67] Runcie, A. C., Chan, K. H., Zengerle, M., and Ciulli, A. (2016) Chemical genetics approaches 
for selective intervention in epigenetics, Curr Opin Chem Biol 33, 186-194. 
[68] Bamborough, P., Chung, C. W., Demont, E. H., Furze, R. C., Bannister, A. J., Che, K. H., Diallo, 
H., Douault, C., Grandi, P., Kouzarides, T., Michon, A. M., Mitchell, D. J., Prinjha, R. K., 
Rau, C., Robson, S., Sheppard, R. J., Upton, R., and Watson, R. J. (2016) A Chemical Probe 
for the ATAD2 Bromodomain, Angew Chem Int Edit 55, 11382-11386. 
[69] Sdelci, S., Lardeau, C. H., Tallant, C., Klepsch, F., Klaiber, B., Bennett, J., Rathert, P., Schuster, 
M., Penz, T., Fedorov, O., Superti-Furga, G., Bock, C., Zuber, J., Huber, K. V., Knapp, S., 
209 
 
Muller, S., and Kubicek, S. (2016) Mapping the chemical chromatin reactivation 
landscape identifies BRD4-TAF1 cross-talk, Nat Chem Biol 12, 504-510. 
[70] Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., and Schapira, M. (2012) Epigenetic protein 
families: a new frontier for drug discovery, Nat Rev Drug Discov 11, 384-400. 
[71] Portela, A., and Esteller, M. (2010) Epigenetic modifications and human disease, Nature 
biotechnology 28, 1057-1068. 
[72] Milite, C., Feoli, A., Viviano, M., Rescigno, D., Cianciulli, A., Balzano, A. L., Mai, A., Castellano, 
S., and Sbardella, G. (2016) The emerging role of lysine methyltransferase SETD8 in 
human diseases, Clin Epigenetics 8, 102. 
[73] Falkenberg, K. J., and Johnstone, R. W. (2014) Histone deacetylases and their inhibitors in 
cancer, neurological diseases and immune disorders, Nat Rev Drug Discov 13, 673-691. 
[74] Jones, P. A., Issa, J. P., and Baylin, S. (2016) Targeting the cancer epigenome for therapy, 
Nat Rev Genet 17, 630-641. 
[75] Stresemann, C., and Lyko, F. (2008) Modes of action of the DNA methyltransferase inhibitors 
azacytidine and decitabine, International journal of cancer 123, 8-13. 
[76] Richon, V. M. (2006) Cancer biology: mechanism of antitumour action of vorinostat 
(suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor, British journal 
of cancer 95, S2-S6. 
[77] Marks, P. A., and Breslow, R. (2007) Dimethyl sulfoxide to vorinostat: development of this 
histone deacetylase inhibitor as an anticancer drug, Nature biotechnology 25, 84-90. 
[78] Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, 
R., and Pavletich, N. P. (1999) Structures of a histone deacetylase homologue bound to 
the TSA and SAHA inhibitors, Nature 401, 188-193. 
[79] Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., and Pazdur, R. (2007) FDA approval 
summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma, 
Oncologist 12, 1247-1252. 
[80] Galdeano, C., and Ciulli, A. (2016) Selectivity on-target of bromodomain chemical probes by 
structure-guided medicinal chemistry and chemical biology, Future Med Chem 8, 1655-
1680. 
[81] Mirguet, O., Gosmini, R., Toum, J., Clement, C. A., Barnathan, M., Brusq, J. M., Mordaunt, J. 
E., Grimes, R. M., Crowe, M., Pineau, O., Ajakane, M., Daugan, A., Jeffrey, P., Cutler, L., 
Haynes, A. C., Smithers, N. N., Chung, C. W., Bamborough, P., Uings, I. J., Lewis, A., 
Witherington, J., Parr, N., Prinjha, R. K., and Nicodeme, E. (2013) Discovery of epigenetic 
regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET 
bromodomains, J Med Chem 56, 7501-7515. 
[82] Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., 
Keates, T., Hickman, T. T., Felletar, I., Philpott, M., Munro, S., McKeown, M. R., Wang, 
Y., Christie, A. L., West, N., Cameron, M. J., Schwartz, B., Heightman, T. D., La Thangue, 
N., French, C. A., Wiest, O., Kung, A. L., Knapp, S., and Bradner, J. E. (2010) Selective 
inhibition of BET bromodomains, Nature 468, 1067-1073. 
[83] Milosevich, N., and Hof, F. (2016) Chemical Inhibitors of Epigenetic Methyllysine Reader 
Proteins, Biochemistry 55, 1570-1583. 
[84] Bonetta, L. (2010) Interactome under construction, Nature 468, 851-854. 
[85] Jones, S., and Thornton, J. M. (1996) Principles of protein-protein interactions, P Natl Acad 
Sci USA 93, 13-20. 
[86] Cheng, A. C., Coleman, R. G., Smyth, K. T., Cao, Q., Soulard, P., Caffrey, D. R., Salzberg, A. C., 
and Huang, E. S. (2007) Structure-based maximal affinity model predicts small-molecule 
druggability, Nature biotechnology 25, 71-75. 
[87] Arkin, M. R., Tang, Y. Y., and Wells, J. A. (2014) Small-Molecule Inhibitors of Protein-Protein 
Interactions: Progressing toward the Reality, Chem Biol 21, 1102-1114. 
210 
 
[88] Guo, W. X., Wisniewski, J. A., and Ji, H. T. (2014) Hot spot-based design of small-molecule 
inhibitors for protein-protein interactions, Bioorg Med Chem Lett 24, 2546-2554. 
[89] Moreira, I. S., Fernandes, P. A., and Ramos, M. J. (2007) Hot spots-A review of the protein-
protein interface determinant amino-acid residues, Proteins-Structure Function and 
Bioinformatics 68, 803-812. 
[90] Cardote, T. A. F., and Ciulli, A. (2016) Cyclic and Macrocyclic Peptides as Chemical Tools To 
Recognise Protein Surfaces and Probe Protein-Protein Interactions, ChemMedChem 11, 
787-794. 
[91] Edfeldt, F. N. B., Folmer, R. H. A., and Breeze, A. L. (2011) Fragment screening to predict 
druggability (ligandability) and lead discovery success, Drug Discov Today 16, 284-287. 
[92] Pauling, L. (1946) Molecular architecture and biological reactions, Chemical & Engineering 
News 24, 1375-1377. 
[93] Hopkins, A. L., and Groom, C. R. (2002) The druggable genome, Nat Rev Drug Discov 1, 727-
730. 
[94] Sugiyama, Y. (2005) Druggability: selecting optimized drug candidates, Drug Discov Today 
10, 1577-1579. 
[95] Jencks, W. P. (1981) On the Attribution and Additivity of Binding-Energies, P Natl Acad Sci-
Biol 78, 4046-4050. 
[96] Scott, D. E., Coyne, A. G., Hudson, S. A., and Abell, C. (2012) Fragment-Based Approaches in 
Drug Discovery and Chemical Biology, Biochemistry 51, 4990-5003. 
[97] Hopkins, A. L., Keseru, G. M., Leeson, P. D., Rees, D. C., and Reynolds, C. H. (2014) The role 
of ligand efficiency metrics in drug discovery, Nat Rev Drug Discov 13, 105-121. 
[98] Jones, M. H., Hamana, N., Nezu, J., and Shimane, M. (2000) A novel family of bromodomain 
genes, Genomics 63, 40-45. 
[99] Ito, T., Levenstein, M. E., Fyodorov, D. V., Kutach, A. K., Kobayashi, R., and Kadonaga, J. T. 
(1999) ACF consists of two subunits, Acf1 and ISWI, that function cooperatively in the 
ATP-dependent catalysis of chromatin assembly, Gene Dev 13, 1529-1539. 
[100] Hulo, N., Bairoch, A., Bulliard, V., Cerutti, L., Cuche, B. A., de Castro, E., Lachaize, C., 
Langendijk-Genevaux, P. S., and Sigrist, C. J. A. (2008) The 20 years of PROSITE, Nucleic 
Acids Res 36, D245-D249. 
[101] Santoro, R., and Grummt, I. (2005) Epigenetic mechanism of rRNA gene silencing: 
Temporal order of NoRC-mediated histone modification, chromatin remodeling, and 
DNA methylation, Mol Cell Biol 25, 2539-2546. 
[102] Santoro, R., Li, J. W., and Grummt, I. (2002) The nucleolar remodeling complex NoRC 
mediates heterochromatin formation and silencing of ribosomal gene transcription, Nat 
Genet 32, 393-396. 
[103] Gu, L., Frommel, S. C., Oakes, C. C., Simon, R., Grupp, K., Gerig, C. Y., Bar, D., Robinson, M. 
D., Baer, C., Weiss, M., Gu, Z., Schapira, M., Kuner, R., Sultmann, H., Provenzano, M., 
Cancer, I. P. o. E. O. P., Yaspo, M. L., Brors, B., Korbel, J., Schlomm, T., Sauter, G., Eils, R., 
Plass, C., and Santoro, R. (2015) BAZ2A (TIP5) is involved in epigenetic alterations in 
prostate cancer and its overexpression predicts disease recurrence, Nature genetics 47, 
22-30. 
[104] Arking, D. E., Junttila, M. J., Goyette, P., Huertas-Vazquez, A., Eijgelsheim, M., Blom, M. T., 
Newton-Cheh, C., Reinier, K., Teodorescu, C., Uy-Evanado, A., Carter-Monroe, N., 
Kaikkonen, K. S., Kortelainen, M. L., Boucher, G., Lagace, C., Moes, A., Zhao, X., Kolodgie, 
F., Rivadeneira, F., Hofman, A., Witteman, J. C., Uitterlinden, A. G., Marsman, R. F., 
Pazoki, R., Bardai, A., Koster, R. W., Dehghan, A., Hwang, S. J., Bhatnagar, P., Post, W., 
Hilton, G., Prineas, R. J., Li, M., Kottgen, A., Ehret, G., Boerwinkle, E., Coresh, J., Kao, W. 
H., Psaty, B. M., Tomaselli, G. F., Sotoodehnia, N., Siscovick, D. S., Burke, G. L., Marban, 
E., Spooner, P. M., Cupples, L. A., Jui, J., Gunson, K., Kesaniemi, Y. A., Wilde, A. A., Tardif, 
J. C., O'Donnell, C. J., Bezzina, C. R., Virmani, R., Stricker, B. H., Tan, H. L., Albert, C. M., 
211 
 
Chakravarti, A., Rioux, J. D., Huikuri, H. V., and Chugh, S. S. (2011) Identification of a 
sudden cardiac death susceptibility locus at 2q24.2 through genome-wide association in 
European ancestry individuals, Plos Genet 7, e1002158. 
[105] Xiao, A., Li, H., Shechter, D., Ahn, S. H., Fabrizio, L. A., Erdjument-Bromage, H., Ishibe-
Murakami, S., Wang, B., Tempst, P., Hofmann, K., Patel, D. J., Elledge, S. J., and Allis, C. 
D. (2009) WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase 
activity, Nature 457, 57-62. 
[106] Barnett, C., and Krebs, J. E. (2011) WSTF does it all: a multifunctional protein in 
transcription, repair, and replication, Biochemistry and Cell Biology-Biochimie Et Biologie 
Cellulaire 89, 12-23. 
[107] Bayes, M., Magano, L. F., Rivera, N., Flores, R., and Jurado, L. A. P. (2003) Mutational 
mechanisms of Williams-Beuren syndrome deletions, Am J Hum Genet 73, 131-151. 
[108] Kitagawa, H., Fujiki, R., Yoshimura, K., Oya, H., and Kato, S. (2011) Williams syndrome is an 
epigenome-regulator disease, Endocr J 58, 77-85. 
[109] Lalli, M. A., Jang, J. W., Park, J. H. C., Wang, Y. D., Guzman, E., Zhou, H. J., Audouard, M., 
Bridges, D., Tovar, K. R., Papuc, S. M., Tutulan-Cunita, A. C., Huang, Y. D., Budisteanu, 
M., Arghir, A., and Kosik, K. S. (2016) Haploinsufficiency of BAZ1B contributes to Williams 
syndrome through transcriptional dysregulation of neurodevelopmental pathways, 
Hum Mol Genet 25, 1294-1306. 
[110] Borden, K. L. B., and Freemont, P. S. (1996) The RING finger domain: A recent example of 
a sequence-structure family, Current opinion in structural biology 6, 395-401. 
[111] Short, K. M., and Cox, T. C. (2006) Subclassification of the RBCC/TRIM superfamily reveals 
a novel motif necessary for microtubule binding, J Biol Chem 281, 8970-8980. 
[112] Liu, J., Zheng, Q., Deng, Y. Q., Cheng, C. S., Kallenbach, N. R., and Lu, M. (2006) A seven-
helix coiled coil, P Natl Acad Sci USA 103, 15457-15462. 
[113] Reymond, A., Meroni, G., Fantozzi, A., Merla, G., Cairo, S., Luzi, L., Riganelli, D., Zanaria, E., 
Messali, S., Cainarca, S., Guffanti, A., Minucci, S., Pelicci, P. G., and Ballabio, A. (2001) 
The tripartite motif family identifies cell compartments, Embo Journal 20, 2140-2151. 
[114] Khetchoumian, K., Teletin, M., Mark, M., Lerouge, T., Cervino, M., Oulad-Abdelghani, M., 
Chambon, P., and Losson, R. (2004) TIF1 delta, a novel HP1-interacting member of the 
transcriptional intermediary factor 1 (TIF1) family expressed by elongating spermatids, 
J Biol Chem 279, 48329-48341. 
[115] Liu, J. L., Wu, W. X., Xie, Y. H., Lv, X. D., Ling, D. Y., and Yang, Z. P. (2016) Overexpression of 
TRIM66 functions as an oncogene in lung cancer progression, Int J Clin Exp Patho 9, 
4966-4977. 
[116] Chen, Y., Guo, Y. F., Yang, H. S., Shi, G. D., Xu, G. H., Shi, J. G., Yin, N., and Chen, D. Y. (2015) 
TRIM66 overexpresssion contributes to osteosarcoma carcinogenesis and indicates 
poor survival outcome, Oncotarget 6, 23708-23719. 
[117] Bortoluzzi, A., and Ciulli, A. (2017) Protein-Based NMR Methods Applied to Drug Discovery, 
In Applied Biophysics for Drug Discovery, pp 153-173, John Wiley & Sons, Ltd. 
[118] Williamson, M. P. (2013) Using chemical shift perturbation to characterise ligand binding, 
Prog Nucl Mag Res Sp 73, 1-16. 
[119] Ziarek, J. J., Peterson, F. C., Lytle, B. L., and Volkman, B. F. (2011) Binding Site Identification 
and Structure Determination of Protein-Ligand Complexes by Nmr: A Semiautomated 
Approach, Fragment-Based Drug Design: Tools, Practical Approaches, and Examples 
493, 241-275. 
[120] Xu, Y., and Matthews, S. (2013) TROSY NMR spectroscopy of large soluble proteins, Top 
Curr Chem 335, 97-119. 
[121] Śledź, P., Abell, C., and Ciulli, A. (2012) Ligand-Observed NMR in Fragment-Based 
Approaches, In NMR of Biomolecules, pp 264-280, Wiley-VCH Verlag GmbH & Co. KGaA. 
212 
 
[122] Dias, D. M., Van Molle, I., Baud, M. G., Galdeano, C., Geraldes, C. F., and Ciulli, A. (2014) Is 
NMR Fragment Screening Fine-Tuned to Assess Druggability of Protein-Protein 
Interactions?, ACS medicinal chemistry letters 5, 23-28. 
[123] Ciulli, A. (2013) Biophysical screening for the discovery of small-molecule ligands, Methods 
in molecular biology 1008, 357-388. 
[124] Martin-Pastor, M., Vega-Vazquez, M., De Capua, A., Canales, A., Andre, S., Gabius, H. J., 
and Jimenez-Barbero, J. (2006) Enhanced signal dispersion in saturation transfer 
difference experiments by conversion to a 1D-STD-homodecoupled spectrum, Journal 
of biomolecular NMR 36, 103-109. 
[125] Dalvit, C., Fogliatto, G., Stewart, A., Veronesi, M., and Stockman, B. (2001) WaterLOGSY as 
a method for primary NMR screening: practical aspects and range of applicability, 
Journal of biomolecular NMR 21, 349-359. 
[126] Carr, H. Y., and Purcell, E. M. (1954) Effects of Diffusion on Free Precession in Nuclear 
Magnetic Resonance Experiments, Phys Rev 94, 630-638. 
[127] Carvalho, A. L., Trincao, J., and Romao, M. J. (2010) X-Ray Crystallography in Drug 
Discovery, Ligand-Macromolecular Interactions in Drug Discovery: Methods and 
Protocols 572, 31-56. 
[128] Blundell, T. L., and Patel, S. (2004) High-throughput X-ray crystallography for drug 
discovery, Curr Opin Pharmacol 4, 490-496. 
[129] Hassell, A. M., An, G., Bledsoe, R. K., Bynum, J. M., Carter, H. L., 3rd, Deng, S. J., Gampe, R. 
T., Grisard, T. E., Madauss, K. P., Nolte, R. T., Rocque, W. J., Wang, L., Weaver, K. L., 
Williams, S. P., Wisely, G. B., Xu, R., and Shewchuk, L. M. (2007) Crystallization of protein-
ligand complexes, Acta crystallographica. Section D, Biological crystallography 63, 72-
79. 
[130] Rich, R. L., and Myszka, D. G. (2007) Higher-throughput, label-free, real-time molecular 
interaction analysis, Analytical biochemistry 361, 1-6. 
[131] Ciulli, A. (2013) Biophysical screening for the discovery of small-molecule ligands, Methods 
in molecular biology 1008, 357-388. 
[132] Niesen, F. H., Berglund, H., and Vedadi, M. (2007) The use of differential scanning 
fluorimetry to detect ligand interactions that promote protein stability, Nat Protoc 2, 
2212-2221. 
[133] Dai, R., Geders, T. W., Liu, F., Park, S. W., Schnappinger, D., Aldrich, C. C., and Finzel, B. C. 
(2015) Fragment-Based Exploration of Binding Site Flexibility in Mycobacterium 
tuberculosis BioA, J Med Chem 58, 5208-5217. 
[134] Morreale, F. E., Bortoluzzi, A., Chaugule, V. K., Arkinson, C., Walden, H., and Ciulli, A. (2017) 
Allosteric Targeting of the Fanconi Anemia Ubiquitin-Conjugating Enzyme Ube2T by 
Fragment Screening, J Med Chem 60, 4093-4098. 
[135] Bielefeld-Sevigny, M. (2009) AlphaLISA immunoassay platform- the "no-wash" high-
throughput alternative to ELISA, Assay and drug development technologies 7, 90-92. 
[136] Ferguson, F. M., Dias, D. M., Rodrigues, J. P. G. L. M., Wienk, H., Boelens, R., Bonvin, A. M. 
J. J., Abell, C., and Ciulli, A. (2014) Binding Hotspots of BAZ2B Bromodomain: Histone 
Interaction Revealed by Solution NMR Driven Docking, Biochemistry 53, 6706-6716. 
[137] Chen, P., Chaikuad, A., Bamborough, P., Bantscheff, M., Bountra, C., Chung, C. W., Fedorov, 
O., Grandi, P., Jung, D., Lesniak, R., Lindon, M., Muller, S., Philpott, M., Prinjha, R., 
Rogers, C., Selenski, C., Tallant, C., Werner, T., Willson, T. M., Knapp, S., and Drewry, D. 
H. (2016) Discovery and Characterization of GSK2801, a Selective Chemical Probe for the 
Bromodomains BAZ2A and BAZ2B, J Med Chem 59, 1410-1424. 
[138] Drouin, L., McGrath, S., Vidler, L. R., Chaikuad, A., Monteiro, O., Tallant, C., Philpott, M., 
Rogers, C., Fedorov, O., Liu, M., Akhtar, W., Hayes, A., Raynaud, F., Muller, S., Knapp, S., 
and Hoelder, S. (2015) Structure enabled design of BAZ2-ICR, a chemical probe targeting 
the bromodomains of BAZ2A and BAZ2B, J Med Chem 58, 2553-2559. 
213 
 
[139] Spiliotopoulos, D., Wamhoff, E. C., Lolli, G., Rademacher, C., and Caflisch, A. (2017) 
Discovery of BAZ2A bromodomain ligands, Eur J Med Chem 139, 564-572. 
[140] Zhu, J. Y., Ye, Q., Zhang, L. J., Song, Y. N., Zhang, M., Wang, W. H., and Zhang, H. (2017) 
TRIM66 knockdown inhibits cell growth, but induces cell cycle arrest and apoptosis of 
hepatocellular carcinoma cells, Int J Clin Exp Patho 10, 1030-1040. 
[141] McAllister, T. E., England, K. S., Hopkinson, R. J., Brennan, P. E., Kawamura, A., and 
Schofield, C. J. (2016) Recent Progress in Histone Demethylase Inhibitors, J Med Chem 
59, 1308-1329. 
[142] Jung, M., Philpott, M., Muller, S., Schulze, J., Badock, V., Eberspacher, U., Moosmayer, D., 
Bader, B., Schmees, N., Fernandez-Montalvan, A., and Haendler, B. (2014) Affinity Map 
of Bromodomain Protein 4 ( BRD4) Interactions with the Histone H4 Tail and the Small 
Molecule Inhibitor JQ1, J Biol Chem 289, 9304-9319. 
[143] Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., 
Murray, L. W., Richardson, J. S., and Richardson, D. C. (2010) MolProbity: all-atom 
structure validation for macromolecular crystallography, Acta Crystallogr D 66, 12-21. 
[144] Pace, C. N., and Scholtz, J. M. (1998) A helix propensity scale based on experimental studies 
of peptides and proteins, Biophysical journal 75, 422-427. 
[145] Klein, B. J., Simithy, J., Wang, X., Ahn, J., Andrews, F. H., Zhang, Y., Cote, J., Shi, X., Garcia, 
B. A., and Kutateladze, T. G. (2017) Recognition of Histone H3K14 Acylation by MORF, 
Structure 25, 650-654 e652. 
[146] Wang, X. Y., Moore, S. C., Laszckzak, M., and Ausio, J. (2000) Acetylation increases the 
alpha-helical content of the histone tails of the nucleosome, J Biol Chem 275, 35013-
35020. 
[147] Arita, K., Isogai, S., Oda, T., Unoki, M., Sugita, K., Sekiyama, N., Kuwata, K., Hamamoto, R., 
Tochio, H., Sato, M., Ariyoshi, M., and Shirakawa, M. (2012) Recognition of modification 
status on a histone H3 tail by linked histone reader modules of the epigenetic regulator 
UHRF1, P Natl Acad Sci USA 109, 12950-12955. 
[148] Kostrhon, S., Kontaxis, G., Kaufmann, T., Schirghuber, E., Kubicek, S., Konrat, R., and Slade, 
D. (2017) A histone-mimicking interdomain linker in a multidomain protein modulates 
multivalent histone binding, The Journal of biological chemistry 292, 17643-17657. 
[149] Bird, G. H., Crannell, W. C., and Walensky, L. D. (2011) Chemical synthesis of hydrocarbon-
stapled peptides for protein interaction research and therapeutic targeting, Current 
protocols in chemical biology 3, 99-117. 
[150] Chang, Y. S., Graves, B., Guerlavais, V., Tovar, C., Packman, K., To, K. H., Olson, K. A., 
Kesavan, K., Gangurde, P., Mukherjee, A., Baker, T., Darlak, K., Elkin, C., Filipovic, Z., 
Qureshi, F. Z., Cai, H., Berry, P., Feyfant, E., Shi, X. E., Horstick, J., Annis, D. A., Manning, 
A. M., Fotouhi, N., Nash, H., Vassilev, L. T., and Sawyer, T. K. (2013) Stapled alpha-helical 
peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-
dependent cancer therapy, Proc Natl Acad Sci U S A 110, E3445-E3454. 
[151] Yin, H., Lee, G. I., Sedey, K. A., Kutzki, O., Park, H. S., Orner, B. P., Ernst, J. T., Wang, H. G., 
Sebti, S. M., and Hamilton, A. D. (2005) Terphenyl-based bak BH3 alpha-helical 
proteomimetics as low-molecular-weight antagonists of Bcl-X-L, J Am Chem Soc 127, 
10191-10196. 
[152] Ziarek, J. J., Peterson, F. C., Lytle, B. L., and Volkman, B. F. (2011) Binding site identification 
and structure determination of protein-ligand complexes by NMR a semiautomated 
approach, Methods in enzymology 493, 241-275. 
[153] Hermann, J. C., Chen, Y. S., Wartchow, C., Menke, J., Gao, L., Gleason, S. K., Haynes, N. E., 
Scott, N., Petersen, A., Gabriel, S., Vu, B., George, K. M., Narayanan, A., Li, S. H., Qian, 
H., Beatini, N., Niu, L. H., and Gan, Q. F. (2013) Metal Impurities Cause False Positives in 
High-Throughput Screening Campaigns, ACS medicinal chemistry letters 4, 197-200. 
214 
 
[154] Vranken, W. F., Boucher, W., Stevens, T. J., Fogh, R. H., Pajon, A., Llinas, M., Ulrich, E. L., 
Markley, J. L., Ionides, J., and Laue, E. D. (2005) The CCPN data model for NMR 
spectroscopy: development of a software pipeline, Proteins 59, 687-696. 
[155] Kimple, A. J., Muller, R. E., Siderovski, D. P., and Willard, F. S. (2010) A capture coupling 
method for the covalent immobilization of hexahistidine tagged proteins for surface 
plasmon resonance, Methods in molecular biology 627, 91-100. 
[156] Etemadzadeh, M. H., Arashkia, A., Roohvand, F., Norouzian, D., and Azadmanesh, K. (2015) 
Isolation, cloning, and expression of E. coli BirA gene for biotinylation applications, 
Advanced biomedical research 4, 149. 
[157] Fairhead, M., and Howarth, M. (2015) Site-specific biotinylation of purified proteins using 
BirA, Methods in molecular biology 1266, 171-184. 
[158] Zhang, J. H., Chung, T. D. Y., and Oldenburg, K. R. (1999) A simple statistical parameter for 
use in evaluation and validation of high throughput screening assays, J Biomol Screen 4, 
67-73. 
[159] Liebschner, D., Afonine, P. V., Moriarty, N. W., Poon, B. K., Sobolev, O. V., Terwilliger, T. C., 
and Adams, P. D. (2017) Polder maps: improving OMIT maps by excluding bulk solvent, 
Acta crystallographica. Section D, Structural biology 73, 148-157. 
[160] Collins, B., Stevens, R. C., and Page, R. (2005) Crystallization Optimum Solubility Screening: 
using crystallization results to identify the optimal buffer for protein crystal formation, 
Acta Crystallogr F 61, 1035-1038. 
[161] Dong, A. P., Xu, X. H., and Edward, A. M. (2007) In situ proteolysis for protein crystallization 
and structure determination, Nat Methods 4, 1019-1021. 
[162] D'Arcy, A., Bergfors, T., Cowan-Jacob, S. W., and Marsh, M. (2014) Microseed matrix 
screening for optimization in protein crystallization: what have we learned?, Acta 
crystallographica. Section F, Structural biology communications 70, 1117-1126. 
[163] D'Arcy, A., Villard, F., and Marsh, M. (2007) An automated microseed matrix-screening 
method for protein crystallization, Acta crystallographica. Section D, Biological 
crystallography 63, 550-554. 
[164] Stewart, P. D. S., Kolek, S. A., Briggs, R. A., Chayen, N. E., and Baldock, P. F. M. (2011) 
Random Microseeding: A Theoretical and Practical Exploration of Seed Stability and 
Seeding Techniques for Successful Protein Crystallization, Cryst Growth Des 11, 3432-
3441. 
[165] Obmolova, G., Malia, T. J., Teplyakov, A., Sweet, R. W., and Gilliland, G. L. (2014) Protein 
crystallization with microseed matrix screening: application to human germline 
antibody Fabs, Acta crystallographica. Section F, Structural biology communications 70, 
1107-1115. 
[166] Ireton, G. C., and Stoddard, B. L. (2004) Microseed matrix screening to improve crystals of 
yeast cytosine deaminase, Acta crystallographica. Section D, Biological crystallography 
60, 601-605. 
[167] Abuhammad, A., Lowe, E. D., McDonough, M. A., Shaw Stewart, P. D., Kolek, S. A., Sim, E., 
and Garman, E. F. (2013) Structure of arylamine N-acetyltransferase from 
Mycobacterium tuberculosis determined by cross-seeding with the homologous protein 
from M. marinum: triumph over adversity, Acta crystallographica. Section D, Biological 
crystallography 69, 1433-1446. 
[168] Walter, T. S., Meier, C., Assenberg, R., Au, K. F., Ren, J. S., Verma, A., Nettleship, J. E., 
Owens, R. J., Stuart, D. I., and Grimes, J. M. (2006) Lysine methylation as a routine rescue 
strategy for protein crystallization, Structure 14, 1617-1622. 
[169] Derewenda, Z. S., and Vekilov, P. G. (2006) Entropy and surface engineering in protein 
crystallization, Acta Crystallogr D 62, 116-124. 
[170] Clamp, M., Cuff, J., Searle, S. M., and Barton, G. J. (2004) The Jalview Java alignment editor, 
Bioinformatics 20, 426-427. 
215 
 
[171] Sultana, A., and Lee, J. E. (2015) Measuring protein-protein and protein-nucleic Acid 
interactions by biolayer interferometry, Current protocols in protein science 79, 19 25 
11-26. 
[172] Pascual, J., Martinez-Yamout, M., Dyson, H. J., and Wright, P. E. (2000) Structure of the 
PHD zinc finger from human Williams-Beuren syndrome transcription factor, J Mol Biol 
304, 723-729. 
[173] Oppikofer, M., Sagolla, M., Haley, B., Zhang, H. M., Kummerfeld, S. K., Sudhamsu, J., Flynn, 
E. M., Bai, T., Zhang, J., Ciferri, C., and Cochran, A. G. (2017) Non-canonical reader 
modules of BAZ1A promote recovery from DNA damage, Nat Commun 8, 862. 
[174] Plotnikov, A. N., Yang, S., Zhou, T. J., Rusinova, E., Frasca, A., and Zhou, M. M. (2014) 
Structural insights into acetylated-histone H4 recognition by the bromodomain-PHD 
finger module of human transcriptional coactivator CBP, Structure 22, 353-360. 
[175] Zeng, L., Yap, K. L., Ivanov, A. V., Wang, X. Q., Mujtaba, S., Plotnikova, O., Rauscher, F. J., 
and Zhou, M. M. (2008) Structural insights into human KAP1 PHD finger-bromodomain 
and its role in gene silencing, Nat Struct Mol Biol 15, 626-633. 
[176] Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N., and Sternberg, M. J. (2015) The Phyre2 
web portal for protein modeling, prediction and analysis, Nat Protoc 10, 845-858. 
[177] Dosztanyi, Z., Csizmok, V., Tompa, P., and Simon, I. (2005) IUPred: web server for the 
prediction of intrinsically unstructured regions of proteins based on estimated energy 
content, Bioinformatics 21, 3433-3434. 
[178] Dosztanyi, Z., Csizmok, V., Tompa, P., and Simon, I. (2005) The pairwise energy content 
estimated from amino acid composition discriminates between folded and intrinsically 
unstructured proteins, J Mol Biol 347, 827-839. 
[179] Vagenende, V., Yap, M. G., and Trout, B. L. (2009) Mechanisms of protein stabilization and 
prevention of protein aggregation by glycerol, Biochemistry 48, 11084-11096. 
[180] Bennion, B. J., and Daggett, V. (2003) The molecular basis for the chemical denaturation 
of proteins by urea, Proc Natl Acad Sci U S A 100, 5142-5147. 
[181] Wilkins, M. R., Gasteiger, E., Bairoch, A., Sanchez, J. C., Williams, K. L., Appel, R. D., and 
Hochstrasser, D. F. (1999) Protein identification and analysis tools in the ExPASy server, 
Methods in molecular biology 112, 531-552. 
[182] Dumon-Seignovert, L., Cariot, G., and Vuillard, L. (2004) The toxicity of recombinant 
proteins in Escherichia coli: A comparison of overexpression in BL21(DE3), C41(DE3), and 
C43(DE3), Protein expression and purification 37, 203-206. 
[183] Kim, D. E., Chivian, D., and Baker, D. (2004) Protein structure prediction and analysis using 
the Robetta server, Nucleic Acids Res 32, W526-W531. 
[184] Barbieri, I., Cannizzaro, E., and Dawson, M. A. (2013) Bromodomains as therapeutic targets 
in cancer, Brief Funct Genomics 12, 219-230. 
[185] Marley, J., Lu, M., and Bracken, C. (2001) A method for efficient isotopic labeling of 
recombinant proteins, Journal of biomolecular NMR 20, 71-75. 
[186] Williamson, M. P. (2014) Using chemical shift perturbation to characterise ligand binding 
(vol 73, pg 1, 2013), Prog Nucl Mag Res Sp 80, 64-64. 
[187] Kabsch, W. (2010) Xds, Acta Crystallogr D 66, 125-132. 
[188] Kabsch, W. (2010) Integration, scaling, space-group assignment and post-refinement, Acta 
Crystallogr D 66, 133-144. 
[189] Battye, T. G., Kontogiannis, L., Johnson, O., Powell, H. R., and Leslie, A. G. (2011) iMOSFLM: 
a new graphical interface for diffraction-image processing with MOSFLM, Acta 
crystallographica. Section D, Biological crystallography 67, 271-281. 
[190] Evans, P. R., and Murshudov, G. N. (2013) How good are my data and what is the 
resolution?, Acta Crystallogr D 69, 1204-1214. 
[191] Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of 
Coot, Acta Crystallogr D 66, 486-501. 
216 
 
[192] Painter, J., and Merritt, E. A. (2006) TLSMD web server for the generation of multi-group 
TLS models, J Appl Crystallogr 39, 109-111. 
[193] Schuttelkopf, A. W., and van Aalten, D. M. (2004) PRODRG: a tool for high-throughput 
crystallography of protein-ligand complexes, Acta crystallographica. Section D, 
Biological crystallography 60, 1355-1363. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
217 
 
APPENDIX  
 
 
Primer Name DNA sequence from 5’ to 3’ 
FW_BAZ1B_PHD(1182) CTGATCATATGGCGGAAATGAGCGCAGAAAATGCACGT   
RV_BAZ1B_ PHD(1237) CTAGCTCGAGTCACTATTAACGTGCGGTTGCAGGCTG 
FW-BrD1B-105-(1338) 
 
CTACCATATGGAGAACCTGTACTTCCAATCCAGCAGCCGTCGTCAG
AG 
FW-TEV-PHD1B-(1237) 
 
ATCTCATATGGAGAACCTGTACTTCCAATCCGCACGTTGTAAAGTGT
GTC 
 
FW_BrD1B_(1310) 
 
CTGATCATATGCATAGCACCCGTCGTAG 
FW_BrD1B_(1321) CTGATCATATGCCTGTTGATGATGCCGAA 
RV_BrD1B_(1449) 
 
CTACCTCGAGTCACTAATACGGATGACCAGGCAG 
FW_BrD1B_TEV(1310) 
 
CTGATCATATGGAGAACCTGTACTTCCAATCCCATAGCACCCGTCGT
AG 
FW_BrD1B_TEV(1321) CTGATCATATGGAGAACCTGTACTTCCAATCCCCTGTTGATGATGCC
GAA 
 
Table 1. Primers designed for BAZ1B constructs 
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Primer Name DNA sequence from 5’ to 3’ 
FW-TEV-PHD-
T66(970) 
 
CTGATCATATGGAGAACCTGTACTTCCAATCCGAAGATTTTTGTGCCGTTTG 
RV-PHD-
T66(1150) 
CTACCTCGAGTCACTAGGTCAGGCTACGACACA  
 
RV-BRD-
T66(1150) 
 
CTACCTCGAGTCACTATTCCGGATAGATCTCTTTCA  
 
FW-TEV-BRD-
TRIM66 
CTGATCATATGGAGAACCTGTACTTCCAATCCCCTGGTATGCGTGCAAGT  
FW-TEV-PHD-
TRIM66(1168)  
CTGATCATATGGAGAACCTGTACTTCCAATCCCCGATTGAAAATGAAGATTTTT 
RV-BRD-
TRIM66/189 
 
CTACCTCGAGTCACTATGCAAAGCGTTTTTCCGGA  
 
RV-BRD-
T66/194 
 
CTACCTCGAGTCACTATTCTTGACGAGGCTGTGC  
 
RV-BRD-
T66/203 
 
CTACCTCGAGTCACTAGCTGCTAACTTCTTCGCTA   
 
FW-BRD-
TRIM66 
CTGATCATATGAATCCCCTGGTATGCGTGCAAGT  
FW-PHD-
TRIM66/LONG 
CTGATCATATGAATCCCCGATTGAAAATGAAGATTTTT 
 
Table 2. Primers designed for TRIM66 constructs 
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Primer Name DNA sequence from 5’ to 3’ 
FW-BAZ2A-PHD-
D1688N/E1689Q  
CGCAAAGGCGATAATAATCAGTTTCTGCTGCTGTGTGAT 
RV-BAZ2A-PHD-
D1688N/E1689Q 
ATCACACAGCAGCAGAAACTGATTATTATCGCCTTTGCG 
 
Table 3. Primers designed for mutation on PHD of BAZ2A. 
 
 
 
 
Figure A1. 
Deconvoluted electrospray mass spectrum of PHD of BAZ1B. 
 
 
 
Figure A2. 
Deconvoluted electrospray mass spectrum of 15N/13C PHD of BAZ1B. 
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Figure A3. 
Deconvoluted electrospray mass spectrum of PHD of BAZ1B methylated at Lys residues. 
 
 
Figure A4. 
Deconvoluted electrospray mass spectrum of 15N PHD of BAZ2B. 
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Figure A5. 
Deconvoluted electrospray mass spectrum of Trim66/194. 
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Figure A6. MS analysis of BAZ2A 6His-Sumo-PHD 
Deconvoluted electrospray mass spectrum of 6His-Sumo-PHD of BAZ2A. A) Mass relative 
to MW of 6His-SUMO. B) Mass relative to MW of PHD of BAZ2A and 6His-Sumo-PHD. 
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Figure A.7. 1D NMR of BAZ2A PHD D1688N/E1689Q 
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Figure A8.1 
LC-MS H3K4me2 10-mer (MW ~1226 Da) 
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Figure A8.2 
LC-MS H3K4ac 10-mer (MW ~ 1186) 
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Figure A8.2 
LC-MS of peptide H3K9ac 10-mer (MW ~ 1186 Da) 
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Figure A8. 3 
LC-MS H3K4me 10-mer (MW ~1158 Da) 
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Figure A8.4 
LC-MS H3K4me2 10-mer (MW ~1173 Da) 
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Figure A8.5 
LC-MS H3K4me2 10-mer (MW ~1186 Da) 
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Figure A8.6 
LC-MS H3wt 20-mer (MW ~2254 Da) 
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Figure A8.7 
LC-MS H3K9ac 20-mer (MW ~2294 Da) 
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Figure A8.8 
LC-MS H3K14acK18ac 21-mer (MW ~2334 Da) 
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Figure A8.9 
LC-MS H3K23ac 30-mer (MW ~3205 Da) 
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Figure A8.10 
LC-MS H3K27ac 30-mer (MW ~3205 Da) 
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Figure A8.11 
LC-MS H3wt 10-mer (MW ~1146 Da) 
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